A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease
Phase: PHASE3
Conditions: Crohn's Disease
Sponsor: Bausch Health Americas, Inc.

RECD3125 
Version Date: 15 May2014 FINAL 
Confidential 
Salix(!). 
PHARMACEUTICALS, )NC. 
AtrlANONG TRCATMLMT 111 GAS1Jt0UflU0l0GY 
Salix Pharmace-uticals, 
Inc. CRP-47  
NCT#: NCT02240121 
CLINICAL RESEARCH PROTOCOL 
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One 
Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed 
Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16\Veeks 
followed by Clinical and Endoscopic Remission at 52 "'eeks in Subjects with Active 
Moderate Crohn's Disease 
Protocol ID: 
IND Number: 
Clinical Phase: 
Treatment Regimen: 
Indication: 
Sponsor: 
Study Director: 
Medical Monitor: 
P1incipal Investigator: 
Protocol Date: 
Amendment Date: 
RECD3125 
115,638 
3 
EudraCT Number: 
2014-001644-38 
Rifaximin Delayed Release (DR) Tablets 800 mg BID or Placebo 
BID 
Moderate Crohn's Disease 
Salix Pharmaceuticals, Inc. 
8510 Colonnade Center Drive 
Raleigh, North Carolina, USA 27615 
Salix Pharmaceuticals, Inc. 
Multicenter 
18 February 2014 
Amendment 1: 15 May 2014 FINAL 
This protocol contains confidential information about a product provided by Salix Pharmaceuticals, Inc. This 
information is provided for the exclusive use of the Investigators participating in this study. Any and all confidential 
information contained herein may not be disclosed to any other person or party without the prior written consent of 
Salix Pharmaceuticals, Inc. 
Page 1 of 116 

Page 2 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
 
 
  
Confidential 
 
SIGNATURE PAGE 
 
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One 
Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed 
Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks 
followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active 
Moderate Crohn's Disease 
 
 
This study protocol has been reviewed and approved by the undersigned persons. It is confirmed 
that the information and guidance given in this protocol complies with scientific principles, the 
guidelines of Good Clinical Practices, the Declaration of Helsinki in the latest relevant version 
and the applicable legal and regulatory requirements. 
 
 
 
 
 
 
 
 
Medical Monitor: 
Salix Pharmaceuticals, Inc. 
 
.'.JI1s-/ao1 
 
Date 
 
Salix Pharmaceuticals, Inc. 
Date 
Study Director: 

P a ge 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n Date: 1 5 Ma y 2 0 1 4 FI N A L  
S ali x P h a r m a c e uti c als,  I n c. 
C R P -4 7  
C o nfi de ntial  
 
 
 
R E C D 3 1 2 5 I n vesti g at o r Pr ot o c ol A gree me nt  
 
I a gree: 
• 
T o ass u me res p o nsi bilit y f or t he pr o per c o n d u ct of t he st u d y at t his  site. 
• 
T o c o n d uct t he st u d y i n c o m plia nce wit h t his pr ot oc ol, a n y f ut ure a me n d m e nts, a n d wit h  a n y 
ot h er st u d y c o n d uct pr oce d ures pr o vi d e d b y t he S p o ns or, Sali x P har mace uticals, I n c.  ( Sali x). 
• 
N ot t o i m ple me nt a n y de viati o ns fr o m or c ha n ges t o t he pr ot oc ol wit h o ut a gree me nt fr o m  t he 
S p o ns or a n d pri or re vi e w a n d writte n a p pr o v al fr o m t he I nstit uti o nal Re vie w  
B oar d/I nstit uti o nal Et hics C o m mittee (I R B/I E C), e x ce pt w here n ecess ar y t o eli mi nate a n 
i m me diate hazar d t o t he s u bjects, or f or a d mi nistrati ve as pects of t h e st u d y ( w here per mitte d 
b y all a p plica ble r e g ulat or y  r e q uire me nts). 
• 
T hat I a m t h or o u g hl y fa miliar wit h t he a p pr o priate use of t he i n vesti gati o nal dr u g(s), as 
descri be d i n  t his pr ot oc ol  a n d a n y ot her i nf or mati o n  pr o vi de d  b y  t he S p o ns or  i ncl u di n g, b ut 
n ot li mite d t o t he f oll o wi n g: t he c urre nt i n vesti gat or’s br oc h ure or e q ui vale nt d oc u me nt 
pr o vi de d b y Sali x a n d a p pr o ve d pr o d uct la b el, if a p plica ble.  
• 
T hat  I a m a war e of,  a n d will  c o m pl y wit h,  “ g o o d cli nical practices ”  ( G C P) a n d all a p plica ble 
re g ulat ory  re q uire me nts. 
• 
T o e ns ure t hat all pers o ns assisti n g me wit h t he st u d y are a de q u atel y i nf or me d a b o ut the 
i n vesti gati o nal dr u g(s) a n d of t heir st u d y-relate d d uties a n d f u ncti o ns as d escri be d i n t he 
pr ot oc ol.  
• 
T o peri o dic o n -site m o nit ori n g of t he cas e re p ort f or ms ( C R Fs) a n d s o urce d oc u me nts by 
Sali x or desi g nee a n d t o o n -site i ns pecti o n of C R Fs a n d s o urce d oc u me nts b y a p pr o priate 
re g ulat or y a ut h orities, i ncl u di n g b ut n ot li mite d t o t he U nite d States ( U S) F o o d a n d Dr u g 
A d mi nistrati o n ( F D A), l ocal g o ver ni n g re g ulat or y b o dies, a n d I R B/I E C  i ns pect ors. 
• 
T hat I ha ve b ee n i nf or me d t hat certai n re g ulat or y a ut h orities re q uire t h e S p o ns or t o o btai n 
a n d s u p pl y d etails a b o ut t he i n vesti gat or’s o w ners hi p i nterest i n t he S p o ns or or st u d y dr u g, 
a n d m ore ge n erall y a b o ut his/ her fi na ncial ties wit h t he S p o ns or. Sali x will use a n d  discl ose 
t he i nf or mati o n s olel y f or t he p ur p ose of c o m pl yi n g wit h re g ulat or y re q uire me nts. 
He nce I:  
ñ  A gree t o s u p pl y Sali x wit h a n y i nf or mati o n re gar di n g o w ners hi p i nterest a n d  fi na ncial 
ties (i ncl u di n g t h ose of m y s p o use a n d de pe n d e nt c hil dre n);  
ñ  A gree t o pr o m ptl y u p dat e t his i nf or mati o n if a n y rele va nt c h a n ges o cc ur d uri n g  t he 
c o urse of t he st u d y a n d f or 1 year f oll o wi n g c o m pleti o n of t he st u d y;  a n d  
ñ  A gree t hat Sali x ma y dis cl ose t his i nf or mati o n a b o ut s uc h o w ners hi p i nterests  a n d 
fi na ncial ties t o re g ulat or y a ut h orities.  
 
 
 
I n vesti g at or N a me [ Pri nt] 
 
I n vesti g at or Si g n at ure 
 
D ate  

P a ge 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n Date: 1 5 Ma y 2 0 1 4 FI N A L  
S ali x P h a r m a c e uti c als,  I n c. 
C R P -4 7  
C o nfi de ntial  
 
 
 
S Y N O P SI S  
 
P R O T O C O L TI T L E:  
A D o u ble -Bli n d, Place b o -C o ntr olle d, Parallel -Gr o u p, M ultice nter, 
M ultire gi o nal, O n e Year St u d y t o Ass ess t he Effi cac y a n d Safet y of 
T wice Dail y Oral Rifa xi mi n Dela ye d Releas e Ta blets f or I n d ucti o n 
of Cli nical Re missi o n wit h E n d osc o pic Res p o nse at 1 6 Wee ks 
f oll o we d b y Cli nical a n d E n d osc o pic Re missi o n at 5 2 Wee ks i n 
S u bjects wit h Acti ve M o derate Cr o h n’s  Diseas e  
P R O T O C O L N U M B E R:  R E C D 3 1 2 5  
S P O N S O R:  
Sali x P har mace uticals, I n c.  
T R E A T M E N T:  
Treat me nt A: Rifa xi mi n Dela ye d Release ( D R) Oral Ta blets 8 0 0 
m g BI D a d mi nistere d c o nti n u o usl y wit h o ut d ose -a dj ust me nt f or 5 2 
wee ks  
Treat me nt B: Matc hi n g place b o BI D a d mi nistere d c o nti n u o usl y 
wit h o ut d ose -a dj ust me nt f or 5 2 wee ks  
P RI M A R Y O B J E C TI V E:  T o deter mi ne t he efficac y of Rifa xi mi n D R 8 0 0 m g BI D vs. 
place b o f or t he i n d ucti o n of cli nical re missi o n a n d e n d osc o pic 
res p o nse f oll o wi n g 1 6 w ee ks of treat me nt i n s u bjects prese nti n g 
wit h acti ve m o derat e Cr o h n’s disease.  
K E Y S E C O N D A R Y 
O B J E C TI V E:  
A ke y sec o n d ar y o bjecti ve is t o e val uate cli nical a n d e n d osc o pic 
re missi o n f oll o wi n g a n a d diti o nal 3 6-wee k l o n g ter m treat me nt 
p hase of Rifa xi mi n D R 8 0 0 m g BI D vs. place b o.  
S T U D Y D E SI G N:  
R E C D 3 1 2 5 is a d o u ble -bli n d, place b o -c o ntr olle d, parallel -gr o u p, 
m ultice nter, m ultire gi o nal, 5 2 -wee k st u d y t o assess t he efficac y 
a n d safet y of Rifa xi mi n D R ta blets f or t he i n d ucti o n of cli nical 
re missi o n a n d e n d osc o pi c res p o nse at 1 6 wee ks f oll o we d b y 
cli nical a n d e n d osc o pi c re missi o n after 5 2 wee ks of c o nti n u o us 
t hera p y i n s u bjects wit h acti ve m o derate Cr o h n’s disease. S u bjects 
will be eli gi ble if t he y h a ve acti ve, m o derate disease defi ne d b y a 
Cr o h n’s disease A cti vit y I n d e x ( C D AI) sc ore of ≥ 2 2 0 a n d ≤ 4 5 0 
p oi nts at scree ni n g, a n d e vi de nce of acti ve ile oc ol o nic Cr o h n’s 
disease defi n e d b y a Si m ple E n d osc o pic Sc ore f or Cr o h n’s disease 
( S E S-C D) of ≥ 7 o n baseli ne ile oc ol o n osc o p y as assesse d b y 
bli n de d ce ntral rea di n g. Eli gi ble s u bjects wi ll c o m plete a 2- t o 3- 
wee k Scr ee ni n g Peri o d, a 5 2 -wee k Treat me nt Peri o d c o nsisti n g of 
a 1 6-wee k I n d ucti o n P hase a n d 3 6 -Wee k L o n g T er m Treat me nt 
P hase, a n d a 2 -wee k F oll o w -u p Peri o d. S u bjects will be 
ra n d o mize d i n a 1: 1 all ocati o n t o Rifa xi mi n D R 8 0 0 m g BID or 
place b o at t he b e gi n ni n g of t he treat me nt p eri o d a n d will mai ntai n  

P a ge 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
treat me nt assi g n me nt t hr o u g h o ut t he d urati o n of t he st u d y. 
Ile o c ol o n osc o p y will be perf or me d o n all s u bjects at baseli ne 
( bet wee n Visits 1 a n d 2), bet wee n Wee ks 1 6 a n d 1 7 (e n d of t he 
I n d u cti o n P hase), a n d f oll o wi n g c o m pleti o n of t he 3 6-wee k L o n g 
Ter m Treat me nt P hase ( Wee k 5 2) t o assess t he effects of treat me nt 
o n t he de gree of m uc osal heali n g. S u bjects will be assesse d d uri n g 
cli nic visits w hic h are sc he d ule d at Wee ks 0 ( b aseli ne), 2, 4, 8, 1 2, 
a n d 1 6; t he n e ver y f o ur wee ks t hr o u g h Wee k 5 2. All s u bjects will 
be re q uir e d t o c o m plete a dail y diar y. All s u bjects will c o m plete a 
2 -wee k (st u d y dr u g free) F oll o w -u p Peri o d f oll o wi n g c o m pleti o n 
of t he 5 2 -wee k Treat me nt Peri o d, a n d will ret ur n t o t he cli nic f or 
fi nal assess me nts ( E n d-of -St u d y [ E O S] visit; Wee k 5 4). See 
Fi g ure  1.  
S T U D Y D U R A TI O N:  
Per S u bject: 2 - t o 3-wee k Scree ni n g Peri o d, 5 2 -wee k Treat me nt 
Peri o d, a n d a 2 -w ee k F oll o w -u p Peri o d. T he ma xi m u m d urati o n of 
s u bject partici pati o n will be 5 7 wee ks. 
S U B J E C T 
P O P U L A TI O N:  
S u bjects wit h acti ve, m o derate disease defi ne d b y a C D AI sc ore of  
≥ 2 2 0 a n d ≤ 4 5 0 p oi nts at scree ni n g, a n d e vi de n ce of acti ve 
ile oc ol o nic Cr o h n’s disease defi ne d b y a S E S-C D sc ore of ≥ 7 as 
deter mi ne d fr o m b aseli ne ile oc ol o n osc o p y.  
N U M B E R O F 
S U B J E C T S:  
A p pr o xi matel y 6 6 0 t otal: 3 3 0 t o Treat me nt A ( 8 0 0 m g Rifa xi mi n 
D R BI D) a n d 3 3 0 t o Treat me nt B ( Place b o BI D)  
N U M B E R O F C E N T E R S:  A p pr o xi matel y 2 0 0  
L O C A TI O N:  
U nite d States, Ca na da, R ussia, Israel a n d c o u ntries i n E ur o pe 
C O -P RI M A R Y 
E F FI C A C Y E N D P OI N T:  
T here will be t w o c o -pri mar y m eas ures of efficac y ass esse d d uri n g 
t he I n d u cti o n of Cli nical Re missi o n a n d E n d osc o pic Res p o nse 
P hase. T he first c o -pri mar y e n d p oi nt is:  
• 
Cli nical S y m pt o m Re missi o n defi ne d b y ( 1) t he t otal n u m ber  of 
li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o t he Wee k 1 6 visit 
bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n a b d o mi nal pai n 
rati n g of ≤ 1 (fr o m C D AI Ite m 2) o n eac h da y f or t he 7 da ys 
pri or t o t he Wee k 1 6 visit.  
T he sec o n d c o -pri mar y e n d p oi nt is:  
• 
E n d osc o pic Res p o nse defi ne d as a ≥ 3 -p oi nt decrease i n t he 
S E S -C D fr o m baseli ne t o t he S E S -C D sc ore o btai ne d bet wee n 
Wee k 1 6 a n d Wee k 1 7. S E S -C D sc ores will be calc ulate d  fr o m 
ce ntrall y-rea d di gital vi d e o of ile oc ol o n osc opies p erf or me d  at  

P a ge 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
baseli ne a n d bet w ee n Wee k 1 6 a n d Wee k 1 7.  
K E Y C O -S E C O N D A R Y 
E N D P OI N T:  
T here will be t w o k e y c o -sec o n dar y e n d p oi nts of efficac y ass esse d 
d uri n g t he L o n g T er m Treat me nt P hase. T he first is:  
 
• 
Cli nical s y m pt o m re missi o n defi ne d b y ( 1) t he t ot al n u m ber  of 
li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o t he Wee k 5 2 visit 
bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n a b d o mi nal pai n 
rati n g of ≤ 1(fr o m C D AI Ite m 2) o n eac h da y f or t he 7 da ys 
pri or t o t he Wee k 5 2 visit.  
T he sec o n d is:  
 
• 
E n d osc o pic re missi o n defi ne d as a S E S -C D sc ore of ≤ 2 at 
Wee k 5 2. S E S -C D sc ores will be calc ulate d fr o m ce ntrall y - 
rea d di gital vi de o of ile o c ol o n osc o pies perf or me d at Wee k 5 2  
S E C O N D A R Y 
E N D P OI N T S:  
T he f oll o wi n g s ec o n dar y e n d p oi nts will be assesse d:  
 
• 
I n d u cti o n of cli nical re missi o n defi ne d as a C D AI sc ore of less 
t ha n 1 5 0 p oi nts at Wee k 1 6.  
 
• 
Pr o p orti o n of s u bjects wit h S E S -C D sc ore of 0 at Wee k  5 2.  
• 
Cli nical re missi o n defi ne d as a C D AI sc ore of l ess t ha n  1 5 0 
p oi nts at p ost -baseli ne  visits.  
 
• 
C ha n ge fr o m bas eli ne i n S E S -C D sc ore at Wee k 1 6 a n d Wee k 
5 2.  
 
• 
Cli nical s y m pt o m re missi o n o ver ti me: T he t otal n u m ber of 
li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o eac h cli nic visit 
bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n a b d o mi nal pai n 
rati n g of ≤ 1(fr o m C D AI Ite m 2) o n eac h da y f or t he last 7 
da ys pri or t o ea c h cli nic visit i n ≥ 8 0 % of t he st u d y visits 
d uri n g t he 5 2 -Wee k Treat me nt P hase, i ncl u di n g Wee k  5 2.  
• 
Ti me t o l oss of C D AI res p o nse defi ne d b y a C D AI sc ore of  ≥ 
1 5 0 p oi nts d uri n g t he L o n g Ter m Treat me nt P hase.  
 
• 
Ti me u ntil d ura ble res p o nse t o t he li q ui d/ ver y s oft st o ol 
c o m p o ne nt of t he c o -pri mar y e n d p oi nt d uri n g t he 5 2 -Wee k 
Treat me nt  P hase.  

P a ge 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
• 
Ti me u ntil d ura ble res p o nse t o t he a b d o mi nal pai n c o m p o ne nt 
of t he c o -pri mar y e n d p oi nt d uri n g t he 5 2 -Wee k Treat me nt 
P hase.  
 
• 
Pr o p orti o n of s u bjec ts wit h res p o nse t o t he a b d o mi nal pai n 
c o m p o ne nt of t he c o -pri mar y e n d p oi nt at p ost -baseli ne ti me 
p oi nts.  
 
• 
Pr o p orti o n of s u bjects wit h res p o nse t o t he li q ui d/ ver y s oft 
st o ol c o m p o ne nt of t he c o-pri mar y e n d p oi nt at  p ost -baseli ne 
ti me p oi nts.  
 
• 
Pr o p orti o n of s u bjects w h o ac hie ve cli nical re missi o n b y  t he 
C D AI e n d p oi nt at p ost -b aseli ne ti me  p oi nts.  
 
• 
Perce nta ge of s u bjects w h o ac hie ve cli nical res p o nse at p ost - 
baseli ne ti me p oi nts. Cli nical res p o nse is defi ne d as a re d ucti o n 
of at least 1 0 0 p oi nts  fr o m t he baseli ne C D AI sc ore. 
 
• 
Ti me t o cli nical res p o nse base d o n Wee k 1 6 c o -pri mar y 
e n d p oi nts. 
S A F E T Y E N D P OI N T S:  
• 
I n ci de nce, i nte nsit y, a n d t y pes of a d vers e e v e nts ( A Es). 
• 
C ha n ges fr o m bas eli ne i n t he la b orat or y  para meters 
( he mat ol o g y, cli nical c h e mistr y, uri nal ysis).  
• 
C ha n ges fr o m bas eli ne i n vital si g n  meas ure me nts.  
O T H E R E N D P OI N T S:  
E x pl orat or y assess me nts will i ncl u de:  
• 
C haracterizati o n of st o ol micr o bi ota at baseli ne a n d after  1 6 
a n d 5 2 wee ks of treat me nt.  
 Baseli ne a n d p ost -treat me nt bacteri al D N A is olate d 
fr o m st o ol f or 1 6 S r R N A ge n e a m plificati o n.  
 Descri pti ve c h aracterizati o n of bacteri a i n st o ol  b y:  
• 
Is olati o n a n d i d e ntificati o n of selecte d Gra m - 
ne gati ve a n d Gra m -p ositi ve  bacteria.  
• 
Resista nce t o select e d a nti bi otics, i ncl u di n g 
rifa xi mi n a n d rifa m pi n. 
• 
Ge n o mic pr ofili n g of pre g na n e X rece pt or ( P X R) i n  bl o o d.  
• 
P o p ulati o n p har mac o ki netics of  rifa xi mi n. 

Page 8 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
SAMPLE SIZE: 
The information below provides the background information for 
sample size determination for the induction of clinical remission 
with endoscopic response at 16 weeks followed by clinical and 
endoscopic remission at 52 weeks. For placebo, the expected rates 
are based on data from a Phase 2 study (RETIC 03/06) conducted 
in subjects with active moderate Crohn’s disease. The rates for 
Rifaximin DR are based on the assumption that Rifaximin DR will 
provide a somewhat higher induction of remission rate. 
Expected rates for induction of clinical remission with endoscopic 
response at Week 16 are 40% for placebo and 55% for Rifaximin 
DR. 
Based on a significance level of 5% (alpha 0.05), a sample size of 
approximately 240 subjects per treatment group will have at least 
90% power to test the hypothesis that Rifaximin DR is superior to 
placebo for each co-primary endpoint considered individually. 
Approximately 80% power is available to detect significant 
differences between Rifaximin DR and placebo for each of the co- 
primary endpoints. 
For the long term treatment phase, a 15% treatment effect is 
expected for both clinical symptom and endoscopic remission at 
Week 52. Based on this assumption and testing at a significance 
level of 5% (alpha 0.05), a sample size of approximately 210 
subjects per treatment group will have at least 90% power to test 
the key secondary efficacy hypothesis that Rifaximin DR is 
superior to placebo when each key co-secondary endpoint is 
considered individually. In addition, approximately 80% power is 
available to detect significant differences between Rifaximin DR 
and placebo for each of the key co-secondary endpoints. 
An additional consideration for sample size determination is the 
application of an inflation factor of 20% to account for drop-out 
rates during the Induction and Long Term Treatment Phases of the 
study. This consideration suggested that 330 subjects per treatment 
group would be required at study entry. 

P a ge 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
T a ble of C o nte nts  
SI G N A T U R E  P A G E  ...................................................................................................................... 2  
R E C D 3 1 2 5 I N V E S TI G A T O R  P R O T O C O L  A G R E E M E N T  ................................................... 3  
S Y N O P SI S  ...................................................................................................................................... 4  
LI S T  O F  A B B R E VI A TI O N S  ..................................................................................................... 1 4  
1. 0  
I N T R O D U C TI O N............................................................................................................ 1 7  
1. 1  
Disease Bac k gr o u n d a n d Scie ntific Rati o nale f or t he Use of Rifa xi mi n D R i n 
Cr o h n’s  Diseas e  ..................................................................................................... 17 
1. 2  
C urre nt T her a p y f or  Cr o h n’s  Disease  .................................................................... 1 9  
1. 3  
Rifa xi mi n  D R  Bac k gr o u n d  .................................................................................... 2 0  
1. 4  
Cli nical E x perie nce  wit h  Rifa xi mi n  ....................................................................... 2 0  
1. 5  
St u d y  Rati o nale  ...................................................................................................... 2 3  
1. 6  
Pri mar y E n d p oi nt De v el o p me nt f or t he  U nite d  States  ........................................... 2 4  
2. 0  
O B J E C TI V E S  A N D E N D P OI N T S  ................................................................................ 2 8  
2. 1  
O bjecti ves  .............................................................................................................. 2 8  
2. 1. 1  
Pri mar y  O bjecti ve  ................................................................................. 2 8  
2. 1. 2  
Sec o n dar y  O bjecti ves  ............................................................................ 2 8  
2. 2  
E n d p oi nts  ............................................................................................................... 2 8  
2. 2. 1  
Pri mar y  Efficac y  E n d p oi nts  .................................................................. 2 8  
2. 2. 2  
Ke y  Sec o n d ar y  E n d p oi nts  ..................................................................... 2 9  
2. 2. 3  
Sec o n dar y  Efficac y  E n d p oi nts  .............................................................. 2 9  
2. 2. 4  
Safet y  E n d p oi nts  ................................................................................... 3 0  
2. 2. 5  
E x pl orat or y  Assess me nts  ...................................................................... 3 0  
3. 0  
I N V E S TI G A TI O N A L P L A N  ......................................................................................... 3 1  
3. 1  
O ver vie w of  St u d y  Desi g n  ..................................................................................... 3 1  
3. 2  
Rati o nale f or Pr o p ose d  St u d y  D esi g n  .................................................................... 3 2  
3. 3  
Treat me nt  Assi g n me nt/ Ra n d o mizati o n  .................................................................. 3 2  
3. 4  
Pr oce d ures f or Brea ki n g  t he Bli n d  ......................................................................... 3 3  
4. 0  
S E L E C TI O N A N D WI T H D R A W A L  O F  S U B J E C T S  ................................................ 3 4  
4. 1  
I n cl usi o n Criteria .................................................................................................... 3 4  
4. 2  
E x cl usi o n  Criteria  .................................................................................................. 3 5  
4. 3  
C o nc o mita nt  T hera pies  .......................................................................................... 3 7  
4. 3. 1  
Per mitte d  T hera p y  ................................................................................. 3 7  
4. 3. 2  
Pr o hi bite d  T hera p y  ................................................................................ 3 8  

P a ge 1 0  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
4. 4  
Fe males of  R e pr o d u cti ve  P ote ntial  ........................................................................ 3 8  
4. 5  
Pre mat ure  S u bject  Disc o nti n uati o n  ........................................................................ 3 9  
4. 6  
St u d y  C o ntact  I nf or mati o n ..................................................................................... 3 9  
5. 0  
T R E A T M E N T O F  S U B J E C T S  ...................................................................................... 4 1  
5. 1  
F or m ulati o n  a n d S u p pl y ......................................................................................... 4 1  
5. 2  
Pac ka gi n g  ............................................................................................................... 4 1  
5. 3  
La b eli n g  ................................................................................................................. 4 1  
5. 4  
St ora ge  a n d H a n dli n g  ............................................................................................. 4 2  
5. 5  
D osi n g a n d D osi n g Sc h e d ule  ................................................................................. 4 2  
5. 6  
Rati o nale f or  D os e  Selecti o n  ................................................................................. 4 2  
5. 7  
St u d y  Dr u g Acc o u nta bilit y  .................................................................................... 4 2  
5. 8  
Assess me nt  of  C o m plia nce  .................................................................................... 4 3  
6. 0  
S T U D Y P R O C E D U R E S  A N D  A S S E S S M E N T S  .......................................................... 4 4  
6. 1  
St u d y Sc h e d ule b y  Treat me nt  Visit  ........................................................................ 4 4  
6. 1. 1  
Visit 1: Scree ni n g ( Da y – 2 1 t o  Da y  -1 4)  ............................................... 4 4  
6. 1. 2  
Visit 2: Baseli ne/ Ra n d o mizati o n, Wee k  0/ Da y  1  .................................. 4 5  
6. 1. 3  
Visits 3, 4, 5, 6: Wee ks 2, 4, 8, 1 2 / Da ys 1 4, 2 8, 5 6, 8 4 ( ±  3  da ys)  ...... 4 5  
6. 1. 4  
Visit 7: Wee k 1 6/ Da y 1 1 2 ( ±  3 da ys)  .................................................... 4 6  
6. 1. 5  
Visits 8, 9, 1 0, 1 1, 1 2, 1 3, 1 4, 1 5: Wee ks 2 0, 2 4, 2 8, 3 2, 3 6, 4 0,  4 4,  
4 8 / Da ys 1 4 0, 1 6 8, 1 9 6, 2 2 4, 2 5 2, 2 8 0, 3 0 8, 3 3 6 ( ± 3  da ys)  ............... 4 7  
6. 1. 6  
Visit 1 6: E n d of Treat me nt ( E O T) Visit, Wee k 5 2/ Da y 3 6 4 ( ±  3  
da ys)  ...................................................................................................... 4 7  
6. 1. 7  
Visit 1 7: E n d of St u d y ( E O S) Visit, Wee k 5 4/ Da y 3 7 8 ( ±  3 da ys)  ....... 4 8  
6. 1. 8  
U nsc he d ule d Visit  ................................................................................. 4 8  
6. 1. 9  
Dail y Di ar y ( a n d/ or ot her  s u bject-c ollecte d data)  ................................. 4 9  
6. 2  
Assess me nt  of  Efficac y  .......................................................................................... 4 9  
6. 2. 1  
Cr o h n’s Disease A cti vit y I n d e x  ( C D AI) Sc ore ..................................... 4 9  
6. 2. 2  
Si m ple E n d osc o pic Sc ore f or Cr o h n’s  Disease  ( S E S-C D)  ................... 4 9  
6. 2. 3  
I nfla m mat or y B o wel Dis ease Q u esti o n naire (I B D Q)  ........................... 5 0  
6. 2. 4  
W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q u esti o n naire  f or 
Cr o h n's Disease  ( W P AI-C D)  ................................................................ 5 0  
6. 3  
Assess me nt  of  Saf et y  ............................................................................................. 5 0  
6. 3. 1  
Cli nical  La b orat or y  T ests  ...................................................................... 5 0  
6. 3. 2  
Assess me nt of  I nfla m mati o n Mar kers  .................................................. 5 1  
6. 3. 3  
St o ol Sa m ple C ollecti o n  a n d Testi n g  .................................................... 5 2  
6. 3. 4  
Uri ne a n d Ser u m  Pre g n a nc y  T ests  ........................................................ 5 3  

P a ge 1 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
6. 3. 5  
Safet y M o nit ori n g f or  C. difficile  .......................................................... 5 3  
6. 3. 6  
A d verse  E v e nts  ..................................................................................... 5 3  
6. 3. 7  
P h ysical  E x a mi nati o n  ............................................................................ 5 3  
6. 3. 8  
Vital  Si g n  Assess me nts  ......................................................................... 5 4  
6. 3. 9  
Electr ocar di o gra m  ( E C G) ..................................................................... 5 4  
6. 4  
Ot her  Assess me nts  ................................................................................................. 5 4  
6. 4. 1  
Me dical  Hist or y  ..................................................................................... 5 4  
6. 5  
P har mac o ki netics  ................................................................................................... 5 4  
7. 0  
S A F E T Y  R E P O R TI N G  .................................................................................................. 5 5  
7. 1  
O perati n g Defi niti o ns f or  Assessi n g  Safet y  ........................................................... 5 5  
7. 1. 1  
A d verse  E v e nt  ....................................................................................... 5 5  
7. 1. 2  
Seri o us  A d vers e  E ve nt  .......................................................................... 5 6  
7. 2  
Cli nical La b or at or y A b n or m alities a n d Ot her A b n or mal Assess me nts as  A Es  
a n d S A Es  ................................................................................................................ 5 7  
7. 3  
Met h o d, Fre q u e nc y, a n d Ti me Peri o d f or Det ecti n g A Es  a n d S A Es  ..................... 5 7  
7. 3. 1  
T he Ti me Peri o d f or D et ecti n g a n d Re p orti n g of A Es  a n d S A Es  ......... 5 8  
7. 3. 2  
P ost -St u d y  S A Es  ................................................................................... 5 8  
7. 4  
D oc u me nti n g A Es  a n d S A Es  ................................................................................. 5 8  
7. 5  
F oll o w -u p of A Es  a n d S A Es  .................................................................................. 5 9  
7. 6  
Pr o m pt Re p orti n g of S A Es t o  Sali x P har mace uticals  ............................................ 5 9  
7. 7  
Pre g n a nc y  Re p orti n g  .............................................................................................. 5 9  
7. 8  
Tra ns missi o n of S A E Re p ort F or ms a n d Pre g n a nc y  N otificati o n  F or ms  .............. 6 0  
7. 9  
Re g ulat or y Re p orti n g Re q uire me nts  f or S A Es ...................................................... 6 0  
8. 0  
S T A TI S TI C A L  C O N SI D E R A TI O N S  ........................................................................... 6 1  
8. 1  
Ra n d o mizati o n  ....................................................................................................... 6 1  
8. 2  
Deter mi nati o n of  Sa m ple  Size  ............................................................................... 6 1  
8. 3  
A nal ysis  P o p ulati o ns  .............................................................................................. 6 2  
8. 4  
S u bject  Dis p ositi o n  ................................................................................................ 6 2  
8. 5  
De m o gra p hic a n d  Baseli ne C haracteristics  ........................................................... 6 2  
8. 6  
A nal ysis  Met h o ds  .................................................................................................. 6 3  
8. 6. 1  
Pri mar y  Efficac y  A n al ysis  .................................................................... 6 3  
8. 6. 2  
Sec o n dar y  Efficac y  A n al ys es  ................................................................ 6 5  
8. 6. 3  
Safet y  A na l yses ..................................................................................... 6 7  
8. 6. 4  
E xte nt of E x p os ure a n d  Treat me nt  C o m plia nce  ................................... 6 7  
8. 6. 5  
A d verse  E v e nts  ..................................................................................... 6 7  
8. 6. 6  
Cli nical  La b orat or y  Assess me nts  .......................................................... 6 7  

P a ge 1 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
8. 6. 7  
Vital  Si g ns  ............................................................................................. 6 8  
8. 6. 8  
C o nc o mita nt  Me dicati o ns  ..................................................................... 6 8  
8. 6. 9  
P h ysical  E x a mi nati o ns  .......................................................................... 6 8  
8. 6. 1 0  
Electr ocar di o gra m  ................................................................................. 6 8  
8. 7  
Statistical a n d  A nal ytical  Iss u es ............................................................................ 6 9  
8. 7. 1  
A dj ust me nt  f or C o variates .................................................................... 6 9  
8. 7. 2  
Ha n dli n g of Dr o p o uts or  Missi n g  Dat a  ................................................. 6 9  
8. 7. 3  
I nteri m A nal yses a n d D ata  M o nit ori n g  ................................................. 7 0  
8. 7. 4  
M ultice nter  St u dies  ............................................................................... 7 0  
8. 7. 5  
M ulti ple  C o m paris o ns/ M ulti plicit y  ....................................................... 7 0  
8. 7. 6  
Use of a n Efficac y S u bset  of  S u bjects  ................................................... 7 0  
8. 7. 7  
E x pl orati o n of t he Effects of Vari o us Pr o g n ostic Fact ors  o n  
Efficac y  ................................................................................................. 7 0  
8. 7. 8  
Criteria f or St o p pi n g  t he St u d y  ............................................................. 7 1  
9. 0  
S T U D Y  A D MI NI S T R A TI O N  ......................................................................................... 7 2  
9. 1  
I n v esti gat or I nf or mati o n a n d Trai ni n g  ................................................................... 7 2  
9. 2  
M o nit ori n g  ............................................................................................................. 7 2  
9. 3  
A u dits  ..................................................................................................................... 7 2  
1 0. 0  
E T HI C A L A N D  L E G A L A S P E C T S  ............................................................................. 7 3  
1 0. 1  
I nstit uti o nal Re vie w B oar d/ I n d e pe n d e nt Et hics C o m mittee (I R B/I E C) 
A p pr o val  ................................................................................................................ 7 3  
1 0. 2  
S u bject I nf or mati o n a n d  I nf or me d C o nse nt  ........................................................... 7 4  
1 0. 3  
St u d y a n d Site Cl os ure  or  Disc o nti n uati o n  ............................................................ 7 4  
1 0. 3. 1  
St u d y  Disc o nti n uati o n  ........................................................................... 7 5  
1 0. 3. 2  
St u d y  Site  Disc o nti n uati o n  .................................................................... 7 5  
1 0. 4  
Ha n dli n g a n d Rec or d  Kee pi n g  ............................................................................... 7 6  
1 0. 4. 1  
Case Re p ort F or ms a n d  Data base  Pr o cessi n g  ....................................... 7 6  
1 0. 4. 2  
S o urce  D oc u m e nts  ................................................................................ 7 6  
1 0. 4. 3  
S u bject  Trac ki n g  ................................................................................... 7 6  
1 0. 4. 4  
St u d y  Files  ............................................................................................. 7 6  
1 0. 4. 5  
Data  Ma n a ge me nt  ................................................................................. 7 6  
1 0. 5  
C o nfi de ntialit y  ....................................................................................................... 7 6  
1 0. 6  
Rec or d Rete nti o n  ................................................................................................... 7 7  
1 0. 7  
Fi na nci n g  a n d I ns ura n ce ........................................................................................ 7 7  
1 0. 7. 1  
Fi na nce  .................................................................................................. 7 7  
1 0. 7. 2  
I ns ura nce a n d I n de m nificati o n .............................................................. 7 8  

P a ge 1 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
1 0. 8  
P u blicati o n  P olic y  .................................................................................................. 7 8  
1 0. 9  
O w ners hi p  .............................................................................................................. 7 8  
1 1. 0  
R E F E R E N C E S  ................................................................................................................. 7 9  
A p pe n di x 1: O verall Ti me a n d  E ve nts Sc he d ul e  ............................................................... 8 3  
A p pe n di x 2: Cr o h n’s Disease A cti vit y  I n de x ( C D AI) ....................................................... 8 4  
A p pe n di x 3:  Brist ol St o ol F or m  Scale  ( B S F S) ................................................................. 8 5  
A p pe n di x 4: Si m ple E n d osc o pic Sc ore f or Cr o h n’s Disease ( S E S -C D) D efi niti o ns of  
S E S -C D Varia bles  ................................................................................................. 8 6  
A p pe n di x 5: I nfla m mat or y B o wel Disease  Q uesti o n naire (I B D Q)  ................................... 8 7  
A p pe n di x 6: W or k Pr o d ucti vit y a n d A cti vit y I m pair m e nt Q uesti o n naire  ( W P AI: C D)  .... 9 8  
A p pe n di x 7: S u bject Dail y  Diar y  Rec or di n g  ................................................................... 1 0 1  
A p pe n di x 8: I deal B o d y Mass of N or mal A d ults ( Me n  &  W o me n)  ................................ 1 0 2  
A p pe n di x 9: S u m mar y of C ha n ges f or Re visi o n date d 0 1  Ma y  2 0 1 4 .............................. 1 0 4  

P a ge 1 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
LI S T O F A B B R E VI A TI O N S  
 
A b bre vi ati o n  
Defi niti o n  
5 -A S A  
5 -A mi n osalic ylic Aci d  
A E  
A d verse E v e nt  
A L T  
Ala ni ne A mi n otra nsferas e  
A S T  
As partate A mi n otra nsferase  
A U C  
Area U n der t he Plas ma C o nce ntrati o n -ti me C ur ve 
BI D  
T w o Ti mes a Da y  
B S F S  
Brist ol St o ol F or m Scale  
C. difficile  
Cl ostri di u m difficile  
C D  
Cr o h n’s Disease  
C D AI  
Cr o h n’s Disease A cti vit y I n d e x  
C D EI S  
Cr o h n’s Disease E n d os c o pic I n d e x of Se verit y  
C L SI  
Cli nical La b or at or y Sta n dar ds I nstit ute  
C ma x  
Ma xi m u m O bser ve d Plas ma C o nce ntrati o n  
C M H  
C oc hra n -Ma nt el -Hae nszel  
C R F  
Case Re p ort F or m  
C R P  
C -Reacti ve Pr otei n  
D N A  
De o x yri b o n ucleic Aci d  
D S M -5  
Dia g n ostic a n d Statistical Ma n ual of Me ntal Dis or ders, 5t h. E diti o n  
D R  
Dela ye d Release  
E C G  
Electr ocar di o gra m  
E. C oli  
Esc heric hi a c oli  
E D C  
Electr o nic D ata Ca pt ure  
EI A  
E nz y m e I m m u n oassa y 
EI R  
E xte n de d I ntesti nal Release  
E M A  
E ur o pea n Me dici nes A ge nc y  
E O S  
E n d of St u d y  
E O T  
E n d of Treat me nt  
F D A  
F o o d a n d Dr u g A d mi nistrati o n  
G C P  
G o o d Cli nical Practices  
GI  
Gastr oi ntesti nal  
H b A 1c  
He m o gl o bi n A 1 c  

Page 15 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
Abbreviation 
Definition 
HDPE 
High Density Polyethylene 
HIV 
Human Immunodeficiency Virus 
IB 
Investigator’s Brochure 
IBDQ 
Inflammatory Bowel Disease Questionnaire 
IBS 
Irritable Bowel Syndrome 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IEC 
Institutional Ethics Committee 
IL 
Interleukins 
IND 
Investigational New Drug 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IUD 
Intrauterine Device 
LFT 
Liver Function Test 
LLN 
Lower Limit of Normal 
LOCF 
Last Observation Carried Forward 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMP-9 
Matrix Metalloproteinase-9 
NASH 
Non-alcoholic Steatohepatitis 
NC 
North Carolina 
NF-kB 
Nuclear Factor kappa-light-chain-enhancer of activated B Cells 
PCR 
Polymerase Chain Reaction 
PHI 
Protected Health Information 
PK 
Pharmacokinetic(s) 
PP 
Per Protocol 
PSAP 
Pharmacokinetics Statistical Analysis Plan 
PXR 
Pregnane X Receptor 
rCRT 
Clinical Remission Rate Treatment 
rCRP 
Clinical Remission Rate Placebo 
RNA 
Ribonucleic Acid 
ROC 
Receiver Operating Characteristics 
SAE 
Serious Adverse Event 
SAS 
Statistical Analysis System 

P a ge 1 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
A b bre vi ati o n  
Defi niti o n  
S E S -C D  
Si m ple E n d osc o pic Sc ore f or Cr o h n’s Dis ease  
S D  
Sta n dar d De viati o n  
tc d B 
C. difficile T o xi n B  
T ma x  
Ti me of Ma xi m u m O bser ve d Plas ma C o nce ntrati o n  
T N B S  
Tri nitr o be nze ne S ulf o nic Aci d  
T N F α  
T u m or Necr osis Fact or al p ha  
U L N  
U p per Li mit of N or mal  
U S  
U nite d States  
W P AI: C D  
W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q u esti o n naire - Cr o h n’s 
Disease  
W H O  
W orl d Healt h Or ga nizati o n  

P a ge 1 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
1. 0  
I N T R O D U C TI O N 
 
1. 1  
Dise ase B ac k gr o u n d a n d Scie ntific R ati o n ale f or t he Use of Rif a xi mi n D R  i n 
Cr o h n’s  Dise ase  
 
Cr o h n’s disease ( C D) is a c hr o nic, rela psi n g, re mitti n g, s yste mic disease w hic h ma y res ult i n 
tra ns m ural i nfla m mati o n of t he gastr oi ntesti nal tract. T he i nci de n ce a n d pre vale nce rates f or 
C D i n Ca ucasia n pe o ple i n N ort her n E ur o p e a n d N ort h A merica are n ot e d i n Ta ble 1.  
 
T a ble 1: E pi de mi ol o g y of Cr o h n’s Dise ase  
Fact or  
Cr o h n’s disease  
I n ci de nce per 1 0 0, 0 0 0  
1 -6  
Pre vale nce per 1 0 0, 0 0 0  
1 0 -1 0 0  
Racial I nci de n ce  
Hi g h i n Ca ucasia ns  
Et h nic I n ci de nce  
Hi g h i n J e wis h pe o ple  
Ge n der  
Sli g ht fe male pre p o n dera nce  
A ge of O nset  
1 5 -2 5 ( pea k)  
5 5 -6 5 ( 2 n d s maller pea k)  
Refere nce ( 1)  
Cr o h n’s disease ma y aff ect a n y part of t h e ali me ntar y tract, b ut mai nl y affects t he ile u m ( 3 0 - 
4 0 %), ile oc ol o nic r e gi o n ( 4 0 -5 5 %) or c ol o n ( 1 5 -2 5 %). Gastr oi ntesti nal s y m pt o ms are 
deter mi ne d b y t he a n at o mical l ocati o n a n d t he se verit y of t he diseas e a n d i ncl u de:  
 
• Ge ner al ma nifestati o ns: f ati g ue, l oss of a p petite,  fe ver. 
• B o wel s pecific s y m pt o ms: irre g ul ar b o w el m o ve me nts, m uc us a n d / or bl o o d i n  st o ols, 
c hr o nic r ec urre nt diarr hea, rec urre nt a b d o mi nal pai n, a b d o mi nal te n der ness, na usea, 
wei g ht l oss, peria nal  diseases.  
• Strict ures a n d fist ulae,  w hic h ma y l ea d t o o bstr ucti o ns, a bscesses a n d  mala bs or pti o n.  
• E xtrai ntesti nal ma nifestati o ns: prese nt i n u p t o 3 0 % of C D patie nts a n d i ncl u de 
art hr o pat hies, b o ne d e mi neralizati o n, s ki n lesi o ns, oc ular ma nifestati o ns, he patic  diseases.  
 
Se verit y of disease ge ner all y is assess e d b y b ot h n o n -i n vasi ve a n d i n vasi ve meas ures. T h e 
Cr o h n’s disease A cti vit y I n d e x ( C D AI) sc ore is a wei g ht e d, c o m p osite i n de x of ei g ht ite ms 
(st o ol fre q ue n c y, se verit y of a b d o mi nal pai n, de gree of ge n eral well-bei n g, prese nce or 
a bse nce of e xtrai ntesti nal ma nifestati o ns i ncl u di n g fist ula, use or n o n use of a nti diarr heal 
a ge nts, prese n ce or a bse n ce of a b d o mi nal mass, h e mat ocrit a n d b o d y wei g ht). Sc ores ra n ge 
fr o m 0 t o a p pr o xi matel y 6 0 0 wit h hi g her s c ores i n dicati n g greater diseas e se verit y. Cli nical 
(as y m pt o matic) re missi o n is defi ne d as a s c ore of ≤ 1 5 0 p oi nts. Mil d-t o-m o derate disease a n d 
se vere disease are d efi ne d b y sc ores of >  1 5 0 t o ≤ 4 5 0, a n d >  4 5 0 p oi nts, res pecti vel y. ( See 
A p pe n di x 2: Cr o h n’s Disease A cti vit y I n d e x). 

Page 18 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
 
The Simple Endoscopic Score for Crohn’s disease (SES-CD) is a validated instrument 
reflecting an endoscopist’s global appraisal of mucosal lesions in Crohn’s disease. The SES- 
CD grades lesions by location (ileum, right colon, transverse colon, left colon and rectum) 
using ulcer size, extent of ulcerated surface, extent of affected surface, and presence/type of 
narrowing. (See Appendix 4: Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
Definitions of SES-CD Variables). 
 
The disease course is variable with some patients experiencing a very mild disease with 
infrequent flare-ups while others may suffer from more severe disease with frequent 
hospitalizations. Epidemiological studies show that over 1 year from diagnosis, 10-30% of 
patients have at least one exacerbation; 67-73% of patients have a chronic intermittent course; 
and 27% and 29% of patients develop strictures or penetrating disease, respectively (2-6). For 
refractory CD or CD complicated by perforation, intestinal obstruction, stenosis or fistulae, 
patients frequently require bowel surgery (3;6-8). 
 
Considerable clinical and experimental evidence exists to demonstrate that an altered immune 
response to commensal enteric bacteria in a genetically susceptible host plays a key role both 
in the development and persistence of the intestinal inflammation present in CD (9-11). 
Recent evidence indicates the presence of characteristic changes in the biostructure of the 
fecal microbiota in CD patients (12). Additionally, fecal microbiota of CD patients is 
unstable over time as compared with healthy subjects (13), with increased Enterobacteria and 
decreased density of beneficial bacteria such as Firmicutes (in particular F. prausnitzii), 
Bifidobacteria, and Lactobacilli (13-16). Furthermore, the correlation between the 
quantification of E. coli in ileal biopsies and the extent of disease activity in CD patients, 
coupled with the ability of CD-associated E. coli to demonstrate pathogen-like adherent and 
invasive behaviors in cultured cells, support the role of E. coli in the inflammatory process 
(17;18). 
 
Rifaximin is an oral, minimally absorbed, non-systemic, antibacterial agent that exerts its 
activity in the intestinal lumen. By decreasing the triggers of immune activation as well as 
enteric inflammatory response, rifaximin may reduce the uncontrolled immune response to 
enteric bacteria, without the safety concerns associated with systemic broad spectrum 
antibiotics, including metronidazole and ciprofloxacin. 
 
The use of rifaximin in the treatment of CD is supported by recent microbiologic and 
pharmacodynamic evidence which suggests both antibacterial and anti-inflammatory effects 
as mechanisms of action as outlined below: 

P a ge 1 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
A nti b acteri al eff ect a n d i m p act o n i ntesti n al mi cr o bi ot a:  
 
• Rifa xi mi n is acti ve a gai nst t he bacteria t hat ha ve b e e n i n vesti gate d as p ossi ble pat h o ge nic 
a ge nts f or C D.  
• Rifa xi mi n i n d uces i n e nter oa g gr e gati ve a n d e nter ot o xi ge nic E. c oli a l oss of vir ule nce 
fact ors s uc h as e nter ot o xi ns, s urface a d hesi o n fact ors a n d matri x metall o pr otei nase -9 
( M M P-9), a n d c ha n ges i n e pit helial cell p h ysi ol o g y ass o ciate d wit h c h a n ges i n  bacte rial 
attac h me nt/i nter nalizati o n  ( 1 9; 2 0). 
• Rifa xi mi n di d n ot alter t he o verall str uct ure of h u ma n c ol o nic micr o bi ota, b ut ca use d a n 
i ncreas e i n c o nce ntrati o ns of Bifi d o bacteri u m, At o p o bi u m a n d F. pra us nitzii, all be neficial 
bacteria, as s h o w n b y a s u p p orti ve  i n vitr o st u d y usi n g a c o nti n u o us c ult ure c ol o nic m o del 
s yste m t o a nal yze t he i m pact of rifa xi mi n a d mi nistrati o n o n t he fecal micr o bi ota of 
patie nts affecte d b y c ol o nic acti ve C D  ( 2 1). 
 
H ost eff ects of Rif a xi mi n:  
 
• Rifa xi mi n affects bacteri al tra nsl ocati o n  t o mese nteric l y m p h n o d es ( 2 2). 
• Rifa xi mi n i n d uce d a d o w n -re g ulati o n of pr o-i nfla m mat or y c yt o ki nes i n b ot h i n vitr o 
( 2 0; 2 1) e x peri me nts a n d a ni mal m o dels [tri nitr o be nze ne s ulf o nic aci d ( T N B S)-i n d uce d 
c olitis]. Rifa xi mi n -i n d uce d i n hi biti o n of c yt o ki ne pr o d ucti o n pr otecte d a ni mals a gai nst  t he 
de vel o p me nt of c olitis  ( 2 3). 
• Data i n dicate t hat t he a nti -i nfla m mat or y acti vit y of rifa xi mi n is d ue t o its g ut -s pecific 
h u ma n pre g na n e -X -rece pt or ( P X R) acti vati o n ( 2 3). Rifa xi mi n acti vati o n of P X R i n d uces 
t he i n hi biti o n of n uclear fact or ka p pa -li g ht-c hai n-e n ha ncer of acti vate d B cells ( N F -κ B) 
me diate d e x pressi o n of pr o -i nfla m mat or y fact ors ( 2 4; 2 5). T he d o w n-re g ulati o n of N F-κ B 
tar get ge nes is c o u pl e d wit h a n i m pr o ve me nt i n cli nical s y m pt o ms of c olitis  ( 2 6). 
 
1. 2  
C urre nt T her a p y f or C r o h n’s  Dise ase  
 
T here is c urre ntl y n o c ur e f or C D. T he c h oice of t hera p y de p e n ds o n t he a n at o mical l ocati o n 
of t he disease, disease se verit y, a n d g oals of t hera p y w hic h i n cl u de i n d ucti o n a n d 
mai nte na nce of cli nical r e missi o n, treat me nt of i nfe cti o us a n d ot her c o m plicati o ns ass ociate d 
wit h t he disease, a n d a v oi di n g h os pitalizati o ns a n d s ur geries. C urre nt treat me nts f or C D 
i ncl u de 5-a mi n osalic ylat e ( 5 -A S A) c o m p o u n ds, gl uc oc ortic oi ds, i m m u ne m o d ulat ors ( 6- 
merca pt o p uri n e, met h otr e x ate, azat hi o pri n e), bi ol o gic res p o nse m o d ulat ors ( T u m or Necr osis 
Fact or al p ha ( T N F α ) i n hi bit ors), a n d a nti bi otics. F or mil d t o m o derate C D, t w o a p pr oac h es t o 
t hera p y are use d i n t he o ut patie nt setti n g. Ste p-u p t hera p y is a gra de d t hera p y t hat i nitiall y 
uses less p ote nt me dicati o ns ( wit h fe wer a d verse effects) s uc h as t h e 5 -A S A dr u gs. If 
res p o nse is i na de q u ate, m ore p ote nt me dicati o ns s uc h as t he i m m u n o m o d ulat ors a n d bi ol o gi cs  

Page 20 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
are added. Top-down therapy begins with more potent therapies earlier in the course of the 
disease. Induction of remission for patients in an acute flare is typically achieved using 5- 
ASA drugs, antibiotics (see below), and/or a glucocorticoid. Patients with severe or 
fulminant disease are treated aggressively with available pharmacologic agents, bowel rest, 
parenteral nutrition, and intravenous glucocorticoids. 
 
Antibiotics, primarily metronidazole and ciprofloxacin, are used to treat complications of CD 
such as perianal disease, small intestinal bacterial overgrowth, postoperative infections, toxic 
colitis, and secondary infections such as Clostridium difficile (C. difficile). Given the 
association between enteric bacteria and CD as noted above, antibiotics have been evaluated 
as primary therapy for active CD. Metronidazole, a broad spectrum antibiotic with activity 
against enteric anaerobes, and ciprofloxacin, a broad spectrum antibiotic with activity against 
aerobic bacteria, have been investigated in several randomized, controlled trials. Results from 
these trials show that metronidazole given alone or with ciprofloxacin for 12 to 16 weeks is 
better than placebo, and comparable to methylprednisolone and sulfasalazine at reducing the 
CDAI score in patients with mild to moderate CD; however, it has been less effective than 
methylprednisolone at inducing clinical remission (26-29). Ciprofloxacin administered alone 
for up to 6 weeks has shown similar efficacy to mesalazine at inducing clinical remission 
(56% and 55%) in patients with mild to moderate disease. Early clinical evidence indicates 
that metronidazole may be more effective in patients with colonic disease (27;30-32). 
Metronidazole was more effective than steroids at reducing symptoms of CD including 
abdominal pain, diarrhea, fever, and general well-being (22). A retrospective review of 
patients with CD receiving rifaximin 600 mg/day for a median duration of 16.6 weeks 
demonstrated clinical improvements in CDAI score (33). While the efficacy of antibiotics 
supports the hypothesis that colonic flora contribute to the etiology of CD, both 
metronidazole and ciprofloxacin are potent broad spectrum antibiotics with significant side 
effect profiles and high systemic exposures. 
 
1.3 
Rifaximin DR Background 
 
Rifaximin Delayed Release (Rifaximin DR) tablets contain a new pharmaceutical formulation 
that has been designed to release the active drug following passage through the stomach, and 
to achieve a homogeneous distribution of rifaximin in the intestinal tract. The intent of the 
formulation is to provide uniform coverage of the active drug in the intestinal lumen, and to 
maximize contact with the intestinal mucosa. 
 
1.4 
Clinical Experience with Rifaximin 
 
A summary of the clinical studies conducted with rifaximin are provided in the Investigator’s 
Brochure. 

P a ge 2 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
Rifa xi mi n D R ta blets wer e descri be d as E xte n de d I ntesti nal Release ( Rifa xi mi n EI R) ta blets 
i n pre vi o usl y c o n d u cte d st u dies. T he release des cri pt or was c ha n ge d t o ‘ del a ye d rel ease’ t o 
reflect c o n ve nti o nal sta n dar d d osa ge f or m ter mi n ol o g y a n d t he release rate of t he dr u g 
pr o d uct fr o m t he f or m ulati o n.  
 
T hree p h ar mac o ki n etic st u dies wit h Rifa xi mi n EI R 4 0 0 m g ta blets ( R E TI C/ 0 1/ 0 6, 
R E TI C/ 0 2/ 0 6 a n d R E TI C -P K/ 0 0 4/ 2 0 0 9) a n d o ne s u p p orti ve st u d y wit h a n 8 0 0 m g sac het 
f or m ulati o n ( C C R U-0 1 5 1 4) ha ve bee n c o m plete d t o assess bi oa vaila bilit y.  
 
R E TI C/ 0 1/ 0 6 was a n o p e n la bel, ra n d o mize d cr oss -o ver st u d y t hat assess e d t he effect of a 
hi g h -f at brea kfast o n t he bi oa vaila bilit y of a si n gle 1 2 0 0 m g d ose of Rifa xi mi n EI R (ta blet 
f or m ulati o n), c o m par e d t o t he faste d state i n healt h y v ol u nteers. Ei g ht ee n s u bjects ( 9 males 
a n d 9 fe males) were r a n d o mize d. All s u bjects recei ve d t he treat me nt b ot h i n fasti n g sit uati o n 
a n d after f o o d. T he was h -o ut peri o d bet wee n t he t w o treat me nts was 8 d a ys. A d mi nistrati o n 
i n t he faste d a n d f e d state pr o d uce d si milar res ults in ter ms of mea n C ma x (sta n dar d de vi ati o n 
[ S D]) [ 5. 1 ( 3. 8) a n d 4. 4 ( 2. 9) n g/ m L, res pecti vel y], mea n A U Ct [ 1 1. 3 ( 8. 8) a n d 1 0. 2 ( 6. 0) 
n g· h/ m L, r es pecti vel y] a n d me dia n T ma x ( 1 a n d 1. 5 h o urs, res pecti vel y). I n a d diti o n, t he 
a d mi nistrati o n of Rifa xi mi n EI R wit h f o o d di d n ot affect t he uri nar y e x creti o n, w hic h 
re pres e nte d < 0. 0 2 % of t he d ose i n b ot h c o n diti o ns. T he l o w s yste mic a bs or pti o n was 
c o nfir me d b y a st u d y i n healt h y s u bj ects ( N = 9) a d mi nistere d Rifa xi mi n EI R 8 0 0 m g (sac het) 
as a si n gl e d ose ( C C R U -0 1 5 1 4).  
 
T he ver y l o w a bs or pti o n of rifa xi mi n was als o o bser ve d i n patie nts wit h acti ve C D 
( R E TI C/ 0 2/ 0 6). Ei g htee n patie nts wit h acti ve C D ( Har v e y Bra ds ha w i n de x of ≤ 7) a n d n o 
c onc o mita nt treat me nt wit h ot her a nti bi otics (fr o m t he wee k b ef ore scree ni n g), or oral a n d 
rectal ster oi ds (l ess t ha n 3 0 da ys pri or t o scree ni n g) recei ve d a si n gle oral d ose of 1 2 0 0 m g ( 3 
x 4 0 0 m g) Rifa xi mi n EI R ta blets. Rifa xi mi n pea k c o nce ntrati o n i n plas m a was reac he d o n 
a vera ge at 1. 8 h o urs. T h e C ma x ( S D) a vera ge d 1 1. 8 ( 1 0. 3) n g/ m L a n d mea n A U C0 -t ( S D) was 
4 7. 8 ( 3 0. 9) n g· h/ m L.  
 
A n o pe n -la bel st u d y w as perf or me d t o assess t he bi oa vaila bilit y of a re peat d ose of 1 2 0 0 m g 
( 3 x 4 0 0 m g) Rifa xi mi n EI R ta blets a dmi nistere d t wice dail y (t otal dail y d ose 2 4 0 0 m g) f or 7 
da ys i n 1 2 ( 1 0 e val ua bl e) acti ve C D patie nts ( R E TI C -P K/ 0 0 4/ 2 0 0 9). O n Da ys 1 a n d 7, o nl y 
t he m or ni n g d ose was a d mi nistere d. S yste mic e x p os ure t o rifa xi mi n was l o w after b ot h si n gle 
[ Cma x ( S D) = 7. 8 ( 3.5) n g/ m L; A U C 0 -t ( S D) = 3 4. 6 ( 1 9. 4) n g. h/ m L] a n d re peat d osi n g [ Cma x 
( S D) = 6. 1 ( 2. 4) n g/ m L; A U C0 -t ( S D) = 4 1. 4 ( 1 7. 4) n g. h/ m L). Stea d y-st ate was reac he d b y 
Da y 3 of m ulti ple d osi n g wit h a mi ni mal e xte nt of acc u m ulati o n ( R C = 1. 4 2). T he a m o u nt of 
rifa xi mi n ex crete d i n uri ne (c u m ulati ve uri n ar y e x creti o n ra n gi n g fr o m 0. 0 0 8 t o 0. 0 1 3 6 % of 
t he a d mi nistere d d ose) c o nfir me d t he l o w a bs or pti o n. 
 
T w o P hase 2 pil ot/ pr o of of c o nce pt st u dies ( G R A C E 0 1 a n d G R A C E 0 2), a n d a P hase 2 d ose - 
ra n ge fi n di n g st u d y ( R E TI C/ 0 3/ 0 6) ha v e bee n c o m plete d; a sac het d os a ge f or m of Rifa xi mi n  

P a ge 2 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
EI R w as use d i n G R A C E 0 1 a n d 0 2, a n d t he prese nt f or m ulati o n was use d i n R E TI C/ 0 3/ 0 6. 
G R A C E 0 1 was a place b o c o ntr olle d st u d y i n 8 3 mil d t o m o derate C D patie nts t hat e val uate d 
Rifa xi mi n E I R 8 0 0 m g Q D a n d BI D vers us place b o; G R A C E 0 2 was a n u n c o ntr olle d st u d y 
t hat e val uate d Rifa xi mi n EI R 8 0 0 m g Q D a n d BI D. Efficac y was e val uat e d pri maril y b y t he 
rate of cli nical re missi o n defi ne d as C D AI sc ore <  1 5 0 p oi nts after 1 2 wee ks of t hera p y.  
Gi ve n t he s mall n u m ber of patie nts i n b ot h st u dies, a n d t he u nc o ntr olle d d esi g n of G R A C E  
0 2, neit her st u d y m et t he pri mar y e n d p oi nt; data di d s u p p ort p ote ntial efficac y i n t he 8 0 0 m g 
BI D re gi me n.  
 
T he c urr e nt ta blet f or m ul ati o n of Rifa xi mi n EI R w as e val uate d i n a  P hase II d ose ra n ge 
fi n di n g st u d y i n 4 0 2 patie nts wit h a n ac ute flare of C D ( R E TI C/ 0 3/ 0 6). Patie nts wit h a C D AI 
bet wee n 2 2 0 a n d 4 0 0 p oi nts were r a n d o mize d t o 4 treat me nt gr o u ps: Rifa xi mi n EI R 4 0 0 m g 
t wice a da y, Rif a xi mi n EI R 8 0 0 m g BI D, Rifa xi mi n EI R 1 2 00 m g BI D or place b o BI D f or 1 2 
wee ks. Patie nts w h o ac hie ve d cli nical re missi o n at t he e n d of t he treat me nt peri o d, defi ne d as 
C D AI s c ore < 1 5 0 p oi nts, were a d mitte d t o a 3 -m o nt h f oll o w -u p p hase. Patie nts were all o we d 
t o c o nti n ue sta ble d oses of oral 5-A S A, merca pt o p uri ne, azat hi o pri ne, a n d/ or met h otre x ate as 
c o nc o mita nt t hera pies t hr o u g h o ut t he st u d y ( u p t o 1 2 wee ks), w hile t h e use of a nti bi otics a n d 
oral, i ntra ve n o us, a n d rectal ster oi ds was n ot per mitte d.  
 
As a d d -o n t her a p y ( 8 3 % of e nr olle d patie nts w ere treate d wit h sta ble d oses of 5 -A S A a n d/ or 
met h otre x ate, azat hi o pri ne a n d mer ca pt o p uri ne), Rifa xi mi n EI R 8 0 0 m g t wi ce a d a y was 
statisticall y s u peri or t o pl ace b o i n i n d uci n g cli nical re missi o n ( C D AI <  1 5 0 p oi nts) after 1 2 
wee ks of t hera p y ( p = 0. 0 0 7) a n d mai ntai ni n g re missi o n f or t hree m o nt hs aft er Rifa xi mi n EI R 
was st o p pe d ( p = 0. 0 2).  
 
Hea dac he ( 6 % of patie nts), C D s y m pt o ms ( 6 % of patie nts), na usea ( 4 % of patie nts), 
flat ule nce ( 2 % of p atie nts), nas o p har y n gitis ( 2 % of patie nts), a n d fe ver ( 2 % of patie nts) were 
t he m ost c o m m o nl y re p orte d dr u g-relate d A Es. O ne case of C. difficile i nfecti o n was 
dia g n ose d 2 0 da ys after t he e n d of t he treat me nt p eri o d i n a patie nt w h o recei ve d Rifa xi mi n 
EI R 8 0 0 m g t wice d ail y. A s u d de n deat h d uri n g t h e f oll o w -u p peri o d, ca use d b y ac ute 
massi ve bilateral p ul m o nar y e de m a, was re p orte d i n a patie nt wit h pree xisti n g c o n c o mita nt 
arr h yt h mia. T he d eat h w as assesse d as u nli kel y relate d t o t he st u d y dr u g. N o cli nicall y 
si g nifica nt c ha n ges i n t he res ults of safet y la b orat or y tests w ere o bs er ve d i n a n y st u d y gr o u p. 
 
I n a d diti o n t o t he st u dies n ote d a b o ve f or Rifa xi mi n EI R, rifa xi mi n has bee n st u die d i n 
a p pr o xi matel y 5 0 0 0 s u bjects i n m ulti ple cli nical st u dies i n irrita ble b o wel disease (I B S) ( N = 
1 1 0 3); a n d i n ot her t her a pe utic areas i ncl u di n g treat me nt of tra velers’ diarr hea ( N = 5 9 3), 
tra velers’ diarr h ea pr o p h yl a xis ( N = 8 2 0), ac ute h e patic e n ce p hal o pat h y ( N = 1 5 2), a n d 
rec urre nce of h e patic e n ce p hal o pat h y ( N = 3 4 8). I n a d diti o n, t here is o ver 2 0 years of p ost - 
mar keti n g e x perie nce wit h t he dr u g.  

Page 23 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
1.5 
Study Rationale 
 
Crohn’s disease is a chronic, relapsing, remitting, systemic disease which may result in 
transmural inflammation of the gastrointestinal tract. Bacteria might be involved in the 
development and persistence of inflammation in patients with CD. Rifaximin has been shown 
to induce in enteroaggregative and enterotoxigenic E. coli a loss of virulence factors such as 
enterotoxins, surface adhesion factors and MMP-9, and changes in epithelial cell physiology 
associated with changes in bacterial attachment/internalization. Rifaximin DR is an oral, 
minimally absorbed, non-systemic, antimicrobial agent that exerts its effects on bacteria in the 
intestinal lumen. By decreasing the triggers of immune activation as well as enteric 
inflammatory response, rifaximin may reduce the uncontrolled immune response to enteric 
bacteria, without the safety concerns associated with systemic broad spectrum antibiotics.  In 
a large Phase 2 dose-ranging study, a Rifaximin EIR regimen of 800 mg twice daily for 12 
weeks induced remission in patients with mild to moderate CD, and was generally well 
tolerated.  Given the need for safe and effective alternatives to immunomodulator and 
biologic therapy for CD in patients with mild to moderate disease, this Phase 3 trial will be 
conducted to assess the viability of Rifaximin DR for the treatment of CD. 
 
Rifaximin is a semisynthetic antibiotic of the rifamycin class. Rifaximin is, however, unique 
in this class due to its gut-targeted activity and minimal systemic absorption. In vitro, 
rifaximin binds to the beta subunit of the bacterial DNA-dependent RNA polymerase to 
inhibit bacterial RNA synthesis, resulting in its classification as a broad spectrum antibiotic. 
However, in vivo, rifaximin does not appear to affect to a clinically significant extent the 
numbers or diversity of the endogenous enteric bacteria at therapeutic doses that have been 
tested. 
The clinical experience with rifaximin is extensive, having been commercially available since 
1987 following its initial approval in Italy. Today rifaximin is approved and in use in over 35 
countries for a number of gastrointestinal (GI) indications which are responsive to its gut- 
targeted effects. There are more than 800 publications involving rifaximin in the scientific 
literature, including approximately 100 preclinical and approximately 200 clinical study 
reports. Rifaximin has also been extensively studied in controlled clinical studies with a total 
of approximately 5,000 subjects enrolled. Two clinical development programs have resulted 
in approvals in many of the markets in North America and Europe and include treatment of 
travelers’ diarrhea and the prevention of overt hepatic encephalopathy recurrence. 
Additionally, there is positive data from prophylaxis of travelers’ diarrhea (PRO3 study, Salix 
data on file) and C. difficile infection studies (Study RFCL3001, Salix data on file). Rifaximin 
possesses a strong safety record and adverse events are well-characterized, generally mild, 
and similar to placebo. 
Crohn’s disease is the fourth major development program that has been undertaken with 
rifaximin. Rifaximin DR has been developed in order to provide a formulation of rifaximin 

Page 24 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
that exerts its targeted effects on bacteria throughout the small and large intestinal lumens. By 
decreasing the triggers of immune activation as well as enteric inflammatory response, 
rifaximin may reduce the uncontrolled immune response to enteric bacteria, without the safety 
concerns associated with systemic broad spectrum antibiotics.  The rationale for Rifaximin 
DR in the treatment of CD is based on its three plausible mechanisms of action. Rifaximin 
affects gut bacteria and reduces bacterial products that negatively affect the host. It may also 
up-regulate gut detoxification mechanisms and decrease the inflammatory response 
mechanisms of the host to bacterial products. Bacteria have been purported to be involved in 
the development and persistence of inflammation in patients with CD. Finally, rifaximin 
impacts both the bacterial and host response and the bacteria host interface. It has been shown 
to induce in enteroaggregative and enterotoxigenic E. coli a loss of virulence factors such as 
enterotoxins, surface adhesion factors and MMP-9, and changes in epithelial cell physiology 
associated with changes in bacterial attachment/internalization. 
Rifaximin DR presents a unique paradigm in the treatment of mild to moderate CD. The 
proposed dosing for Rifaximin DR will remain constant from the induction phase through the 
long term treatment phase with no reduction in dose required. Unlike biologic or 
corticosteroid therapy, there is no known suppression of the host immune system associated 
with the use of Rifaximin DR. In a large Phase 2 dose-ranging study, the delayed release 
formulation of rifaximin (also called Rifaximin EIR) 800 mg, taken twice daily for 12 weeks 
induced remission in patients with mild to moderate CD, and was generally well tolerated. 
1.6 
Primary Endpoint Development for the United States 
 
The primary endpoint for this study was developed in collaboration with the United States 
(US) Food and Drug Administration (FDA). In discussions with Salix, the FDA has indicated 
that use of the CDAI as the primary endpoint in CD trials will no longer be acceptable. It is 
now recommended that a co-primary endpoint for CD studies, as defined during the 
Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT II) 
meeting, be used to assess clinically meaningful outcomes for both symptoms and changes in 
the appearance of the inflamed ileocolonic mucosa. 
 
After further discussions with the FDA and several key opinion leaders regarding the best 
way to meet these recommendations, Salix developed responder criteria based on the 
validated Short CDAI (34) and data from a previous CD study conducted with rifaximin 
(Phase 2 dose-range finding study RETIC/03/06). Symptoms included in the short CDAI 
were “abdominal pain” and “diarrhea frequency”. 
 
Assuming that a CDAI score of < 150 points always reflects the true disease activity of 
clinical remission in Crohn’s disease, Salix developed a symptom index for Crohn’s disease 
to assess a clinically significant “symptomatic response.” The following points were used to 
assess symptomatic activity in Crohn’s disease when a CDAI score of < 150 points is 
considered the “gold standard”: 

P a ge 2 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
 
• Se nsiti vit y e v al uates h o w well a test is at detecti n g a p ositi ve re s p o nse, i.e., s y m pt o m 
re missi o n. 
• S pecificit y esti mates h o w li kel y s u bjects wit h o ut cli nical re missi o n (i.e., C D AI s c ore of  ≥ 
1 5 0 p oi nts) ca n be c orrectl y r ule d o ut bas e d o n t he  test. 
• Acc ur ac y meas ures h o w c orrect a dia g n ostic test i de ntifies a n d e x cl u des a gi ve n  c o n diti o n 
(e. g., C D AI < 1 5 0 p oi nts).  
Usi n g t he p oi nts o utli ne d a b o ve, t he le v el of t he s y m pt o m meas ures (li q ui d/ ver y s oft st o ols 
a n d a b d o mi nal pai n) w er e deter mi ne d t o be s uffici e nt t o defi ne s y m pt o matic re missi o n.  
 
A n a nal ysis of t he data  fr o m t he P hase 2 C D st u d y c o n d ucte d wit h rifa xi mi n was perf or me d 
i n or der t o deter mi ne li q ui d/ ver y s oft st o ol c o u nts f or s u bjects w h o ha d cli nical re missi o n a n d 
s u bjects w h o di d n ot ac hi e ve cli nical re missi o n base d o n a C D AI sc ore of < 1 5 0 p oi nts. T he 
recei v er o perati n g c haracteristics ( R O C) c ur ve a nal ysis f or t he dia g n osis of cli nical re missi o n 
b y li q ui d/ ver y s oft st o ol c o u nts s h o we d a n area u n der t he R O C c ur v e val u e of 0. 7 9. T he area 
u n der t he R O C c ur v e val ue i n dicate d t hat li q ui d/ ver y s oft st o ol c o u nt h a d g o o d acc urac y i n 
pre dicti n g cli nical re missi o n base d o n a C D AI s c ore of < 1 5 0 p oi nts. S u bse q ue ntl y, t he 
n u m ber of li q ui d/ ver y s oft st o ols was use d t o i de ntif y t he c ut -p oi nts t hat res ulte d i n t he 
o pti mal bala nce of s e nsiti vit y, s p ecificit y a n d acc urac y f or pre di cti n g a C D AI sc ore of < 1 5 0 
p oi nts. T he data i n dicate d a c ut p oi nt of 1 0 as o pti mal. T h us, f or li q ui d/ ver y s oft st o ols, 
s u bjects wit h a wee kl y t otal of 1 0 or less will be cl assifie d as res p o n d ers. 
 
A d diti o nal a nal ysis pr o d uce d a r es p o n der defi niti o n  f or a b d o mi nal pai n. A res p o n der f or 
a b d o mi nal pai n is base d o n a dail y rati n g (sc ore) of ≤1.  
 
A res p o n der, base d o n t h e Sali x e n d p oi nt, will meet t he criteria f or li q ui d/ ver y s oft st o ols 
A N D a b d o mi nal pai n i n a gi v e n wee k.  
 
T he Si m ple E n d osc o pic Sc ore f or  Cr o h n's Dis eas e ( S E S -C D) was c h os e n as t he vali date d 
meas ure me nt of e n d osc o pic a p peara nce beca use it c orrelate d w ell wit h t he m ore c o m ple x 
Cr o h n's Disease E n d osc o pic I n d e x of Se verit y ( C D EI S). W hile t he C D EI S has bee n use d f or 
e n d osc o pic sc ori n g of C D les i o ns f or 2 0 years, it is n ot c o m m o nl y us e d i n cli nical practice 
beca use it is c o m plicate d a n d ti me -c o ns u mi n g ( 3 5). Sali x has deter mi ne d t hat a decreas e i n 
t he S E S-C D sc ore of at l east 3 p oi nts is cli nicall y mea ni n gf ul base d o n t he a nal ysis of t he 
S O NI C tri al d ata i n Cr o h n’s disease ( 3 6).  T heir a nal ysis i ncl u de d a n e val u ati o n of 
e n d osc o pic r es p o nse i n p atie nts wit h baseli ne S E S -C D sc ores of ≥ 7 , a n d c o ncl u de d t hat 
e n d osc o pic r es p o nse ( d efi ne d as a decrease fr o m baseli ne i n S E S -C D sc ore of at least 5 0 % 
after 2 6 w ee ks of treat me nt) c o ul d pre dict patie nts m ost li kel y t o ac hie ve c ortic oster oi d-free 
cli nical re missi o n after 5 0 wee ks of treat me nt. T h e pr o p ose d 3 -p oi nt c h a n ge i n S E S -C D i n 
t his st u d y is c o nsiste nt wit h t he res ults of t he S O NI C a n al ysis i n pre dicti n g c ortic oster oi d -free 
cli nical re missi o n a n d reflects a n a p pr o xi mate 5 0 % re d ucti o n i n t he mi ni m u m  S E S -C D  

P a ge 2 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
baseli ne sc or e at st u d y e ntr y of 7. W hereas e n d osc o pic res p o nse, d efi ne d as a re d ucti o n i n t he 
S E S -C D sc ore of at least 3 p oi nts, reflect s a cli nicall y si g nifica nt i m pr o ve me nt i n ile oc ol o nic 
i nfla m mati o n, t here ma y still be i nfla m mati o n prese nt. E n d osc o pic re missi o n has bee n 
defi ne d as a n a bse n ce or near a bs e nce of e n d os c o picall y e vi de nt i nfla m mati o n as reflect e d i n 
S E S -C D sc ore of 0 t o 2 ( 3 7).  
 
I n or der t o f ull y ass ess f or t he prese n ce of ile oc ol o nic Cr o h n’s disease a n d calc ulate a n 
acc ur ate S E S -C D sc or e, t he e n d osc o pist m ust atte m pt t o i nt u bate a n d vis ualize t he ter mi nal 
ile u m i n or der t o deter mi ne prese n ce a n d e xte nt of disease d uri n g eac h ile oc ol o n osc o p y. T o 
re d uce t h e p ote ntial f or bias or varia bilit y i n e n d os c o p y s c ori n g, bli n de d ce ntral rea di n g will 
be utilize d t o deter mi ne t he S E S -C D sc ores f or all ile oc ol o n osc o pies o btai n e d d uri n g t he 
st u d y. As s uc h, e ver y eff ort m ust be ma de at eac h pr oced ure t o f ull y vis u alize eac h se g me nt 
of t he ter mi nal ile u m a n d c ol o n t o facilitate ce ntral rea di n g of t he rec or de d pr oce d ures. T he 
rate of wit h dr a wal of t h e c ol o n osc o pe d uri n g t he pr oce d ure s h o ul d als o be s ufficie ntl y sl o w as 
t o all o w f or a de q u ate vis ualizati o n a n d sc ori n g of eac h se g m e nt i n t he vi de o rec or di n g b y a 
ce ntral r ea d er. Strict ures t hat d o n ot per mit f urt her passa ge of t h e c ol o n osc o pe s h o ul d be 
a n n otate d as  s u c h. 
 
T he c o -pri mar y efficac y e n d p oi nts f or i n d ucti o n of cli nical re missi o n wit h  e n d osc o p ic 
res p o nse are defi ne d b y  
 
• Cli nical  s y m pt o m re missi o n defi ne d  b y  ( 1) t he t otal n u m ber  of  li q ui d/ ver y s oft st o ols f or 
t he 7 da ys pri or t o t he Wee k 1 6 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1(fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 1 6  visit.  
• E n d osc o pic res p o ns e defi ne d as a ≥ 3 -p oi nt decrease i n t he S E S -C D fr o m baseli ne t o t he 
S E S -C D sc ore o btai ne d bet wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D sc ores will be 
calc ulate d fr o m  ce ntrall y-rea d di gital  vi de o  of  ile o c ol o n osc o pies perf or me d  at baseli ne  a n d 
bet wee n Wee k 1 6 a n d Wee k  1 7.  
Si milarl y,  t h ere will  be  t w o ke y  c o -sec o n d ar y e n d p oi nts  of  efficac y assesse d  d uri n g  t he L o n g 
Ter m Treat me nt  P hase.  
 
• Cli nical s y m pt o m r e missi o n defi ne d b y ( 1) t he t ot al n u m ber of li q ui d/ ver y s oft st o ols f or 
t he 7 da ys pri or t o t he Wee k 5 2 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1(fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 5 2  visit.  
• E n d osc o pic re missi o n defi ne d as a S E S -C D sc ore  of ≤ 2 at Wee k 5 2. S E S -C D sc ores will 
be calc ul ate d fr o m ce ntrall y -r ea d di gital vi de o of ile oc ol o n osc o pies perf or me d at Wee k 5 2.  
I n t he P h ase 3 st u dies Sali x is c o n d ucti n g, t hese e n d p oi nts will be e val uate d f or 
res p o nsi ve ness (i.e., d e m o nstrate t he a bility t o det ect cli nicall y mea ni n gf ul c ha n ge i n diseas e 
acti vit y i n de x es of C D, f or e x a m ple f ull C D AI) a n d vali dit y (i.e., de m o nstrate c orrelati o ns  

Page 27 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
with other measures of disease activity indexes of CD). These attributes are consistent with 
recommendations in the published FDA Guidance for Industry on the use of patient-reported 
outcomes (2009) (38). 

P a ge 2 8  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
2. 0  
O B J E C TI V E S A N D  E N D P OI N T S  
 
2. 1  
O bjecti ves  
 
2. 1. 1  
Pri m ar y  O bjecti ve  
 
T o deter mi ne t h e efficac y of Rifa xi mi n D R 8 0 0 m g BI D vs. place b o o n t he i n d ucti o n of 
cli nical re missi o n a n d e n d osc o pic res p o nse f oll o wi n g 1 6 wee ks of treat me nt i n s u bjects 
prese nti n g wit h acti ve m o derate Cr o h n’s  diseas e.  
2. 1. 2  
Sec o n d ar y O bjecti ves  
 
A ke y sec o n d a r y o bjecti ve is t o e val uate cli nical a n d e n d osc o pic re missi o n f oll o wi n g a n 
a d diti o nal 3 6 -wee k L o n g Ter m Treat me nt P hase of Rifa xi mi n D R 8 0 0 m g BI D vs. place b o.  
T he sec o n d ar y o bjecti ves of t his st u d y are t he f oll o wi n g:  
• Assess t he safet y of Rifa xi mi n D R f oll o wi n g a 1 6 -wee k i n d ucti o n, a n d a n a d diti o nal 3 6 - 
wee k L o n g T er m Treat me nt P hase (i.e., u p t o 5 2 wee ks of treat me nt f or eli gi ble  s u bjects). 
• Assess t he p o p ulati o n p har mac o ki netics of Rifa xi mi n  D R.  
• C haracterize t he gastr oi ntesti nal micr o bi ota  fr o m st o ol sa m ples, a n d a nti bi otic resista nce 
fr o m bacteria c ult ure d fr o m st o ol sa m ples bef ore a n d after treat me nt wit h Rifa xi mi n D R.  
• E val uate t he effects of Rifa xi mi n D R treat me nt o n i n dices of healt h  o utc o m es.  
• Assess t he effects of Rifa xi mi n D R treat me n t o n bi ol o gical (i nfl a m mat or y) mar kers of 
disease.  
2. 2  
E n d p oi nts  
 
2. 2. 1  
Pri m ar y Effic ac y E n d p oi nts  
 
T here will be t w o c o -pri mar y m eas ures of efficac y f or I n d ucti o n of Cli nical Re missi o n a n d 
E n d osc o pic Res p o nse. T he first c o -pri mar y e n d p oi nt is:  
 
• Cli nical  s y m pt o m re missi o n defi ne d  b y  ( 1) t he t otal n u m ber  of  li q ui d/ ver y s oft st o ols f or 
t he 7 da ys pri or t o t he Wee k 1 6 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1(fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 1 6  visit.  
T he sec o n d c o -pri mar y e n d p oi nt is:  
 
• E n d osc o pic res p o ns e defi ne d as a ≥ 3 -p oi nt decrease i n t he S E S -C D fr o m baseli ne t o t he 
S E S -C D sc ore o btai ne d bet wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D sc ores will be 
calc ulate d fr o m  ce ntrall y-rea d di gital  vi de o  of  ile o c ol o n osc o pies perf or me d  at baseli ne  a n d 
bet wee n Wee k 1 6 a n d Wee k  1 7.  

P a ge 2 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
F or t he d ail y st o ol data, t he n u m ber of d ail y li q ui d/ ver y s oft st o ols wit h a c o nsiste nc y of a 
Brist ol St o ol F or m Scale [ B S F S] sc ore of T y pe 6 or T y p e 7 will be assess e d usi n g t he 
i nf or mati o n rec or de d b y t he s u bject via a n el ectr o nic diar y s yste m. T he n u m ber of 
li q ui d/ ver y s oft st o ols i n a gi v e n wee k will be cal c ulate d as f oll o ws: 
( N u m ber of li q ui d/ ver y s oft st o ols d uri n g t hat wee k ÷ N u m ber of da ys wit h n o n- 
missi n g assess me nts d uri n g t hat w ee k) × 7  
 
2. 2. 2  
Ke y Sec o n d ar y E n d p oi nts  
 
T he ke y sec o n dar y e n d p oi nt is cli nical a n d e n d osc o pic re missi o n. T w o ke y c o -sec o n d ar y 
e n d p oi nts of efficac y will assess t his e n d p oi nt d uri n g t he L o n g T er m Treat me nt P hase. T he 
first is: 
 
• Cli nic al s y m pt o m re missi o n defi ne d b y ( 1) t he t otal n u m ber of li q ui d/ ver y s oft st o ols f or 
t he 7 da ys pri or t o t he Wee k 5 2 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1(fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 5 2  visit.  
T he sec o n d is:  
 
• E n d osc o pic re missi o n defi ne d as a S E S -C D sc ore of ≤ 2 at Wee k 5 2. S E S -C D sc ores will 
be calc ul ate d fr o m ce ntrall y -r ea d di gital vi de o of ile oc ol o n osc o pies perf or me d at Wee k 5 2.  
2. 2. 3  
Sec o n d ar y Effic ac y  E n d p oi nts  
 
• I n d u cti o n of cli nical r e missi o n defi ne d as a C D AI Sc ore of less t ha n 1 5 0 p oi nts  at 
Wee k  1 6.  
• Cli nical s y m pt o m r e missi o n o ver ti me: T he t otal n u m ber of li q ui d/ ver y s oft st o ols f or t he 
7 da ys pri or t o eac h cli nic visit bei n g ≤ 1 0; A N D ( 2) a n a b d o mi nal pai n rati n g of ≤ 1 o n 
eac h d a y f or t he l ast 7 da ys pri or t o eac h cli nic visit i n ≥ 8 0 % of t he st u d y visits d uri n g  the 
5 2 -Wee k Treat me nt Peri o d, i ncl u di n g Wee k  5 2.  
• Ti me u ntil d ura ble res p o nse (see Secti o n 8. 6. 2) t o t he li q ui d/ ver y s oft st o ol c o m p o ne nt  of 
t he c o-pri mar y e n d p oi nt d uri n g t he 5 2 -Wee k Treat me nt  Peri o d.  
• Ti me u ntil d ura ble res p o nse ( See Secti o n 8. 6. 2) t o t he a b d o mi nal pai n c o m p o ne nt of  t he 
c o-pri mar y e n d p oi nt d uri n g t he 5 2 -Wee k Treat me nt  Peri o d.  
• Pr o p orti o n of s u bjects wit h res p o nse t o t he a b d o mi nal p ai n c o m p o ne nt of t he c o -pri mar y 
e n d p oi nt at p ost -baseli ne ti me  p oi nts.  
• Pr o p orti o n of s u bjects wit h res p o nse t o t he li q ui d/ ver y s oft st o ol c o m p o ne nt of t he  c o - 
pri mar y e n d p oi nt at p ost -baseli ne ti me  p oi nts.  
• C ha n ge fr o m bas eli ne i n S E S -C D sc ore at Wee k 1 6 a nd Wee k  5 2.  
• Pr o p orti o n of s u bjects wit h S E S -C D sc ore of 0 at Wee k  5 2.  

P a ge 3 0  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Pr o p orti o n of s u bjects w h o ac hie ve cli nical re missi o n b y t he C D AI e n d p oi nt at  p ost - 
baseli ne ti me  p oi nts.  
• Ti me t o l oss of C D AI res p o nse defi ne d b y a C D AI sc ore of ≥ 1 5 0 p oi nts d uri n g t he Long 
Ter m Treat me nt  P hase.  
• Perce nta ge of s u bjects w h o ac hie ve cli nical res p o nse at p ost -baseli ne ti me p oi nts. Cli nical 
res p o nse is defi n e d as a r e d ucti o n of at least 1 0 0 p oi nts fr o m t he baseli ne C D AI  sc ore. 
• Ti me t o cli nical re missi o n base d o n a b d o mi nal pai n a n d li q ui d st o ol c o m p o ne nts of t he c o- 
pri mar y  e n d p oi nts.  
• Ti me t o cli nical re missi o n base d o n C D AI <  1 5 0.  
• C ha n ge fr o m bas eli ne i n i n dices of healt h o utc o m es (I nfla m mat o r y B o w el Disease 
Q uesti o n naire [I B D Q], W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q u esti o n naire  f or 
Cr o h n's Disease [ W P AI -C D]) at p ost -baseli ne ti me  p oi nts.  
• C ha n ge fr o m bas eli ne i n mar kers of i nfl a m mati o n (e. g. C R P, i nterle u ki ns, c yt o ki nes,  fecal 
cal pr otect i n) at p ost-baseli ne ti me  p oi nts.  
2. 2. 4  
S af et y  E n d p oi nts  
 
• I n ci de nce, i nte nsit y, a n d t y pes of a d vers e e v e nts ( A Es). 
• C ha n ges fr o m bas eli ne i n t he la b orat or y p ara met ers ( he mat ol o g y, cli nical  c h e mistr y, 
uri nal ysis).  
• C ha n ge fr o m bas eli ne i n vital si g n  meas ure me nts.  
2. 2. 5  
E x pl or at or y Assess me nts  
E x pl orat or y assess me nts will i ncl u de:  
• C haracterizati o n of st o ol micr o bi ota at baseli ne a n d after 1 6 a n d 5 2 wee ks of  treat me nt. 
 Baseli ne a n d p ost -treat me nt bacteri al D N A is olate d fr o m st o ol f or 1 6 S r R N A ge ne 
a m plificati o n.  
 Descri pti ve c h aracterizati o n of bacteri a i n st o ol  b y:  
• 
Is olati o n a n d i d e ntificati o n of selecte d Gra m-n e gati ve a n d  Gra m -p ositi ve 
bacteria.  
• 
Resista nce t o select e d a nti bi otics, i ncl u di n g rifa xi mi n a n d  rifa m pi n. 
• Ge n o mic pr ofili n g of pr e g na n e X rece pt or ( P X R) i n  bl o o d.  
• P o p ulati o n p har mac o ki netics of  rifa xi mi n. 

P a ge 3 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
3. 0  
I N V E S TI G A TI O N A L P L A N  
 
3. 1  
O ver vie w of St u d y  Desi g n  
 
R E C D 3 1 2 5 is a d o u ble -bli n d, place b o -c o ntr olle d, parallel -gr o u p, m ultice nt er, m ultire gi o nal, 
5 2 -wee k st u d y t o assess t he effi cac y a n d safet y of Rifa xi mi n D R ta blets f or t he i n d ucti o n of 
cli nical re missi o n a n d e n d osc o pic res p o nse at 1 6 wee ks f oll o we d b y cli nical a n d e n d osc o pic 
re missi o n after 5 2 w ee ks of c o nti n u o us t hera p y i n s u bjects wit h acti ve m o d erate Cr o h n’s 
disease.  S u bjects wit h acti ve, m o derate disease defi ne d b y a C D AI sc ore of ≥ 2 2 0 a n d ≤ 4 5 0 
p oi nts at scree ni n g, a n d e vi de nce of acti ve ile oc ol o nic Cr o h n’s disease d efi ne d b y a mi ni m u m 
S E S -C D of 7 deter mi ne d d uri n g b aseli ne ile oc ol o n osc o p y will be eli gi ble f or t he st u d y. 
Eli gi ble s u bjects will c o m plete a 2 - t o 3-w ee k Scree ni n g Peri o d, a 5 2 -wee k Treat me nt Peri o d 
c o nsisti n g of a 1 6 -wee k I n d ucti o n P hase a n d 3 6 -Wee k L o n g T er m Treat me nt P hase, a n d a 2 - 
wee k F oll o w -u p Peri o d. S u bjects w h o s uccessf ull y c o m plet e t he 2 - t o 3-w ee k Scree ni n g 
Peri o d a n d q ualif y base d o n C D AI a n d S E S -C D sc ores will e nter t he 5 2 -wee k Treat me nt 
Peri o d of t he trial a n d will be ra n d o mize d i n a 1: 1 all ocati o n t o Rifa xi mi n D R 8 0 0 m g BI D or 
place b o. Ra n d o mize d s u bjects will ha ve s u bse q ue nt ile oc ol o n osc o pies c o n d ucte d at t he e n d 
of t he I n d ucti o n P hase ( b et wee n Wee ks 1 6 a n d 1 7), a n d f oll o wi n g c o m pleti o n of t he 3 6 -wee k 
L o n g T er m Treat me nt P hase ( Wee k 5 2) t o assess t he effects of treat me nt o n t he de gree of 
m uc osal heali n g. Assess me nts of efficac y a n d safet y will be p erf or m e d d uri n g cli nic visits at 
Wee ks 0 ( baseli ne), 2, 4, 8, 1 2, a n d 1 6; t he n e ver y f o ur wee ks t hr o u g h Wee k 5 2. All s u bjects 
will c o m plete a 2 -wee k (st u d y dr u g free) F oll o w -u p Peri o d f oll o wi n g c o m pleti o n of t he 5 2 - 
wee k Tr eat me nt Peri o d, a n d will  ret ur n t o t he cli nic f or fi nal ass ess me nts ( E n d-of -St u d y 
[ E O S] visit; Wee k 5 4). See Fi g ur e 1. 

P a ge 3 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
Fi g ure 1 Desi g n Sc he m atic  
 
 
3. 2  
R ati o n ale f or Pr o p ose d St u d y  Desi g n  
 
T he desi g n of St u d y R E C D 3 1 2 5 i ncl u di n g t he 5 2 -wee k Treat me nt Peri o d assessi n g b ot h 
i n d ucti o n of cli nical re missi o n wit h e n d osc o pic res p o nse at Wee k 1 6 a n d cli nical re missi o n 
wit h e n d osc o pic re missi o n at Wee k 5 2, t he c o -pri mar y e n d p oi nts selecte d f or i n d ucti o n a n d 
t he c o-meas ures of efficac y f or t he L o n g T er m Treat me nt p has e are c o nsiste nt wit h re g ulat or y 
g ui da n ce ( F D A m eeti n g a d vice/ mi n utes wit h Sali x/ Alfa Wasser ma n n), a n d t he cli nical 
ma na ge me nt of p atie nts wit h Cr o h n’s disease.  
 
E n d p oi nt de vel o p me nt is pr o vi de d i n Secti o n 1. 6.  
 
3. 3  
Tre at me nt Assi g n me nt/ R a n d o miz ati o n  
 
S u bjects  w h o s uccessf ull y c o m plet e t he Scree ni n g Peri o d will e nter t he Treat me nt Peri o d a n d 
will be ra n d o mize d i n a 1: 1 all ocati o n t o o ne of t w o treat me nt gr o u ps f or t h e d urati o n of t he 
st u d y as assi g ne d b y t h e mea ns of ce ntralize d electr o nic ra n d o mizati o n s yst e m. 
Ra n d o mizati o n will be stratifie d b y st u d y ce nter wit hi n a c o u ntr y. Treat me nt gr o u ps are as 
f oll o ws: 
• Treat me nt  A:  
Rifa xi mi n D R Ta blets 8 0 0 m g  BI D  
• Treat me nt  B:  
Place b o  BI D  

Page 33 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
 
3.4 
Procedures for Breaking the Blind 
 
Only in the case of an emergency, when knowledge of the study drug is essential for the 
clinical management or welfare of the subject, will the investigator be allowed to unblind a 
subject’s treatment assignment. To discuss breaking of the blind or to break the blind, please 
contact the study manager at Salix Pharmaceuticals, Inc. by using the following contact 
information: 
 
Clinical Project Manager 
Rifaximin DR RECD3125 Study 
Salix Pharmaceuticals, Inc. 
8510 Colonnade Center Drive 
Raleigh, NC 27615 
 
 
For sites outside the USA and Canada: 
See your Study Reference Manual for your country specific 
information. 
 
 
If the investigator breaks the blind for an individual subject, the reason must be recorded on 
the CRF and the subject will be removed from the study. 

P a ge 3 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
4. 0  
S E L E C TI O N A N D WI T H D R A W A L O F  S U B J E C T S  
 
4. 1  
I ncl usi o n Criteri a  
 
A s u bject will be eli gi ble f or i ncl usi o n i n t his st u d y if he/s h e meets all of t h e f oll o wi n g 
criteria:  
 
1.  
S u bject is ≥ 1 8 years of a ge at  Scree ni n g.  
2.  
S u bject is male or  f e male. 
Fe males of c hil d beari n g (re pr o d u cti ve) p ote ntial m ust ha ve a ne gati ve s er u m pre g n a nc y 
test at scree ni n g a n d a gr ee t o use a n acce pt a ble met h o d of c o ntrace pti o n t hr o u g h o ut 
t heir partici pati o n i n t he st u d y. Acce pta ble m et h o ds of c o ntrace pti o n i ncl u de d o u ble 
barrier m et h o ds (c o n d o m wit h s per mici dal jell y or a dia p hra g m wit h s per mi ci de), 
h or m o nal met h o ds (e. g., oral c o ntrace pti ves, pat c hes or me dr o x y pr o gester o ne acetate), 
or a n i ntra uteri n e de vice (I U D) wit h a d oc u me nte d fail ure rate o f less t ha n 1 % per year. 
A bsti ne nce or p art ner(s) wit h a vasect o m y ma y be c o nsi dere d a n acce pta bl e met h o d of 
c o ntrace pti o n at t he discr eti o n of t he i n vesti gat or.  
N O T E: Fe m ales w h o ha v e bee n s ur gi call y sterilize d (e. g., h ysterect o m y) or w h o are 
p ost me n o pa us al (t otal cessati o n of me nses f or > 1 year) will n ot be c o nsi dere d “fe males 
of c hil d beari n g p ote ntial ”.  
3.  
S u bject has m o derate, n o n -fist ulizi n g Cr o h n’s disease i n t he ile u m a n d/ or c ol o n as 
defi ne d b y a C D AI sc or e of ≥ 2 2 0 a n d ≤ 4 5 0 p oi nts pri or t o ra n d o mizat i o n; a n d a S E S - 
C D sc ore of ≥7. T h e S E S -C D sc ore will be calc ulate d usi n g t he bas eli ne 
ile oc ol o n osc o p y p erf or m e d d uri n g t he Scree ni n g Peri o d.  
N O T E: E n d osc o pists fr o m t he Ce ntral E n d osc o p y La b orat or y will deter mi ne w het her 
t he s u bject meets t he S E S-C D i ncl u si o n criteri o n. E n d osc o pists perf or mi n g t he 
pr oce d ur es s h o ul d e ns ure t hat all areas of t he c ol o n, i ncl u di n g t he ter mi nal ile u m, are 
a de q uatel y vis ualize d as t o e ns ure t hat a ce ntral rea der ca n ma ke a deter mi nati o n of t he 
S E S -C D sc ore base d o n t he vi de o rec or di n g of t he pr oce d ure. Strict ures t hat d o n ot 
per mit f urt her p assa ge of t he c ol o n osc o pe s h o ul d be a n n otate d as s uc h.  
4.  
D uri n g t h e Scree ni n g Peri o d, t he s u bject has t he f oll o wi n g a vera ge d ail y s c ores  f or 
a b d o mi nal pai n a n d a v er a ge n u m ber of li q ui d/ ver y s oft  st o ols : 
• A n a ver a ge dail y sc ore of > 1. 5 f or a b d o mi nal pai n (fr o m C D AI It e m 2);  a n d 
• A n a ver a ge dail y c o u nt of > 1. 5 f or li q ui d/ ver y s oft st o ols (fr o m C D AI  It e m 
1). Li q ui d/ ver y s oft st o ol will be defi ne d as a c o nsiste nc y of T y pe 6 or T y p e 7 o n t he 
B S F S.  
5.  
S u bject is ca p a ble of u n d ersta n di n g t he re q uire me nts of t he st u d y, is willi n g t o c o m pl y 
wit h all st u d y pr oce d ures, a n d de m o nstrates a bilit y t o c o m pl y wit h t he st u d y  el ectr o nic  

P a ge 3 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
s yste ms (i ncl u di n g access t o Wi-Fi) re q uire d t o rec or d Cr o h n’s diseas e s y m pt o ms a n d 
C D AI c o m p o ne nts.  
6.  
S u bject u n dersta n ds t he l a n g u a ge of t h e i nf or me d c o nse nt f or m (I C F), a n d is ca pa ble 
a n d willi n g t o si g n t he i nf or me d c o nse nt  f or m. 
4. 2  
E xcl usi o n  Criteri a  
 
A s u bject will n ot be eli gi ble f or i ncl usi o n i n t his st u d y if he/s he m eets a n y of t he f oll o wi n g 
criteria:  
1.  
S u bject has a dia g n osis of ulcerati ve or i n deter mi nate c olitis. 
2.  
S u bject has a dia g n osis of Celiac  Disease.  
3.  
S u bject has ha d b o wel s ur ger y wit hi n 1 2 wee ks pri or t o scree ni n g a n d/ or has s ur ger y 
pla n ne d or dee me d li kel y f or Cr o h n's disease d uri n g t he st u d y p eri o d.  
4.  
S u bject has ha d m ore t ha n o ne se g me ntal c ol o nic resecti o n (i.e. m ore t ha n o ne of t he 
f oll o wi n g: ri g ht he mic olect o m y, left he mic olect o m y, tra ns vers e c olect o m y, ile ocecal 
resecti o n, si g m oi d c olect o m y).  
5.  
S u bject has prese nce of a n ile ost o m y or  c ol ost o m y. 
6.  
S u bject has k n o w n fi x e d s y m pt o matic ste n osis/strict ure of t he s mall or lar ge b o wel.  
7.  
S u bject has ha d m ore t h a n 3 s mall b o wel resecti o ns, or s y m pt o ms ass ociat e d wit h s h ort 
b o wel  s y n dr o me. 
8.  
S u bject has c urre nt e vi de nce of  perit o nitis.  
9.  
S u bject ha d hist or y or e vi de nce of c ol o nic m uc osal  d ys plasia.  
1 0.  
S u bject ha d hist or y or e vi de nce of a de n o mat o us c ol o nic p ol y ps t hat ha ve n ot bee n 
re m o ve d. N O T E: S u bjects ca n n ot be e nr olle d if a n y a d e n o mato us p ol y p(s)  re m o ve d 
d uri n g t he s cree ni n g ile o c ol o n osc o p y has e vi de n ce of d ys plasia or  mali g n a nc y.  
1 1.  
S u bject has e vi de nce of h e patic d ysf u ncti o n, viral he patitis, or c urre nt or c hr o nic 
hist or y of li ver disease i n cl u di n g n o n -alc o h olic steat o he patitis ( N A S H) a s well as li ver 
f u ncti o n tests ( L F Ts) wit h val ues ≥ 1. 5 ti mes t he u p per li mit of n or mal ( U L N) f or a n y 
of t he f oll o wi n g L F Ts: al a ni ne a mi n otra nsferas e ( A L T), as partate a mi n otra nsferas e 
( A S T), al kali ne p h os p hat ase, or bilir u bi n (e x ce pt is olate d ele vati o n of u n c o nj u gate d 
bilir u bi n d ue t o Gil bert’s S y n dr o me) at  Scree ni n g.  
N O T E: La b or at or y tests nee de d f or eli gi bilit y as relate d t o I ncl usi o n a n d E x cl usi o n 
criteria ca n be re peate d o nce bef ore c o nsi deri n g a s u bject a Scree ni n g fail ure.  
1 2.  
S u bject has dia b etes ( T y pe 1 or T y pe 2) t hat is p o orl y c o ntr olle d i n t h e o pi ni o n of t he 
i n vesti gat or, or has ha d a n H b A 1c >  1 2 % wit hi n 3 m o nt hs pri or t o Scree ni n g or at the 
Scree ni n g  Visit.  

P a ge 3 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
1 3.  
S u bject has hist or y of t h e f oll o wi n g c o n diti o ns per Dia g n ostic a n d Statistical Ma n ual of  
Me ntal Dis or ders, 5t h e diti o n  ( D S M-5):  
• a maj or ps yc hiatric dis or der (i ncl u di n g maj or de pressi o n or  ps yc h osis)  
• alc o h ol or s u bsta nce a b us e wit hi n 2 4 m o nt hs pri or t o si g ni n g t he i nf or me d c o nse nt  
1 4.  
S u bject has a hist or y of s eiz ure  dis or ders.  
1 5.  
S u bject has re nal disease ma nifeste d b y ele v ati o ns i n ser u m creati ni ne a n d/ or  bl o o d 
urea nitr o ge n c o nce ntrati o ns of ≥1. 5 ti mes t he  U L N.  
1 6.  
S u bject has u nsta ble car di o vasc ular or p ul m o nar y disease, cate g orize d b y a w orse ni n g 
i n t he disease c o n diti o n t hat re q uires a c ha n ge i n treat me nt or me dical car e wit hi n 3 0 
da ys pri or t o  r a n d o mizati o n. 
1 7.  
S u bject has a n acti ve mali g na n c y wit hi n t he last 5 years (e x ce pti o ns: basal cell 
carci n o mas of t he s ki n, or if fe male, i n sit u cer vical carci n o ma t hat has bee n s ur gicall y 
e x cise d).  
1 8.  
S u bject has d o nate d bl o o d or bl o o d  pr o d ucts wit hi n t he past 4 wee ks pri or t o 
ra n d o mizati o n. 
1 9.  
S u bject has k n o w n varicella, her pes z oster, or ot her se vere viral i nfecti o n wit hi n 6 
wee ks of  ra n d o mizati o n. 
2 0.  
S u bject has k n o w n h u ma n i m m u n o deficie nc y vir us ( HI V)  i nfecti o n. 
2 1.  
S u bject has a p ositi ve st o ol test f or Y ersi ni a e nter oc olitic a , C a m pyl o b acter jej u ni , 
S al m o nell a , S hi ge lla, o v u m a n d parasites, a n d/ or Cl ostri di u m difficile . N O T E: Res ults 
of st o ol tests m ust be c o nfir me d as ne gati ve pri or t o  ra n d o mizati o n. 
2 2.  
S u bject has a hist or y of t u berc ul osis i nfecti o n a n d/ or has recei v e d treat me nt f or a 
t u berc ul osis i nfecti o n. If s u bject has ha d a pre vi o us p ositi ve test f or t u berc ul osis 
a nti ge n t h e n t he y m ust ha ve a c urre nt ne gati ve c h est X -ra y t o b e eli gi ble.  
2 3.  
S u bject use d a n y bi ol o gi c (e. g., T N F α i n hi bit or, n ataliz u ma b, or si milar dr u gs) wit hi n 
1 2 wee ks pri or t o  ra n d o mizati o n. 
2 4.  
S u bject is u n willi n g t o be ta pere d off c ortic oster oi ds b y Wee k 8 of t h e Treat me nt 
Peri o d or t he s u bject is k n o w n b y t he I n vesti gat or t o be ster oi d de pe n d e nt. N O T E: Use 
of oral c ortic ost er oi ds f or t he treat me nt of acti ve Cr o h n’s disease is per mitte d at st u d y 
e ntr y. Per mitte d me dicati o ns are: pre d nis o n e if t he d ose is ≤ 2 0 m g ( or e q ui vale nt) per 
da y or b u des o ni de if t he d ose is ≤ 9 m g/ da y. T he s u bject m ust be ta pere d off t he 
c ortic oster oi ds as n ote d  a b o ve. 
2 5.  
S u bject use d c ycl os p ori n e, tacr oli m us, sir oli m us, m yc o p h e n olate m ofetil, or  si milar 
dr u gs wit hi n 8 wee ks pri or t o  ra n d o mizati o n. 
2 6.  
S u bject use d a n y oral or i ntra ve n o us a nti bi otic i ncl u di n g rifa xi mi n, rifa m pi n or a n y 
dr u gs i n t he rifa m yci n gr o u p, wit hi n 4 wee ks pri or t o t he scree ni n g  visit.  

P a ge 3 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
2 7.  
S u bject ha d rectal a d mi nistrati o n of 5-A S A or c ortic oster oi d 
e ne mas/f oa ms/s u p p osit ories wit hi n 2 wee ks pri or t o scree ni n g  visit.  
2 8.  
S u bjects use d  t u be or e nteral fee di n g, a n ele me ntal diet, or pare nteral ali me ntati o n 
wit hi n 2 wee ks pri or t o Scree ni n g Visit. N ote: diet ar y  s u p ple m e nts (e. g. B o ost, E ns ure) 
are all o we d.  
2 9.  
S u bjects w h o are pla n ni n g t o be gi n ta ki n g pr o bi oti cs or si milar s u p ple me nts at or after 
t he Scree ni n g Visit, or s u bjects w h o be ga n usi n g t hese s u p ple me nts wit hi n 2 wee ks 
pri or t o t he Scree ni n g Visit. N O T E: T hese s u p ple me nts are all o w e d if t he s u bject has 
bee n o n a sta ble d os e f or 2 wee ks or m ore pri or t o t he Sc ree ni n g Visit a n d t he s u bject 
pla ns t o re mai n o n t hat d ose t hr o u g h o ut t he st u d y. T he s u bject s h o ul d n ot i ntr o d uce 
a n y n e w pr o bi otics or si milar s u p ple me nts f or t he d urati o n of t he st u d y. Pri or a n d 
c urre nt use of pr o bi otics or si milar s u p ple me nts will be rec or d e d i n t he s u bject’s  s o urce 
d oc u me nts a n d  e C R F.  
3 0.  
S u bject is c urre ntl y recei vi n g warfari n or ot her 4 -h y dr o x yc o u mari ns at t he Scree ni n g 
Visit, or has pla ns t o i nitiate t he me dicati o n at a n y ti me d uri n g t he  st u d y. 
3 1.  
S u bject, if fe male, is c urr e ntl y pre g na nt or has pla ns t o bec o me pre g n a nt at a n y ti me 
d uri n g t he st u d y, has a p ositi ve pre g n a nc y test at s cree ni n g or is breast -fee di n g. 
3 2.  
 S u bject has a hist or y of s e nsiti vit y t o rifa xi mi n, rifa m pi n, rifa m yci n  a nti micr o bial 
a ge nts, or a n y of t he c o m p o ne nts of Rifa xi mi n D R.  
3 3.  
S u bject has use d a n y i n v esti gati o nal pr o d u ct wit hi n 3 0 da ys pri or t o ra n d o mizati o n, or 
d uri n g t he  st u d y. 
3 4.  
S u bject has a n y c o nc urre nt ill ness, disa bilit y or circ u msta nce t hat ma y affect t he 
i nter pretati o n of cli nical data, c o ul d ca use n o nc o m plia nce wit h treat me nt or visits or 
ot her wise c o ntr ai n dicates partici pati o n i n t his st u d y i n t he o pi ni o n of t he  i n v esti gat or. 
 
4. 3  
C o nc o mit a nt T her a pies  
 
4. 3. 1  
Per mitte d  T her a p y  
 
S u bjects will be all o we d t o c o nti n ue o n t he f oll o wi n g Cr o h n’s disease -relat e d c o nc o mita nt 
me dicati o ns d uri n g t h e st u d y.  
 
• Oral 5 -A S A dr u gs, if o n a sta ble d ose f or at least 2 wee ks pri or t o t he s cree ni n g visit  (s a me 
d osa ge t o be mai ntai ne d t hr o u g h o ut t he  trial). 
• A nti diarr heals ( e. g., l o pera mi de) will be ass esse d at eac h  visit.  
• Merca pt o p uri n e, azat hi o pri ne, met h otre x ate, if sta ble d ose f or at least 8 w ee ks pri or t o  t he 
scree ni n g visit (sa me d os a ge t o b e mai ntai ne d t hr o u g h o ut t he  tri al). 

P a ge 3 8  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Oral ster oi ds (first 8 wee ks of Treat me nt Peri o d o nl y): Pre d nis ol o ne or pre d nis o ne at  d oses 
of ≤ 2 0 m g ( or e q ui vale nt) per da y, or a b u d es o ni de d ose of ≤ 9 m g per d a y are per mitte d. 
S u bjects m ust be a ble t o be ta pere d off ster oi ds b y Wee k 8 of t he Treat me nt  Peri o d.  
4. 3. 2  
Pr o hi bite d  T her a p y  
 
Use of t he f oll o wi n g me dic ati o ns is pr o hi bite d wit hi n t he i ncl usi o n/e x cl usi o n s pecifie d pre - 
st u d y ti me-fr a mes a n d t hr o u g h o ut t he st u d y u nless ot her wise n ote d: 
• C ortic oster oi ds: Pare nter al a n d rectal ster oi ds are pr o hi bite d fr o m t he scree ni n g  visit 
t hr o u g h t he e n d of t he st u d y. 
• A n y oral or i ntra ve n o us a nti bi otic. N O T E: A s h ort c o urse of a nti bi otic t o treat ac ute 
c o n diti o ns (e. g., si n usitis, uri nar y tract i nfecti o n) is per mitte d.  
• Use of a n y dr u g fr o m t he rifa m yci n class at a n y ti me d uri n g st u d y partici pati o n, i ncl u di n g 
rifa xi mi n, rifa m pi n, rifa pe nti ne, a n d rifa b uti n. C urre nt i nter nati o nal tra d e n a mes of 
rifa xi mi n i ncl u de: Alfa N or mi x, C oli di mi n, Fa xi n or m, Fl o n or m, L or m y x, N or mi x, Refer o, 
Rifac ol, Rifa x -A w, Rifa xa n -A w, S pira xi n, Tar ga x a n, Ti xtar, Ti xteller, Xifa x a n,  Xifa x a nta, 
a n d Za xi ne.  
• A n y bi ol o gicals ( e. g., T N F α i n hi bit or, nataliz u ma b, or si milar dr u gs) 
• C ycl os p ori ne, tacr oli m us, sir oli m us, m yc o p h e n olate m ofetil, or si milar dr u gs  
• Rectal a d mi nistrati o n of 5 -A S A or c ortic oster oi d  e ne mas/f oa ms/s u p p osit ories.  
• Use of t u be or e nter al fee di n g, ele m e ntal diet, or pare nteral  ali me ntati o n.  
• I ntr o d u cti o n of a n y ne w pr o bi otics or si milar s u p ple me nts d uri n g t he st u d y. 
• T he i ntr o d ucti o n of a n y ne w me dicati o n f or t he treat me nt of Cr o h n’s diseas e is pr o hi bite d, 
u nless t he me dica ti o n is r e q uire d i n t he I n v esti gat or’s o pi ni o n as resc u e me dicati o n. 
S u bjects recei vi n g r esc ue me dicati o n will be c o nsi dere d treat me nt fail ures b ut s h o ul d 
re mai n i n t he st u d y. 
All c o nc o mita nt me dicati o ns, i ncl u di n g t h ose ta ke n 3 0 da ys pri or t o scree ni n g vi sit, will be 
d oc u me nte d ( dr u g n a me, start a n d st o p dates, a n d i n dicati o n) i n t he c o nc o mita nt me dicati o n 
secti o n of t he C R F. 
4. 4  
Fe m ales of Re pr o d ucti v e  P ote nti al  
If a f e male s u bject bec o mes pre g na nt w hile p artici pati n g i n t his st u d y, t he st u d y dr u g will be 
i m me diatel y disc o nti n ue d a n d t he s u bject will be f oll o we d u ntil t he o utc o me of t he pre g n a nc y 
is k n o w n. T he pre g n a nc y will be re p orte d t o Sali x usi n g t he g ui deli nes pr o vi de d i n 
Secti o n 7. 7 a n d Secti o n 7. 8.  

P a ge 3 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
4. 5  
Pre m at ure S u bject  Disc o nti n u ati o n  
S u bjects will be e nc o ura ge d t o c o m plete t he st u d y; h o we v er, t he y ma y v ol u ntaril y wit h dra w 
at a n y ti me. S u bjects wit h dra w n fr o m t he st u d y will n ot be re place d.  
 
A s u bject ma y be disc o nti n ue d fr o m st u d y dr u g treat me nt a n d/ or t he st u d y f or t he  f oll o wi n g 
reas o ns: 
 
• Occ urre nce of a n A E a n d/ or S A E, w hic h s u g gests a n u nacce pta ble ris k t o t he s u bject,  i n 
t he j u d g me nt of t he i n v esti gat or, i ncl u di n g w ors e ni n g of t he disease u n der st u d y. 
• Pre g n a nc y (s ee Secti o n 7. 7 f or f urt her  details).  
• S u bject re q uest t o  wit h dr a w.  
• S p o ns or decisi o n t o ter mi nate t he  st u d y. 
F or all cases of pre mat ur e wit h dra wal fr o m t he st u d y liste d a b o ve or a n y ot her, t he 
i n vesti gat or m ust pr o vi de t he reas o n f or disc o nti n uati o n o n t he a p pr o priat e C R F pa ge. T h e 
i n v e sti g at or s h o ul d m a k e e v ery att e m pt t o o bt ai n E n d of Tr e at m e nt a n d E n d of St u d y 
a s s e s s m e nt s, i n cl u di n g il e o c ol o n o s c o p y.  
 
If treat me nt wit h i n vesti gati o nal st u d y dr u g h as bee n pre mat urel y disc o nti n ue d, t he E n d of 
Treat me nt ass ess me nts will be c o m plete d, a n d a n atte m pt s h o ul d be ma de  t o ha ve t he s u bject 
f oll o we d f or 1 4 d a ys after last a d mi nistrati o n of st u d y dr u g t o p erf or m t he E n d of St u d y 
assess me nts.  
If a s u bject pre mat ur el y disc o nti n ues treat me nt wit h i n vesti gati o nal dr u g at a n y ti me d ue t o a n 
A E or S A E, t he E n d of Treat me nt assess me nts will be c o m plete d, a n d a n atte m pt s h o ul d be 
ma de t o ha ve t he s u bject f oll o we d at least 1 4 da ys t o perf or m t he E n d of St u d y ass ess me nts, 
or u ntil res ol uti o n or sta bilizati o n of t he c o n diti o n res ulti n g i n wit h dra w al has bee n 
c o nfir me d.  
 
T he I n v esti gat or ma y dis c o nti n ue i n di vi d ual s u bjects fr o m t he st u d y at a n y ti me d uri n g t he 
st u d y. T he i n vesti gat or m ust pr o vi de t he reas o n f or disc o nti n uati o n o n t he a p pr o priate C R F 
pa ge.  
4. 6  
St u d y C o nt act I nf or m ati o n  
 
T he i n vesti gat or ma y dee m it necessar y t o perf or m s pecial tests, t o h os pitalize t he s u bject, or 
t o prescri be n e w dr u gs. I n t he e ve nt t he i n vesti gat or nee ds t o c o ns ult wit h a Sali x 
re pres e ntati ve, pleas e c o ntact: 
Cli nical Pr oject Ma na ger 
Rifa xi mi n D R R E C D 3 1 2 5 S t u d y 
Sali x P har mace uticals, I n c.  
8 5 1 0 C ol o n na de Ce nter Dri ve  

Page 40 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
Raleigh, NC 27615 
 
 
For sites outside the USA and Canada: 
See your Study Reference Manual for your country specific 
information. 

P a ge 4 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
5. 0  
T R E A T M E N T O F  S U B J E C T S  
 
5. 1  
F or m ul ati o n a n d  S u p pl y  
 
St u d y dr u g will be s u p plie d b y Sali x as ta blets c o ntai ni n g 4 0 0 m g Rifa xi mi n D R or matc hi n g 
place b o.  
 
Rifa xi mi n D R will be s u p plie d as pi n k, c oate d, o v al, bic o n ve x ta blets. Eac h Rifa xi mi n D R 
ta blet will c o ntai n 4 0 0 m g Rifa xi mi n a n d t he f oll o wi n g i nacti ve i n gre die nts: c oll oi dal silic o n 
di o xi de, cr oscar mell ose s o di u m, dis o di u m e detate, h y pr o mell ose, m a g nesi u m stearate, 
met hacr ylic aci d a n d et h yl acr ylate c o p ol y m er, micr ocr ystalli ne c ell ul ose, pr o p yle n e gl yc ol, 
re d ir o n o xi de E 1 7 2, talc, a n d tita ni u m di o xi de. 
Matc hi n g place b o will be s u p plie d as ta blets t hat are i de ntical i n a p p eara nce t o Rifa xi mi n D R 
ta blets wit h i nacti ve i n gr e die nts. T he c o m p o ne nts use d i n t he ma n ufact uri n g of t he m atc hi n g 
place b o ta bles are: calci u m p h os p hate, c oll oi dal silic o n di o xi de, c or n starc h, dis o di u m 
e detate, h y pr o m ell ose, ma g n esi u m stearat e, micr o cr ystalli ne cell ul ose, pr o p yle n e gl yc ol, re d 
ir o n o xi de E 1 7 2, a n d tita ni u m di o xi de. 
 
A d diti o nal details are pr o vi de d i n t he Rifa xi mi n I B ( 3 9).  
 
5. 2  
P ac k a gi n g  
 
Sali x will s u p pl y d o u ble -bli n d st u d y dr u g i n hi g h de nsit y p ol yet h yle ne ( H D P E) b ottles. Eac h 
b ottle will c o ntai n st u d y dr u g f or 3 2 da ys of t hera p y.  
5. 3  
L a beli n g  
 
T he c o nte nts of t he la b el will be i n acc or d a nce wit h all a p plica ble re g ulat or y re q uire me nts 
a n d i n t he official la n g u a ge f or eac h c o u ntr y. Eac h la bel ma y i ncl u de, b ut is n ot li mite d t o, t he 
f oll o wi n g i nf or mati o n. 
 
• Fe deral la w stat e me nt: Ca uti o n Ne w Dr u g -Li mite d b y U nite d States La w t o  I n v esti gati o nal 
Use ( U S  o nl y)  
• St u d y n u m b er:  R E C D 3 1 2 5  
• Q ua ntit y  
• D osi n g i nstr ucti o ns: Ta k e 2 ta blets b y m o ut h 2 ti mes a da y, a p pr o xi matel y e v er y 1 2  h o urs.  
• St ora ge i nf or mati o n: St ore ta blets at 2 0 -2 5° C ( 6 8 -7 7° F); e x c ursi o ns  per mitte d t o  1 5 -3 0° C 
( 5 9-8 6° F).  
• Na me, a d dr ess, a n d tele p h o ne n u m ber of t he s p o ns or, c o ntract researc h or ga nizati o n  or 
i n vesti gat or 
• St u d y dr u g, l ot n u m ber, a n d e x pirati o n or re-test date  

P a ge 4 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• S pace f or rec or di n g visit n u m ber, date dis pe nse d, a n d d ate ret ur ne d  
• S pace f or rec or di n g s u bject n u m ber a n d s u bj ect  i nitials 
• S pace f or rec or di n g i n vesti gat or  na me  
• " F or cli nical trial use o nl y" or si milar w or di n g  
• " Kee p o ut of r eac h of c hil dre n"  
5. 4  
St or a ge a n d  H a n dli n g  
 
All st u d y me dicati o n will be ke pt i n a sec ure st ora ge area wit h li mite d access. T he sec ure 
st ora ge ar ea will be mai ntai ne d u n der c o ntr olle d te m perat ure c o n diti o ns at 2 0-2 5° C ( 6 8 - 
7 7° F); e x c ursi o ns ar e per mitte d t o 1 5 t o 3 0° C ( 5 9 t o 8 6° F).  
5. 5  
D osi n g a n d D osi n g  Sc he d ule  
 
St u d y m e dicati o n will be d os e d orall y as t w o ta blets t wice a da y ( m or ni n g a n d e ve ni n g, 
a p pr o xi matel y 1 2 h o urs a part) wit h or wit h o ut f o o d f or 5 2 wee ks.  
5. 6  
R ati o n ale f or D ose  Selecti o n  
 
T he c urr e nt ta blet f or m ul ati o n of Rifa xi mi n EI R w as e val uate d i n a P hase II d ose ra n ge 
fi n di n g st u d y in 4 0 2 s u bjects wit h a n ac ut e flare of C D ( R E TI C/ 0 3/ 0 6). Patie nts wit h a C D AI 
bet wee n 2 2 0 a n d 4 0 0 p oi nts were r a n d o mize d t o 4 treat me nt gr o u ps: Rifa xi mi n EI R 4 0 0 m g 
t wice a da y, Rif a xi mi n RI R 8 0 0 m g BI D, Rifa xi mi n EI R 1 2 0 0 m g BI D or place b o BI D f or 1 2 
wee ks . S u bjects w h o ac hie ve d cli nical re missi o n at t he e n d of t he treat me nt peri o d, defi ne d as 
C D AI s c ore <  1 5 0 p oi nts, were a d mitte d t o a 3 -m o nt h f oll o w -u p p hase. S u bjects were 
all o we d t o c o nti n ue sta bl e d oses of oral 5 -A S A, m erca pt o p uri ne, azat hi o pri ne, a n d/ o r 
met h otre x ate as c o nc o mita nt t hera pies t hr o u g h o ut t he st u d y ( u p t o 1 2 w ee ks), w hile t he use  of 
a nti bi otics a n d oral, i ntra ve n o us, a n d rectal ster oi ds were n ot per mitte d. As a d d -o n t hera p y 
( 8 3 % of e nr olle d s u bjects were tr eate d wit h sta ble d oses of 5-A S A a n d/ or met h otre x ate, 
azat hi o pri ne a n d merca pt o p uri ne), Rifa xi mi n EI R 8 0 0 m g t wice a da y w as statisticall y 
s u peri or t o place b o i n i n d uci n g cli nical re missi o n ( C D AI <  1 5 0 p oi nts) after 1 2 wee ks of 
t hera p y ( p = 0. 0 0 7), a n d mai ntai ni n g re missi o n f or t hree m o nt hs aft er Rifa xi mi n EI R was 
st o p pe d ( p = 0. 0 2). I n a d diti o n, t he safet y a n d t olera bilit y of t he Rifa xi mi n EI R 8 0 0 m g BI D 
re gi me n i n t his st u d y was acce pta ble t o warra nt f urt her i n vesti gati o n. Bas e d o n t hese data, a 
d ose of 8 0 0 m g t wi ce a d a y was selecte d f or  f urt h er d e vel o p me nt.  
5. 7  
St u d y Dr u g Acc o u nt a bilit y  
 
O nl y a ut h orize d site pers o n nel ma y dis pe ns e st u d y dr u g. D oc u me ntati o n of i n vesti gati o nal 
dr u g or ders, rec or ds of st u d y dr u g recei pt, dis pe nsi n g, a n d o n g oi n g st u d y dr u g i n ve nt or y will 
be e x a mi ne d a n d rec o ncile d t hr o u g h o ut t he st u d y. O nl y s u bjects e nr olle d i n t he st u d y ma y 
recei v e st u d y dr u g, i n acc or da nce wit h all a p plica ble re g ulat or y re q uire m e nts. 

P a ge 4 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
St u d y dr u g rec o nciliati o n will be c o n d ucte d d uri n g m o nit ori n g visits t o e ns ure a p pr o priate  
recei pt, st ora ge, dis pe nsi n g, a n d d o c u me ntati o n of ret ur ne d st u d y dr u g. U p o n c o m pleti o n of 
t he st u d y, t his material will be s u bjecte d t o fi nal i ns pecti o n a n d rec o nciliati o n. 
T he f oll o wi n g i nf or mati o n will be d oc u me nte d re gar di n g st u d y dr u g:  
 
• S u bject  n u m be r. 
• S u bject  i nitials. 
• Dis pe nsi n g dat e a n d q ua ntit y of  ta blets. 
• I nitials of st u d y staff dis p e nsi n g dr u g.  
• Ret ur n date a n d q u a ntit y of dr u g ret ur n e d b y  s u bject. 
• C o m plia nce ( %) i n ta ki n g t he st u d y dr u g at eac h  visit.  
• Start a n d st o p dates of st u d y  dr u g.  
 
5. 8  
Assess me nt of  C o m pli a nce  
 
After st u d y dr u g is dis pe nse d, t he i n vesti gat or or his/ her re prese ntati ve will c o u nt t he u n use d 
st u d y dr u g ta blets t hat w ere r et ur ne d b y t he s u bj ect at eac h visit t o assess c o m plia nce. St u d y 
dr u g c o m plia nce will be rec or d e d i n t he s u bject's s o urce d oc u m e ntati o n a n d C R F. If t he 
s u bject f or gets t o ret ur n u n use d st u d y dr u g at a visit, t he n c o m plia nce will be c o nfir me d after 
direct q uesti o ni n g of t he s u bject. T he i n vesti gat or's j u d g me nt of c o m plia n ce will be acce pte d. 
At te m pts t o o btai n u n use d st u d y dr u g s h o ul d be m a de at s u bse q u e nt visits or b y t he 
c o ncl usi o n of t he s u bject’s partici pati o n i n t he trial.  

P a ge 4 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
6. 0  
S T U D Y P R O C E D U R E S A N D  A S S E S S M E N T S  
 
A sc he d ul e of assess me nts t o be perf or m e d d uri n g t he st u d y is pr o vi de d i n A p pe n di x 1: 
O verall Ti me a n d E ve nts Sc he d ule. F or t his st u d y, Da y 1 s hall be defi n e d as t he da y of 
ra n d o mizati o n/ baseli ne. 
 
S u bjects will be pr o vi de d b o wel pre p f or use pri or t o t he ile oc ol o n osc o pies. T he b o wel pre p 
will be dis pe nse d b y st u d y staff at V isits 1, 7, a n d 1 6. 
6. 1  
St u d y Sc he d ule b y Tre at me nt Visit  
 
6. 1. 1  
Visit 1: Scree ni n g ( D a y – 2 1 t o D a y  -1 4)  
 
Scree ni n g e v al uati o ns m ust be gi n n o less t ha n 1 4 da ys pri or t o t he Baseli ne Visit ( Visit 2). 
T he f oll o wi n g pr oce d ures will occ ur d uri n g t his visit:  
 
• I nf or me d c ons e nt si g n e d b y t he s u bject pri or t o perf or mi n g a n y st u d y e val u ati o ns  or 
pr oce d ur es.  
• Assi g n s u bject  i de ntifi cati o n. 
• Me dical hist or y a n d de m o gr a p hic i nf or mati o n s h o ul d be rec or de d. A p pr o xi mate date  of 
i nitial dia g n osis a n d o nset of s y m pt o ms of Cr o h n’s disease s h o ul d be  d o c u me nte d.  
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns.  
• I n cl usi o n/ E x cl usi o n criteria re vie w t o e ns ure s u bj ect q ualifies f or t he st u d y. 
• F ull p h ysical e x a mi nati o n i ncl u di n g diseas e s pecific e x a mi nati o n (i ncl u di n g ass ess me nts 
f or a b do mi nal mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease b ase d o n C D AI  –  
see A p pe n di x 2).  
• Vital si g ns (t o i ncl u de m eas ure m e nt of hei g ht a n d  wei g ht).  
• Electr ocar di o gra m.  
• Safet y l a b orat or y t ests i ncl u di n g ser u m pre g na n c y test ( he mat ol o g y, bl o o d c he mi str y, a n d 
uri nal ysis).  
• St o ol c ollecti o n a n d pr ocessi n g N O T E: T his sa m ple is c ollecte d i n part t o a d dress 
E x cl usi o n Criteri o n 2 1. Micr o bi ol o g y res ults re q uire d f or e ntr y m ust be recei ve d bef ore 
ra n d o mizati o n. If t he s u bject ca n n ot pr o d u ce a s a m ple d uri n g t he visit, t he s u bject will be 
iss ue d a c ollecti o n kit a n d as ke d t o c ollect a s p eci me n at h o me, refri gerate it i m me diatel y 
a n d ret ur n it t o t he cli nic a mi ni m u m of 7 da ys pri or t o visit 2.  
• Pr o vi de s u bject i nstr ucti o n f or dail y diar y  c o m pleti o n.  
• Sc he d ule eli g i bilit y/ b aseli ne ile oc ol o n osc o p y a n d pr o vi de b o wel pre p.  

P a ge 4 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• S u bjects w h o ac hie ve t h e q ualif yi n g C D AI sc ore s h o ul d ha ve t he baseli ne  il e oc ol o n osc o p y 
(f or eli gi bilit y S E S-C D sc ore) p erf or me d n o later t ha n Da y  -5.  
• Sc he d ule Visit  2  
6. 1. 2  
Visit 2: B aseli ne/ R a n d o miz ati o n, Wee k 0/ D a y  1  
 
T he Baseli ne/ Ra n d o mizati o n Visit will be perf or me d o n Da y 1. T h ere is n o Da y 0 i n t his 
pr ot oc ol. T he f oll o wi n g assess me nts are t o be c o m plete d at Visit 2:  
 
Pri or t o d osi n g:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• In cl usi o n/ E x cl usi o n re vie w t o e ns ure s u bj ect c o nti n ues t o q ualif y f or t he  st u d y 
• Vital si g ns a n d  w ei g ht  
• Disease a n d s y m pt o m dri ve n p h ysi cal e x a mi nati o n (i ncl u di n g ass ess me nts f or a b d o mi nal 
mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease base d o n C D AI –  see A p pe n di x 
2)  
• Safet y l a b orat or y t ests ( h e mat ol o g y, bl o o d c h e mistr y,  uri nal ysis)  
• Uri ne pre g n a nc y  t est 
• Bl o o d dra w pri or t o first d ose a d mi nistrati o n f or i nfla m mat or y mar kers, P X R a n d P K  
• St o ol a n d bl o o d c ollecti o ns f or l o n g -ter m st ora ge 
• I B D Q a n d W P AI-C D  
• Diar y C o m plia nce  C hec k  
• Ra n d o mizati o n  
After first d ose assess me nts:  
 
• St u d y dr u g dis pe nsi n g - first d ose t o be ta ke n at t h e cli nic u n der o bs er vati o n. T he e x act 
ti me of d ose a d mi nistrati o n s h o ul d be rec or d e d. 
• Sc he d ule Visit  3  
6. 1. 3  
Visits 3, 4, 5, 6: Wee ks 2, 4, 8, 1 2 / D a ys 1 4, 2 8, 5 6, 8 4 ( ± 3  d a ys)  
 
T he f oll o wi n g assess me nts are t o be c o m plet e d:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  

P a ge 4 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Disease a n d s y m pt o m dri ve n p h ysi cal e x a mi nati o n (i ncl u di n g ass ess me nts f or a b d o mi nal 
mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease base d o n C D AI –  see A p pe n di x 
2)  
• St u d y dr u g c ollecti o n a n d dis pe nsi n g. N O T E: At Visit 3 n o st u d y dr u g is c ollecte d or 
dis pe nse d.  
• Rec or d ti me a n d dat e of m ost rece nt d ose of st u d y dr u g. T his i nf or mati o n m ust be 
o btai ne d fr o m t he s u bject a n d s h o ul d be his/ her best rec ollecti o n of w h e n t he y t o o k t h eir 
m ost rece nt  d ose.  
• Safet y l a b orat or y t ests ( h e mat ol o g y, bl o o d c h e mistr y,  uri nal ysis)  
• Bl o o d dra w f or P K ( Visit 6 o nl y f or  P K)  
• C D AI assess me nt ( C D AI sc ore will be calc ulate d b y E D C  s yste m) 
• Re vie w d osi n g a n d diar y  c o m plia nce  
• Sc he d ule t he ne xt st u d y visit  
 
6. 1. 4  
Visit 7: Wee k 1 6/ D a y 1 1 2 ( ± 3  d a ys)  
 
T he f oll o wi n g assess me nts are t o be c o m plet e d at Visit  7:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  
• Electr ocar di o gra m  
• F ull p h ysical e x a mi nati o n i ncl u di n g diseas e s pecific e x a mi nati o n (i ncl u di n g ass ess me nts 
f or a b d o mi nal mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease b ase d o n C D AI –  
see A p pe n di x 2).  
• Safet y l a b orat or y t ests ( h e mat ol o g y, bl o o d c h e mistr y,  uri nal ysis)  
• Uri ne pre g n a nc y  t est 
• Bl o o d f or i nfla m mat or y  mar kers  
• St o ol c ollecti o n a n d pr ocessi n g. N O T E: If t he s u bject ca n n ot pr o d u ce a sa m ple d uri n g t he 
visit, t he s u bject will be iss ue d a c ollecti o n kit a n d as ke d t o c ollect a s p eci me n at h o me, 
refri gerate it i m me diatel y, a n d bri n g it t o t he cli nic as s o o n as p ossi ble.  
• St o ol a n d Bl o o d c ollecti o ns f or L o n g -ter m St ora ge 
• C D AI assess me nt ( C D AI sc ore will be calc ulate d b y E D C  s yste m) 
• I B D Q a n d W P AI-C D  
• Re vie w d osi n g a n d diar y  c o m plia nce  
• St u d y dr u g c ollecti o n a n d  dis pe nsi n g  

P a ge 4 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Sc he d ule ile oc ol o n osc o p y a n d dis p e nse b o wel pre p f or ile oc ol o n osc o p y 
• 
Ile o c ol o n osc o p y t o be p erf or me d wit hi n 7 da ys after Visit 7.  
• 
All Visit 7 pr oce d ures t o be c o m plete d pri or t o b e gi n ni n g b o wel  pre p.  
• Sc he d ule Visit  8  
 
6. 1. 5  
Visits 8, 9, 1 0, 1 1, 1 2, 1 3, 1 4, 1 5: Wee k s 2 0, 2 4, 2 8, 3 2, 3 6, 4 0, 4 4, 4 8 / D a ys 1 4 0,  
1 6 8, 1 9 6, 2 2 4, 2 5 2, 2 8 0, 3 0 8, 3 3 6 ( ± 3 d a ys)  
 
T he f oll o wi n g assess me nts are t o be c o m plet e d:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  
• Disease a n d s y m pt o m dri ve n p h ysi cal e x a mi nati o n (i ncl u di n g ass ess me nts f or a b d o mi nal 
mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease base d o n C D AI –  see A p pe n di x 
2)  
• Safet y  la b or at or y t ests ( h e mat ol o g y, bl o o d  c h e mistr y, uri nal ysis)  wit h  uri n e  pre g na n c y  t est 
at Visit 1 0 ( Wee k 2 8) a n d Visit 1 3 ( Wee k 4 0) o nl y; bl o o d dra w f or P K at Visit 1 5  o nl y  
• At Visit 1 5 o nl y: Rec or d ti me a n d date of m ost rece nt d ose of st u d y dr u g. T his 
i nf or mati o n m ust be o btai ne d fr o m t he s u bject a n d s h o ul d be his/ her best rec ollecti o n of 
w he n t he y t o o k t heir m ost rece nt  d ose.  
• C D AI assess me nt ( C D AI sc ore will be calc ulate d b y E D C  s yste m) 
• I B D Q a n d W P AI-C D at Visit 1 0 ( Wee k 2 8) a n d Visit 1 3 ( Wee k 4 0)  o nl y  
• Re vie w d osi n g a n d diar y  c o m plia nce  
• St u d y dr u g c ollecti o n a n d  dis pe nsi n g  
• Sc he d ule t he ne xt st u d y visit ( Visit 1 5 s h o ul d occ ur i n t he  m or ni n g)  
 
6. 1. 6  
Visit 1 6: E n d of Tre at me nt ( E O T) Visit, Wee k 5 2/ D a y 3 6 4 ( ± 3  d a ys)  
 
T he s u bject’s fi nal d os e of st u d y dr u g will be t he e ve ni n g bef ore Visit 1 6. T he f oll o wi n g 
assess me nts are t o b e c o m plete d at t his visit:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  
• Electr ocar di o gra m  
• F ull p h ysical e x a mi nati o n i ncl u di n g diseas e s pecific e x a mi nati o n (i ncl u di n g ass ess me nts 
f or a b d o mi nal mass a n d e xtrai ntesti nal ma nifestati o ns of Cr o h n’s disease b ase d o n C D AI  –  
see A p pe n di x 2).  

P a ge 4 8  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Safet y l a b orat or y t ests ( h e mat ol o g y, bl o o d c h e mistr y, uri n al ysis) i ncl u di n g  bl o o d f or 
ser u m pre g na nc y test a n d i nfla m mat or y m ar kers  
• St o ol c ollecti o n a n d pr ocessi n g. N O T E: If t he s u bject ca n n ot pr o d u ce a sa m ple d uri n g t he 
visit, t he s u bject will be iss ue d a c ollecti o n kit a n d as ke d t o c ollect a s p eci me n at h o me, 
refri gerate it i m me diatel y, a n d bri n g it t o t he cli nic as s o o n as p ossi ble.  
• St o ol a n d Bl o o d c ollecti o ns f or L o n g -ter m St ora ge 
• C D AI assess me nt ( C D AI sc ore will be calc ulate d b y E D C  s yste m) 
• I B D Q a n d W P AI-C D  
• Re vie w d osi n g a n d diar y  c o m plia nce  
• C ollect u n use d st u d y  dr u g  
• Sc he d ule ile oc ol o n osc o p y a n d dis p e nse b o wel pre p f or  ile oc ol o n os co p y  
• 
Ile o c ol o n osc o p y t o be c o n d ucte d wit hi n 7 da ys aft er Visit 1 6.  
• 
All Visit 1 6 pr oce d ures t o be c o m plete d pri or t o b e gi n ni n g b o w el  pre p.  
• Sc he d ule Visit 1 7,  E O S  
6. 1. 7  
Visit 1 7: E n d of St u d y ( E O S) Visit, Wee k 5 4/ D a y 3 7 8 ( ± 3  d a ys)  
 
T he f oll o wi n g assess me nts are t o be c o m plet e d:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  
• Electr ocar di o gra m  
• Safet y l a b orat or y t ests ( h e mat ol o g y, bl o o d c h e mistr y,  uri nal ysis)  
 
6. 1. 8  
U nsc he d ule d  Visit  
 
T he i n vesti gat or ma y perf or m a n u nsc h e d ule d visit at a n y ti me d uri n g t he st u d y at his/ her 
discreti o n. Assess me nts perf or me d at a n u nsc h e d ule d visit s h o ul d be s y m pt o m directe d. At a 
mi ni m u m t he f oll o wi n g assess me nts s h o ul d be perf or me d:  
 
• A d verse e ve nts a n d c o nc o mita nt  me dicati o ns  
• Vital si g ns a n d  w ei g ht  
• S y m pt o m dri ve n p h ysi cal  e x a mi nati o n  
• Safet y l a b orat or y t ests as a p pr o priate ( he mat ol o g y, bl o o d c he mistr y,  uri nal ysis)  

P a ge 4 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
6. 1. 9  
D ail y Di ar y ( a n d/ or ot her s u bject -c ollecte d  d at a)  
 
Electr o nic s yste m diaries will be utilize d t o c ollect s u bje ct’s res p o nses t o t h e C D AI q uesti o ns 
( A p pe n di x 2: Cr o h n’s Disease A cti vit y I n de x). Eac h s u bject will be i nstr ucte d o n t he use of 
t he Electr o nic diar y s yst e m. S u bjects will be pr o vi de d sec ure access i nstr ucti o ns t o t he 
Electr o nic diar y s yste m d uri n g t he Scr ee ni n g Visit. 
6. 2  
Assess me nt of  Effic ac y  
 
Efficac y e n d p oi nts ar e pr ese nte d i n Secti o n 2. 2. A nal yses of efficac y e n d p oi nts are descri be d 
i n Secti o n 8. 6. 1. 
6. 2. 1  
Cr o h n’s Dise ase Acti vit y I n de x ( C D AI)  Sc ore  
 
T he C D AI sc ore is a w ei g hte d, c o m p osite i n de x of ei g ht ite ms (st o ol fre q u e nc y, se verit y of 
a b d o mi nal pai n, de gree of ge ner al well -bei n g, pres e nce or a bse n ce of e xtrai ntesti nal 
ma nifestati o ns i ncl u di n g fist ula, use or n o n -use of a nti diarr heal a ge nts, prese nce or a bse n ce of 
ab d o mi nal mass, he mat o crit a n d b o d y wei g ht). Sc ores ra n ge fr o m 0 t o a p pr o xi matel y 6 0 0 
wit h hi g her s c ores i n dicati n g greater disease se v erit y. Cli nical (as y m pt o matic) re missi o n is 
defi ne d as a sc or e of ≤ 1 5 0 p oi nts. Mil d -t o-m o derate disease a n d se vere dis eas e are d efi ne d 
b y sc ores of > 1 5 0 t o ≤ 4 5 0, a n d > 4 5 0 p oi nts, res pecti vel y. T he C D AI s c ori n g s yste m ca n be 
f o u n d i n A p pe n di x 2: Cr o h n’s Disease A cti vit y I n de x. C D AI will be e v al uate d at all cli nic 
visits f or t he st u d y. C D AI s c ore will be calc ulat e d b y E D C  syste m.  
6. 2. 2  
Si m ple E n d osc o pic Sc ore f or Cr o h n’s Dise ase  ( S E S-C D)  
 
T he S E S -C D is a vali date d i nstr u me nt reflecti n g a n e n d osc o pist’s gl o bal a p praisal of m uc osal 
lesi o ns i n Cr o h n’s disease. T he S E S-C D gra d es lesi o ns b y l ocati o n (ile u m, ri g ht c ol o n, 
tra ns verse c ol on, left c ol o n a n d rect u m) usi n g ulcer size, e xte nt of ulcerate d s urface, e xte nt of 
affecte d s urf ace, a n d pr es e nce/t y pe of n arr o wi n g. T he S E S -C D ca n be f o u n d i n A p pe n di x 4. 
Vi de o rec or di n gs of ile oc ol o n osc o pies will be re vi e we d, a n d S E S -C D sc ores will be 
calc ulate d b y bli n de d ce ntral la b orat or y e n d osc o pists f or t he st u d y. T h e i n de pe n de nt ce ntral 
e n d osc o p y rea ders a n d t h e ce ntr al e n d osc o p y la b orat or y will n ot be ass ociate d wit h a n y 
i nstit uti o n c o n d ucti n g t he st u d y. 
I n or der t o f ull y ass ess f or t he prese n ce of ile oc ol o nic Cr o h n’s disease a n d calc ulate a n 
acc ur ate S E S -C D sc or e, t he e n d osc o pist m ust atte m pt t o i nt u bate a n d vis ualize t he ter mi nal 
ile u m i n or der t o deter mi ne prese n ce a n d e xte nt of disease d uri n g eac h ile o c ol o n osc o p y. T o 
re d uce t h e p ote ntial f or bias or varia bilit y i n e n d os c o p y s c ori n g, bli n de d ce ntral rea di n g will 
be utilize d t o deter mi ne t he S E S -C D sc ores f or all ile oc ol o n osc o pies o btai n e d d uri n g t he 
st u d y. As s uc h, e ver y eff ort m ust be ma de at eac h pr oce d ure t o f ull y vis u alize eac h se g m e nt 
of t he ter mi nal ile u m a n d c ol o n t o facilitate ce ntral rea di n g of t he rec or de d pr oce d ures. T he 
rate of wit h dr a wal of t h e c ol o n osc o pe d uri n g t he pr oce d ure s h o ul d als o be s ufficie ntl y sl o w as 
t o all o w f or a de q u ate vis ualizati o n a n d sc ori n g of eac h se g m e nt i n t he vi de o rec or di n g b y a 

P a ge 5 0  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
ce ntral r ea d er. Strict ures t hat d o n ot per mit f urt her passa ge of t h e c ol o n osc o pe s h o ul d be 
a n n otate d as s uc h.  
6. 2. 3  
I nfl a m m at or y B o w el Dise ase Q uesti o n n aire (I B D Q) 
 
T he I B D Q is a vali dat e d 3 2 -ite m q uesti o n naire wit h 4 di me nsi o ns that assess b o wel f u ncti o n, 
e m oti o nal stat us, s yste mic s y m pt o ms, a n d s ocial f u ncti o n. T he I B D Q ca n b e self - 
a d mi nistere d. T he t otal s c ore o n t he i n de x ra n ges fr o m 3 2 -2 2 4, wit h hi g h er sc ores i n dicati n g 
better q ualit y of life. A relati vel y g o o d c orrel ati o n e x ists bet wee n t he I B D Q a n d t he C D AI (r 
= -0. 6 7; P < 0. 0 0 1). St u dies ha ve bee n perf or me d i n patie nts wit h i nfla m mat or y Cr o h n's 
disease, b ut t here is n o p u blis he d data o n I B D Q s c ores of p atie nts wit h pri maril y fist ulizi n g 
Cr o h n's diseas e. See A p p e n di x 5: I nfl a m mat or y B o wel Disease Q uesti o n naire.  
 
6. 2. 4  
W or k Pr o d ucti vit y a n d Acti vit y I m p air me nt Q uesti o n n aire f or  Cr o h n's 
Dise ase  ( W P AI-C D)  
 
T he W P AI -C D is a q u esti o n naire t hat assesses t h e effect of Cr o h n’s disease o n a patie nt’s 
a bilit y t o w or k a n d p erf or m re g ular acti vities. T he W P AI-C D has discri mi n ati ve vali dit y a n d 
re pr o d uci bilit y i n Cr o h n’s disease. I n a d diti o n, e v al uati ve vali dit y a n d res p o nsi ve ness t o 
cli nicall y mea ni n gf ul c ha n ges i n t he W P AI -C D sc ores ha ve b ee n esta blis he d f or Cr o h n's 
disease. W P AI -C D o utc o mes are e x presse d as i m pair me nt perce nta ges, wit h hi g her n u m bers 
i n dicati n g gr eater i m pair me nt a n d less pr o d ucti vit y (i.e. w orse o ut c o mes). D o mai ns 
e val uate d are c urr e nt e m pl o y me nt, w or k h o urs misse d d ue t o Cr o h n’s disease, w or k h o urs 
misse d f or ot h er r eas o ns, h o urs act uall y w or k e d, d e gree t h at Cr o h n’s diseas e affecte d 
pr o d ucti vit y w hile w or ki n g, a n d d e gree t hat Cr o h n’s disease affecte d re g ular acti vities. See 
A p pe n di x 6: W or k Pr o d ucti vit y a n d A cti vit y I m pair me nt Q uesti o n naire: Cr o h n’s Disease.  
6. 3  
Asses s me nt of S af et y  
 
Safet y e n d p oi nts are pres e nte d i n Secti o n 2. 2. 4. Safet y assess me nts will i ncl u de t he 
f oll o wi n g: 
 
• A Es, b ot h re p orte d a n d o bser ve d  
• Vital si g n meas ur e me nts (seate d bl o o d press ure, p ulse a n d oral  te m p erat ure) 
• R o uti ne he mat ol o g y a n d bl o o d c he mistr y tests a n d  uri nal ysis  
• Electr ocar di o gra ms  
 
6. 3. 1  
Cli nic al L a b or at or y  Tests  
 
T he f oll o wi n g cli nical la b orat or y tests are t o be p erf or me d d uri n g t he st u d y a n d will be 
a nal yze d b y a ce ntral, lice nse d cli nical la b orat or y (e x ce pt f or t he uri n e pre g na nc y tests ). At 
t he i n vesti gat or’s discreti o n, a d diti o nal bl o o d ma y be c ollecte d f or cli nical l a b orat or y tests 

P a ge 5 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
(i.e., he mat ol o g y, bl o o d c he mistr y, a n d uri nal ysis) base d o n patie nt re p orte d si g ns a n d 
s y m pt o ms or pre vi o us cli nical la b orat or y test res ults. 
 
Res ults fr o m la b orat or y s peci me ns c ollect e d d uri n g t he Scree ni n g Visit m ust be recei ve d b y 
t he site pri or t o Visit 2 ( Baseli ne/ Ra n d o mizati o n). 
T he cli nical la b or at or y p ara meters t o be e v al uate d are as f oll o ws:  
 
• He m at ol o g y : He m o gl o bi n, he mat ocrit, re d bl o o d cell c o u nt, w hite bl o o d cell c o u nt wit h 
differe ntial, a n d platelet  c o u nt.  
• Bl o o d c he mistr y : Ala ni n e a mi n otra nsferase, as partate a mi n otra nsferase, al kali ne 
p h os p hatase, t otal bilir u bi n (e x ce pt i n is olate d ele vati o n of u nc o nj u gate d bilir u bi n),  bl o o d 
urea nitr o ge n, creati ni ne, uric aci d, el ectr ol ytes, lactate de h y dr o ge nas e, cal ci u m,  al b u mi n, 
gl uc ose, c h olester ol, a n d  tri gl yceri des. 
• Uri n al ysis : R o uti ne uri ne a nal ysis (i ncl u di n g b ut n ot li mite d t o w hite bl o o d cell c o u nt, red 
bl o o d cell c o u nt, a n d pr ote i n). If t here are a n y p ositi ve fi n di n gs, micr osc o pic e x a mi nati o n 
s h o ul d be perf or m e d t o q ua ntif y t he res ults. 
• St o ol : St o ol testi n g will be perf or me d d uri n g t he scree ni n g p eri o d t o i de ntif y t he prese nce 
of e nteric i nf ecti o ns (e. g. Yersi nia e nter oc olitica, Ca m p yl o bact er jej u ni, Sal m o nella, 
S hi gella, o v u m a n d parasite a n d/ or Cl ostri di u m difficile) a n d a ne gati ve test m ust be 
c o nfir me d f or s u bjects pri or t o  ra n d o mizati o n. 
6. 3. 2  
Assess me nt of I nfl a m m ati o n  M ar kers  
 
Bl o o d sa m ples f or d eter mi nati o n of i n fla m mat or y mar k ers will be c ollect e d at Visit 2 
( Bas eli ne/ Ra n d o mizati o n), Visit 7, a n d Visit 1 6 ( E O T). Bl o o d sa m ples will be c ollecte d i n 
ser u m-se parati n g t u bes t o c ollect ser u m f or i nfla m mat or y mar kers. After all o wi n g bl o o d t o 
cl ot f or a p pr o xi matel y 3 0 mi n utes, t he sa m ples will be ce ntrif u ge d at 1 3 0 0 g t o se parate t h e 
bl o o d cells fr o m ser u m. Ser u m sa m ples will be s hi p pe d a m bie nt ( C R P) or fr oze n ( ot her 
i nfla m mat or y m ar kers) t o t he ce ntral la b orat or y f or i nfla m mat or y mar k er t esti n g. T he 
prese nce of i nfla m mat o r y mar k ers ( w hic h ma y i n cl u de C R P, I L-1 β, I L -2, I L -6, I L -1 2, I L -1 3, 
T N F -α a n d e n d ot o xi n) will be a nal yze d usi n g a p article base d C yt o metric Bea d Arra y 
i m m u n oassa y at t he ce ntr al la b orat or y. 
Bl o o d sa m ples f or d eter mi nati o n of Pre g n a ne X Rece pt or ( P X R) ge n ot y pi n g will be c ollecte d 
at Visit 2. 
 
• 
Bl o o d, Bl o o d Pl as m a, a n d Ser u m f or St or a ge : Bl o o d, bl o o d plas ma, a n d ser u m 
sa m ples will be c ollecte d at Visit 2 ( Baseli ne/ Ra n d o mizati o n), Visit 7, a n d Visit 1 6 
( E O T). Sa m ples will be st ore d at ≤ -2 0° C at t he cli ni cal site a n d s hi p pe d o n dr y ice a n d 
st ore d l o n g-ter m at ≤ -7 0° C. T hese sa m ples ma y b e use d f or e x pl orat or y a n al yses 
( p ote ntiall y i ncl u di n g a d diti o nal i nfla m mat or y mar kers or P X R ge n ot y pi n g) t o  be  

P a ge 5 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
detaile d i n s u bse q ue nt site -s pecifi c a me n d me nts or s u b-st u dies. S u bjects will be a d vise d 
of a n d m ust c o nse nt t o bl o o d a n d bl o o d plas ma c ollecti o n f or st ora ge.  
 
6. 3. 3  
St o ol S a m ple C ollecti o n a n d  Testi n g  
 
St o ol sa m ple c ollecti o n s h o ul d be perf or me d f or t he f oll o wi n g visits: Scree ni n g, Visit 7, a n d 
Visit 1 6 ( E O T). Fr es h st o ol sa m ples will be c ollecte d at eac h of t he a b o ve visits w he ne ver 
p ossi ble. If t h e s u bject ca n n ot pr o d uce a s a m ple d uri n g t he visit, t he s u bject will be iss ue d a 
c ollecti o n kit a n d as ke d t o c ollect a s peci me n at h o me, refri gerat e it i m me diate l y, a n d bri n g it 
t o t he cli nic as s o o n as p ossi ble. St o ol sa m ples will be ali q u ote d i nt o 2-m L p ol y pr o p yle n e 
cr y o vials, st ore d at ≤ -2 0° C at t he cli nical site, s hi p pe d o n dr y ice a n d st ore d l o n g ter m at ≤ - 
7 0° C. St o ol sa m ples will be use d f or t h e f oll o wi n g:  
• 
S af et y  Testi n g  f or C.  diffi cil e : A  st o ol sa m ple f or a nal ysis of  C.  difficile  f or T o xi ns  A  & 
B will be c ollect e d at Scr ee ni n g, Visit 7, a n d Visit 1 6. Testi n g will be perf or me d b y 
e nz y me i m m u n oassa y ( EI A). 
• 
St o ol sa m ples testi n g p ositi ve f or C. difficile T o xi n B will be c ult ure d a n d t este d 
f or resista nce t o select a nti bi otics. 
• Fec al C al pr otecti n I m m u n o ass a y : A st o ol sa m ple f or ass a y of fecal cal pr otecti n will be 
c ollecte d at Scr ee ni n g, Visit 7, a n d Visit 1 6. St o ol sa m ples will be c ollecte d i n sterile 
s peci me n c u ps a n d st or e d i m me diatel y at ≤ -2 0º C. Sa m ples will be s hi p pe d fr oze n o n  dr y 
ice t o t he ce ntr al la b orat or y f or testi n g. Testi n g will be perf or m e d b y i m m u n oassa y. 
• Micr o bi ot a C h ar acteri z ati o n : S usce pti bilit y Testi n g: I n a s u bset of t he st u d y p o p ulati o n 
(a p pr o xi matel y 1 0 %),  t he s usce pti bilit y of  t he st o ol micr o bi ota  t o rifa xi mi n, rifa m pi n, a n d 
ot her select e d a nti bi otics of cli nical i nterest will be c haracterize d. St o ol sa m ples will be 
i n oc ulate d o nt o vari o us me dia t o i de ntif y or ga nis ms. St o ol c ult ures will i de ntif y a n d 
is olate yeast as well as s electe d bacteria, c h ose n t o i nc or p orate t h e m ost pre vale nt s pecies 
of i ntesti nal bacteria. Bacteria will be i de ntifie d a n d c haracterize d b y m or p h ol o g y a n d 
p h ysical tests, wit h i de ntit y c o nfir me d wit h m olec ular i de ntificati o n s yste ms. Yeast will 
be i de ntifie d if pres e nt i n st o ol, b ut will n ot be teste d f urt her. Bacteri al se nsiti vit y testi n g 
will be perf or me d b y br ot h micr o dil uti o n ( per Cli nical La b orat or y Sta n dar ds I nstit ute 
( C L SI) d o c u me nt M 7-A 8) f or aer o bic b acteri a a n d b y a gar dil uti o n f or a n aer o bic bacteria 
usi n g cli nicall y r ele va nt a nti bi otics. D u plicate sa m ples of all is olates a n d st o ol ali q u ots 
will be st ore d t o all o w f or p ote ntial f ut ure  a nal ysis.  
• Micr o bi ot a C h ar acteri z ati o n : C o m p ositi o n, Di versit y, D N A Se q ue n ci n g: I n a s u bset of 
t he st u d y p o p ulati o n (a p pr o xi matel y 1 0 %), t he i ntesti nal micr o bi ota fr o m st o ol sa m ples 
will be c haracterize d i n ter ms of c o m p ositi o n a n d di versit y, as well as se q u e nci n g f or 
s pecific or ga nis ms of i nterest. Bacterial D N A will be is olate d fr o m fecal sa m ples, a n d t he 
h y per -varia ble r e gi o ns of t he 1 6 S r R N A ge ne will be a m plifie d usi n g t w o -ste p P C R 
se q ue nci n g tec h n ol o g y. All st o ol sa m ples a n d D N A is olates will be st ore d t o all o w f or 
p ote ntial f ut ure  a nal ysis. 

P a ge 5 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• L o n g -ter m st o r a ge f or f ut ure e x pl or at or y a n al ysis. S u bjects m ust be a d vise d of a n d 
pr o vi de c o nse nt t o t his st o ol c ollecti o n f or st ora ge. A d diti o nal s u bst u dies ma y b e  defi ne d 
i n t he f ut ure. 
6. 3. 4  
Uri ne a n d Ser u m Pre g n a nc y  Tests  
 
Ser u m pre g na n c y  tests will be perf or me d f or all fe males of c hil d beari n g p ot e ntial a n d t h ose 
w h o ha ve ha d a t u bal li gati o n at Visit 1 ( Scree ni n g) a n d Visit 1 6 ( E O T). Uri ne pre g n a nc y 
tests will be perf or me d f or all fe males of c hil d beari n g p ote ntial a n d t h os e w h o ha ve ha d a 
t u bal li gati o n at Visit 2 ( Baseli ne/ Ra n d o mizati o n) pri or t o ra n d o mizati o n a n d at Visit 7, Visit 
1 0, a n d Visit 1 3. T he Visits 1 a n d 2 pre g na nc y t ests m ust be c o nfir me d as n e gati ve bef ore t he 
a d mi nistrati o n of st u d y dr u g.  
6. 3. 5  
S af et y M o nit ori n g f or C.  difficile  
 
St o ol sa m ples m ust be c ollecte d a n d teste d f or C. difficile T o xi n B ge ne (tc d B) usi n g real - 
ti me p ol y m eras e c h ai n reacti o n ( P C R) met h o d f or a n y s u bject w h o has w orse ni n g, ac ute 
diarr hea a n d a b d o mi nal p ai n d uri n g t he st u d y, d efi ne d b y:  
 
• S u bject ha d at least 3 u nf or me d (l o ose or water y) st o ols i n t he last 2 4 h o urs. 
A N D  
• S u bject has at least 1 ot her si g n of e nt eric i nfecti o n prese nt, s uc h as fe v er, na usea/l oss of 
a p petite, v o miti n g, se ver e a b d o mi nal pai n or  disc o mf ort.  
• 
St o ol sa m ples testi n g p ositi ve f or  C. difficile T o xi n B, will be c ult ure d a n d  teste d 
f or resista nce t o select a nti bi otics. 
All p ositi ve test res ults will be rec or d e d as a n a d verse e ve nt.  
 
6. 3. 6  
A d verse  E ve nts  
 
T he i n vesti gat or is res p o nsi ble f or t he detecti o n a n d d oc u me ntati o n of e ve nts t hat mee t t he 
defi niti o n of a n a d verse e ve nt ( A E) or s eri o us a d v erse e v e nt ( S A E) as pr o vi de d i n t his 
pr ot oc ol ( Secti o n 7. 0). Assess me nts of occ urre nces of A Es or S A Es s h o ul d be c o n d ucte d 
d uri n g eac h st u d y visit or as re p orte d b y t h e s u bject o utsi de of sc he d ule d vi sits. I n or d er t o 
f ulfill i nter nati o nal safet y re p orti n g o bli gati o ns, t he i n vesti gat or s h o ul d i ncl u de i n his or her 
assess me nt a n y A Es r es ulti n g fr o m st u d y p artici pati o n re gar dless of relati o n t o st u d y dr u g 
(e. g., c o m plicati o ns res ulti n g fr o m t he ta ki n g of a bl o o d sa m ple).  
6. 3. 7  
P h ysic al  E x a mi n ati o n  
 
A f ull p h ysical e x a mi nati o n will be perf or m e d d uri n g Visit 1, Visit 7, a n d Visit 1 6 ( E O T). A 
s y m pt o m-direct e d p h ysical e x a mi nati o n will be perf or me d at ot her visits. All p h ysical e x a ms 
will i ncl u de t he assess me nts re q uire d f or C D AI calc ulati o n.  

Page 54 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
6.3.8 
Vital Sign Assessments 
 
Vital sign assessments (sitting blood pressure, pulse, and temperature) will be performed at 
each clinic visit. Vital signs will be measured after the subject has been seated for 5 minutes. 
Weight will be measured at each clinic visit. Height will only be collected at Visit 1. 
6.3.9 
Electrocardiogram (ECG) 
 
A standard 12 lead ECG (at rest) will be performed on all subjects at Visits 1, 7, 16 and 17. 
The baseline ECG obtained at Visit 1 will be performed in triplicate (i.e., three 12-lead ECGs 
obtained 3 minutes apart). A print out of the ECG reports must be available in the source 
documentation. The investigator will evaluate if the patient should enter the study based on 
any findings on ECG. 
6.4 
Other Assessments 
 
6.4.1 
Medical History 
 
Each subject’s relevant medical history is to be recorded in source documents and the 
appropriate CRF pages. Medical history (including past enteric infections) will include a 
detailed history of the subjects CD (e.g., date of onset, surgical history, location of disease, 
etc.). 
6.5 
Pharmacokinetics 
 
Samples will be collected at Visit 2, at Visit 6, and at Visit 15. Collection and recording of 
the date and time of the last dose administered prior to the visit is required at each visit in 
order to most accurately estimate rifaximin exposure. Steady-state rifaximin concentrations 
are anticipated for collections at Visits 6 and 15. 
 
Statistical analysis (including exploratory data analysis and population modeling) will be 
described in detail in the Pharmacokinetics Statistical Analysis Plan (PSAP) document. The 
PSAP will be finalized prior to the pharmacokinetic analysis. 

P a ge 5 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
7. 0  
S A F E T Y  R E P O R TI N G  
 
Sali x mai ntai ns a r o b ust p har m ac o vi gila nce s yste m c o m prise d of a g o ver n a nce fra me w or k 
a n d sta n dar d o perati n g pr oce d ures s u p p orti n g a s yste matic pr ocess f or re vi e w, e val u ati o n, a n d 
ma na ge me nt of acc u m ul ati n g safet y data fr o m cli nical trials a n d ot her s o urces  t o: 
 
• I d e ntif y a p ote ntial new safet y  si g nal; 
• E ns ure t hat a n i n vesti gati o nal pr o d uct’s ris ks are a de q uatel y assess e d a n d c o m m u nicate d 
t o i n vesti gat ors, I R Bs/I E Cs, a n d re g ulat or y b o dies d uri n g cli nical de vel o p m e nt.  
• F or t his st u d y, safet y m o nit ori n g acti vities will i ncl u de b ut are n ot li mite d  t o: 
• Re vie w a n d e v al uati o n of si n gle S A E o cc urre nces i n real -ti me as re p orte d t hr o u g h t he 
S A E re p orti n g pr ocess as o utli ne d i n t his secti o n of t he  pr ot oc ol;  
• Re vie w a n d e v al uati o n, i n real -ti me, of o n e or m ore occ urre n ces of a n u nc o m m o n  S A E 
t hat is n ot c o m m o nl y ass ociate d wit h pr o d uct  e x p os ure;  
• Fi n di n gs a n d/ or saf et y d ata o btai ne d d uri n g t his st u d y will pr o vi de i nf or m ati o n f or t he 
o verall re vi e w of safet y t hat is c o n d u cte d b y Sali x o n a r o uti ne basis. Sali x will re p ort 
e x pe diti o usl y a n y f i n di n gs fr o m cli nical trials ( o n g oi n g or c o m plete d), e pi de mi ol o gical 
st u dies, p o ole d a nal ysis of m ulti ple st u dies, a n d fi n di n gs fr o m a ni mal or i n vitr o testi n g 
t hat s u g gest a si g nifica nt ris k i n h u ma ns e x p ose d t o t he st u d y pr o d u ct.  
Safet y d ata c ollecti o n f or t his st u d y b e gi ns at t he ti me of t he s u bject’s si g ni n g of t he i nf or me d 
c o nse nt acc or di n g t o t he o perati n g defi niti o ns defi ne d i n t his secti o n of t he pr ot oc ol. T he 
i n vesti gat or is r es p o nsi ble f or t he d etecti o n a n d d o c u me ntati o n of e ve nts t h at meet t he 
de fi niti o n of a n u na ntici p ate d pr o ble m (refer t o t he pr ot oc ol Secti o n 1 0. 1), A E or S A E. 
7. 1  
O per ati n g Defi niti o ns f or Assessi n g  S afet y  
 
7. 1. 1  
A d verse  E ve nt  
 
A n A E is a n y u nt o war d me dical occ urre n ce i n a s u bject or cli nical i n vesti gati o n s u bject 
a d mi nistere d a st u d y pr o d uct a n d w hic h d oes n ot necessaril y h a ve a ca us al relati o ns hi p wit h 
t he treat me nt. 
A n A E ca n t her ef or e be a n y u nfa v ora ble a n d u ni nte n de d si g n (t hat c o ul d i ncl u de a cli nicall y 
si g nifica nt a b n or mal la b orat or y fi n di n g), s y m pt o m, or diseas e te m p orall y ass ociate d wit h t he 
use of a st u d y pr o d uct, wit h o ut a n y j u d g m e nt a b o ut ca usalit y (i. e., w het her or n ot c o nsi dere d 
relate d t o t he st u d y pr o d u ct). 
 
A n A E d oes i ncl u de t he f oll o wi n g: 

P a ge 5 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• E x acer bati o n or w orse ni n g of a pre -e xisti n g ill ness. N O T E: if t he pre -e xisti n g ill ness is 
t he disease u n der st u d y, t he n “e x acer b ati o n” refers t o a n u ne x pecte d w orse ni n g fr o m t he 
c o n diti o n at  baseli ne.  
• I n crease i n fr e q ue n c y or i nte nsit y of a pre-e xisti n g e pis o dic e ve nt or  c o n diti o n.  
• C o n diti o n detecte d or dia g n ose d after st u d y pr o d u ct a d mi nistrati o n e ve n t h o u g h it ma y 
ha ve bee n pres e nt pri or t o t he start of t he  st u d y. 
• S y m pt o m ass o ciate d wit h disease n ot pre vi o usl y re p orte d b y t he  s u bject. 
A n A E d oes n ot i ncl u de t he f oll o wi n g: 
• Me dical or s ur gi cal pr o ce d ures (e. g., s ur ger y, e n d osc o p y, t o ot h e xtracti o n, tra nsf usi o n) as 
e ve nt ter ms; t he c o n diti o n t hat le d t o t he pr oce d ure is t he A E if it meets t he defi niti o n of a n 
A E.  
• Sit uati o ns w here a n u nt o war d me dical occ urre n ce has n ot occ urre d (e. g.,  h os pitalizati o n 
f or c os metic el ecti ve s ur ger y; a n d s ocial a n d/ or c o n ve nie nce a d missi o ns).  
• O ver d ose of eit her st u d y pr o d uct or c o nc urre nt me dicati o n wit h o ut a n y si g ns or  s y m pt o ms. 
• S y m pt o ms ass o ciate d wit h disease, w hic h are c o nsiste nt wit h t he s u bject’s us ual cli nical 
c o urse; u nless t he s u bject e x perie nces w orse ni n g of t heir s y m pt o m(s) or t he s y m pt o m(s) 
meet t he criteri a f or a n S A E.  
7. 1. 2  
Seri o us A d verse  E ve nt  
 
A S A E is a n y A E, occ urri n g at a n y d os e, w hic h res ults i n a n y of t he f oll o wi n g o utc o mes 
(“ Occ urri n g at a n y d ose” d oes n ot i m pl y t h at t he s u bject recei ve d st u d y pr o d uct): 
 
• Res ults i n deat h  
• Is life t hreat e ni n g 
N O T E : Lif e-t hr eate ni n g mea ns t hat t he s u bject w as, i n t he vie w of t he i n v esti gat or or 
s p o ns or, at i m me diate ris k of deat h at t he ti me of t he e ve nt. T his defi niti o n d oes n ot refer 
t o a n e ve nt w hic h h y p ot h eticall y mi g ht ha ve ca us e d deat h if it were m ore se vere. 
 
• Re q uires i n patie nt h os pitalizati o n or pr ol o n gati o n of e xisti n g  h os pitalizati o n  
N O T E : C o m plicati o ns t hat occ ur d uri n g h os pitalizati o n are A Es. If a c o m plicati o n 
pr ol o n gs h os pitalizati o n or f ulfills a n y ot h er seri o us criteria, t he e ve nt is seri o us.  
H os pitalizati o n f or electi ve treat me nt of a pre -e xisti n g c o n diti o n t hat di d n ot w orse n fr o m 
baseli ne is n ot c o nsi dere d t o be a n A E. “I n -patie nt” h os pitalizati o n mea ns t he s u bject has 
bee n f or m all y a d mitte d t o a h os pital f or me dical reas o ns. T his ma y or ma y n ot be 
o ver ni g ht. It d o es n ot i ncl u de prese ntati o n at a cas ualt y or e me r ge nc y r o o m. 

P a ge 5 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• A persiste nt or si g nifica nt i nca pacit y or s u bsta ntial disr u pti o n of t he a bilit y t o c o n d uct 
n or mal life  f u ncti o ns. 
N O T E: T he ter m disa bilit y mea ns a s u bsta ntial disr u pti o n of a pers o n’s a bilit y t o c o n d uct 
n or mal life f u ncti o ns. T h is defi niti o n is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y 
mi n or me dical si g nifica n ce s uc h as u n c o m plicate d hea dac he, na us ea, v o miti n g, diarr hea, 
i nfl ue nza, or acci de ntal tr a u ma (e. g., s prai ne d a n kl e) t hat ma y i nterfere or pre ve nt 
e ver y da y lif e f u n cti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pti o n.  
• A c o n ge nital a n o mal y or birt h defect i n t he offs pri n g of a s u bject w h o recei ve d st u d y 
pr o d uct.  
• I m p ort a nt me dical e v e nts t hat d o n ot res ult i n deat h, are n ot life-t hreate ni n g, or  re q uire 
h os pitalizati o n  ma y be c o nsi dere d a n S A E w h e n, base d u p o n a p pr o priate me dical 
j u d g me nt, t he y ma y je o p ar dize t he s u bject a n d ma y re q uire me di cal or s ur gical 
i nter ve nti o n t o pre ve nt o ne of t he o utc o mes liste d i n t his defi niti o n.  
N O T E : E x a m ples of s uc h me dical e ve nts i ncl u de aller gic br o n c h os pas m re q uiri n g 
i nte nsi ve treat me nt i n a n e mer ge n c y r o o m or at h o me, bl o o d d yscrasias or c o n v ulsi o ns 
t hat d o n ot res ult i n i n patie nt h os pitalizati o n, or t he de vel o p me nt of dr u g de pe n de nc y or 
dr u g a b use.  
 
A d diti o nall y, a n a d v erse e ve nt meeti n g a n y of t h e seri o us o utc o mes pre vi o usl y defi n e d a b o ve 
t hat is assesse d b y t he i n vesti gat or as res ulti n g fr o m st u d y partici pati o n (re gar dless of 
relati o ns hi p t o st u d y dr u g) s h o ul d be treate d as a S A E f or t his pr ot oc ol (e. g., c o m plicati o ns 
res ulti ng fr o m t he ta ki n g of a bl o o d sa m ple or perf or ma nce of a pr ot oc ol re q uire d pr oce d ure).  
Me dical a n d sci e ntific j u d g me nt s h o ul d be use d i n deci di n g w het her pr o m pt re p orti n g is 
a p pr o priate i n case of e v e nts t hat d o n ot meet t he seri o us criteria a b o ve.  
7.2 
Cli nic al  L a b or at or y A b n or m alities a n d Ot her A b n or m al Assess me nts as  A Es 
a n d S A Es  
 
A b n or mal la b orat or y fi n di n gs (e. g., cli nical c h e mistr y, he mat ol o g y, a n d uri nal ysis) or ot her 
a b n or mal assess me nts ( e. g., a b n or mal fi n di n gs d uri n g e x a mi nati o ns or E C G m o nit ori n g)  t hat 
are j u d ge d b y t he i n v esti gat or as cli nic all y si g nific a nt m ust be rec or de d as A Es or S A Es if 
t he y meet t he defi niti o n of a n A E or S A E. T he i n vesti gat or s h o ul d e x ercise his or her 
me dical a n d scie ntific j u d g me nt i n deci di n g w h et her a n a b n or mal la b orat or y fi n di n g or ot her 
a b n or mal assess me nt (i n cl u di n g E C G m o nit ori n g) is cli nicall y si g nifi ca nt. 
7.3 
Met h o d, Fre q ue nc y, a n d Ti me Peri o d f or Detecti n g A Es a n d  S A Es  
 
At eac h visit, after t he s u bject has ha d a n o p p ort u nit y t o s p o nta ne o usl y me nti o n a n y 
pr o ble ms, t he i n ves ti gat or s h o ul d i n q uire a b o ut A Es b y as ki n g t he f oll o wi n g sta n dar d 
q uesti o ns:  

Page 58 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
1. "Have you had any (other) medical problems since your last visit/assessment?" 
2. "Have you taken any new medicines, other than those given to you in this study, since 
your last visit/assessment?" 
7.3.1 
The Time Period for Detecting and Reporting of AEs and SAEs 
 
The Time Period for Detecting and Reporting of AEs and SAEs is from the time of informed 
consent through study completion/withdrawal, including the follow-up period. 
7.3.2 
Post-Study SAEs 
 
Investigators are not obligated to actively seek SAE information in former study participants, 
but investigators are encouraged to notify Salix of any SAEs occurring at any time after a 
subject has discontinued or terminated study participation that they judge may reasonably be 
related to study treatment or study participation. 
7.4 
Documenting AEs and SAEs 
 
All AEs that occur after the subject has signed the ICF and during the course of the study, 
regardless of causality or seriousness, will be assessed and recorded in the subject’s medical 
records and in the CRF. In addition, SAEs must be documented on the paper SAE Report 
Form. 
 
A separate paper SAE Report Form should be used for each SAE. However, if at the time of 
initial reporting, multiple SAEs are present that are temporally and/or clinically related, they 
may be reported on the same SAE Report Form. 
 
The investigator should attempt to establish a diagnosis for the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE and SAE and not the individual signs/symptoms. 
For clinically significant abnormal laboratory findings or other abnormal assessments meeting 
the definition of an AE or SAE, a diagnosis, if known (or clinical signs and symptoms if 
diagnosis is unknown), should be recorded by the investigator. If a diagnosis is unknown and 
clinical signs and symptoms are not present, then the abnormal finding should be recorded. 
When documenting as an SAE on the SAE Report Form, relevant laboratory data should 
either be recorded in the ‘Details of Relevant Assessments’ section of the SAE Report Form 
(including the reference range and units) or copies of the laboratory report (with reference 
ranges and units) should be sent with the SAE Report Form. 
The SAE Report Form should be completed as thoroughly as possible and signed by the 
investigator or his/her designee before transmittal to Salix Product Safety or Designee. It is 
very important that the investigator provide his/her assessment of causality to study product 
at the time of initial SAE reporting. 

P a ge 5 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
7. 5  
F oll o w -u p of A Es a n d  S A Es  
 
All A Es, re gar dl ess of seri o us ness, m ust be f oll o we d u ntil res ol uti o n, u ntil t he c o n diti o n 
sta bilizes, u ntil t he e ve nt is ot her wise e x plai ne d, or t he s u bject is l ost t o f oll o w-u p. T he 
i n vesti gat or is r es p o nsi ble t o e ns ure t hat f oll o w-u p i ncl u des a n y s u p ple me ntal i n vesti gati o ns 
as ma y b e i n dicate d t o el uci date as c o m plet el y as practical t he n at ure a n d/ or ca usali t y of t he 
A E. T his ma y i ncl u d e a d diti o nal la b orat or y tests or i n vesti gati o ns, hist o pat h ol o gical 
e x a mi nati o ns, rele va nt h os pital rec or ds (i.e. dis c h ar ge s u m mar y), or c o ns ultati o n wit h ot her 
healt h car e pr of essi o nals.  
Sali x ma y re q u est t hat t he i n vesti gat or perf or m or arra n ge f or t h e c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uati o ns. If a s u bject dies d uri n g partici pati o n i n t he st u d y or d uri n g 
a rec o g nize d f oll o w -u p p eri o d, Sali x s h o ul d be pr o vi de d wit h a c o p y of a n y p ost m orte m 
fi n di n gs, i ncl u di n g histo pat h ol o g y.  
 
F or S A Es, ne w or u p date d i nf or mati o n s h o ul d be rec or de d o n t h e ori gi nall y c o m plete d pa per 
S A E Re p ort F or m a n d all c ha n ges si g ne d a n d date d b y t he I n vesti gat or or d esi g nee. B y 
si g ni n g t he S A E Re p ort F or m, t he i n vesti gat or or desi g nee attests t o t he acc urac y a n d 
c o m plete ness of t he d ata a n d t hat he/s he has re vie we d a n d a p pr o ve d t he re p ort bei n g 
s u b mitte d. T he i n vesti gati o nal sites I R B/I E C m ust be n otifie d a b o ut S A Es i n acc or d a nce 
wit h t he re q uire me nts of t he g o v er ni n g I R B/I E C.  
7. 6  
Pr o m pt Re p orti n g of  S A Es t o S ali x  P h ar m a ce utic als  
 
S A Es m ust be re p orte d pr o m ptl y t o Sali x Pr o d uct Safet y or Desi g n ee o nce t he i n vesti gat or 
deter mi nes t hat t he e v e nt meets t he pr ot oc ol defi niti o n of a S A E.  
 
Pr o m pt re p orti n g of a S A E re q uires:  
 
• C o m pleti o n a n d tra ns missi o n of t he S A E Re p ort F or m t o Sali x Pr o d uct Safet y or Desi g nee 
via fa x wit hi n 2 4 h o urs of t he i n vesti gat or’s k n o wle d ge of t he e v e nt. I n parallel, a 
c orres p o n di n g A E wit h t he S A E details s h o ul d be e ntere d i nt o t he A E  C R F.  
• Pr o m pt re p orti n g of a d diti o nal i nf or mati o n f or pre vi o usl y re p orte d S A Es s h o ul d f oll o w  t he 
sa me re p orti n g ti mefr a m e as i nitial re p orts. I n a d diti o n, t he c orres p o n di n g A E i n t he A E 
C R F (as a p plica bl e) s h o ul d be u p date d t o e ns ure all data p oi nts d oc u me nte d i n t he A E 
C R F are ali g ne d wit h t he matc hi n g d ata p oi nts o n t he pa per S A E Re p ort  F or m.  
7. 7  
Pre g n a nc y Re p orti n g  
 
Pre g n a ncies d etecte d i n s u bjects assi g n e d t o st u d y treat me nt s h o ul d be pr o m ptl y re p ort e d t o 
Sali x Pr o d uct Safet y or Desi g n ee via fa x as s o o n as t he i n vesti gat or is n ot ifie d usi n g t he Sali x 
Pre g n a nc y N otificati o n F or m. If a f e male s u bject bec o mes pre g na nt f oll o wi n g assi g n me nt t o 
st u d y treat me nt, t he st u d y pr o d u ct will be i m me diatel y disc o nti n ue d a n d t h e s u bject will be 

Page 60 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
followed until the outcome of the pregnancy is known. (Refer to the ‘Females of 
Reproductive Potential’ Section 4.4). 
 
Salix Product Safety or Designee should be notified via fax of any updates on the status of the 
pregnancy as soon as the information becomes available by update and/or amendment of the 
initial pregnancy notification form. 
Although pregnancy occurring in a clinical study is not considered to be an AE or SAE, any 
pregnancy complication or elective termination of a pregnancy, for medical reasons, will be 
recorded as an AE or SAE and followed as such. 
7.8 
Transmission of SAE Report Forms and Pregnancy Notification Forms 
 
Completed SAE Report Forms and completed Pregnancy Notification Forms should be 
transmitted via the country specific fax numbers listed in the SAE Form Completion 
Guidelines which are provided in the Study Reference Manual. 
 
For questions regarding SAE and/or Pregnancy reports, country specific phone numbers are 
listed in the SAE Form Completion Guidelines which are provided in the Study Reference 
Manual. 
7.9 
Regulatory Reporting Requirements for SAEs 
 
The investigator, or responsible person per local requirements, must comply with the 
applicable local regulatory requirements related to the reporting of SAEs and expedited safety 
reports to regulatory authorities and their IRB/IEC. 

P a ge 6 1  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
8. 0  
S T A TI S TI C A L  C O N SI D E R A TI O N S  
 
A detaile d statistical a nal ysis pla n will be pre p are d f or t his st u d y. T he pla n will c o ntai n a 
disc ussi o n of t he statistical met h o ds, a descri pti o n of t he c o m p utati o nal al g orit h ms a n d data 
ha n d li n g c o n v e nti o ns, a n d s pecificati o ns f or t h e d ata s u m maries a n d listi n gs. It will be 
fi nalize d bef ore d ata base l oc k. 
8. 1  
R a n d o miz ati o n  
 
S u bjects w h o s uccessf ull y c o m plet e t he Scree ni n g Peri o d will e nter t he Treat me nt Peri o d a n d 
will be ra n d o mize d i n a 1: 1 all o cati o n t o o ne of t w o treat me nt gr o u ps f or t h e d urati o n of t he 
st u d y as assi g ne d b y t h e mea ns of ce ntralize d electr o nic ra n d o mizati o n s yst e m. 
Ra n d o mizati o n will be stratifie d b y st u d y ce nter wit hi n a c o u ntr y. Treat me nt gr o u ps are as 
f oll o ws: 
• Treat me nt  A:  
Rifa xi mi n D R 8 0 0 m g  BI D  
• Treat me nt  B:  
Place b o  BI D  
8. 2  
Deter mi n ati o n of S a m ple  Size  
 
T he i nf or mati o n bel o w pr o vi des t he bac k gr o u n d i nf or mati o n f or sa m ple si ze deter mi nati o n 
f or t he i n d ucti o n of cli nical re missi o n wit h e n d osc o pic res p o nse at 1 6 wee ks f oll o we d b y 
cli nical a n d e n d osc o pi c r e missi o n at 5 2 wee ks. F or place b o, t he e x pecte d rates are base d o n 
data fr o m  a P hase  2  st u d y ( R E TI C 0 3/ 0 6)  c o n d uct e d  i n s u bjects wit h  acti ve m o derate  Cr o h n’s 
disease. T he rates f or Rifa xi mi n D R are base d o n t he as s u m pti o n t hat Rifa xi mi n D R will 
pr o vi de a s o me w h at hi g h er i n d ucti o n of re missi o n  rate. 
E x pecte d rates f or i n d u cti o n of cli nical re missi o n wit h e n d osc o pic res p o ns e at Wee k 1 6 are 
4 0 % f or place b o a n d 5 5 % f or Rifa xi mi n D R.  
 
Base d o n a si g nifica n ce l e vel of 5 %  (al p ha 0. 0 5), a sa m ple size of a p pr o xi matel y 2 4 0 s u bjects 
per treat me nt gr o u p will ha ve at least 9 0 % p o wer t o test t he h y p ot hesis t hat Rifa xi mi n D R is 
s u peri or t o place b o f or eac h c o-pri mar y e n d p oi nt c o nsi dere d i n di vi d uall y. A p pr o xi matel y 
8 0 % p o wer is a v a ila ble t o detect si g nifica nt differe nces bet w ee n Rifa xi mi n D R a n d place b o 
f or b ot h c o-pri mar y e n d p oi nts.  
F or t he L o n g T er m Tr eat me nt P hase, a 1 5 % treat me nt effect is e x pecte d f or b ot h cli nical 
s y m pt o m a n d e n d osc o pi c re missi o n at Wee k 5 2. Base d o n t his ass um pti o n a n d testi n g at a 
si g nifica n ce le v el of 5 % (al p ha 0. 0 5), a sa m ple size of a p pr o xi matel y 2 1 0 s u bjects per 
treat me nt gr o u p will ha v e at least 9 0 % p o w er t o t est t he ke y sec o n d ar y effi cac y h y p ot hesis 
t hat Rifa xi mi n D R is s u peri or t o place b o w he n eac h ke y c o-s ec o n d ar y e n d p oi nt is c o nsi dere d 
i n di vi d uall y. I n a d diti o n, a p pr o xi matel y 8 0 % p o wer is a v aila ble t o detect si g nifi ca nt 
differe n ces b et wee n Rif a xi mi n D R a n d place b o f or eac h of t he ke y c o -sec o n dar y e n d p oi nts. 

P a ge 6 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
A n a d diti o nal c o nsi derati o n f or sa m ple size deter mi nati o n is t he a p plicati o n of a n i nflati o n 
fact or of 2 0 % t o acc o u nt f or dr o p-o ut rates d uri n g t he I n d u cti o n a n d L o n g T er m Treat me nt 
P hases of t he st u d y. T his c o nsi derati o n s u g geste d t hat 3 3 0 s u bjects per treat me nt gr o u p 
w o ul d be re q uir e d at st u d y e ntr y.  
8. 3  
A n al ysis P o p ul ati o ns 
I nte nt-t o-Tre at (I T T)  P o p ul ati o n  
T he I T T p o p ulati o n will i ncl u de all ra n d o mize d s u bjects w h o ta ke at least o ne d ose of st u d y 
dr u g.  
Per Pr ot oc ol ( P P) P o p ul ati o n will i ncl u de all s u bjects i n t he I T T P o p ulati o n wit h t he 
e x ce pti o n of t h ose w h o f aile d t o meet I ncl usi o n Criteria 3 a n d 4; or met E x cl usi o n Criteria 1, 
2, 1 3 or 1 4.  
 
T he a nal yses of baseli ne c haracteristics a n d efficac y will be  perf or me d f or t he I T T 
P o p ulati o n. T he pri mar y efficac y a n al ysis als o will be perf or m e d o n t he P P P o p ulati o n as a 
se nsiti vit y a nal ysis. All safet y a n al ys es will be perf or me d o n t he I T T P o p ul ati o n. 
8. 4  
S u bject  Dis p ositi o n  
 
S u bject dis p ositi o n will be s u m marize d  b y treat me nt a n d st u d y p has e a n d will i ncl u de t he 
n u m ber of s u bjects e nt er e d i n t he st u d y; n u m ber a n d perce nt a ge of s u bjects w h o c o m plete d or 
pre mat urel y disc o nti n ue d (classifie d b y reas o ns f or pre mat ure disc o nti n uati o n); t he n u m ber of 
s u bjects e ntere d i n t he st u d y at eac h st u d y site; a n d t he n u m ber a n d perce nta ge of s u bjects 
w h o c o m plete d or disc o nti n ue d at eac h st u d y site.  
8. 5  
De m o gr a p hic a n d B aseli ne  C h ar acteristics  
 
De m o gra p hic a n d baseli n e c har acteristics will be s u m marize d descri pti vel y b y treat me nt 
gr o u p. Bas eli ne will be d efi ne d as t he l ast assess me nts pri or t o i nitiati n g t he Treat me nt 
Peri o d. T he f oll o wi n g d e m o gra p hi c a n d bas eli ne disease c h aracteristics will be s u m marize d:  
 
De m o gr a p hics : 
 
• A ge ( years) = ( dat e of i nf or me d c o nse nt si g ne d –  d ate of  birt h)/ 3 6 5. 2 5;  
• A ge gr o u p ( < 6 5,  > = 6 5);  
• Se x  ( male/fe male); 
• Et h nicit y ( His pa nic or Lati n o/ n ot His pa nic or  Lati n o);  
• Race ( A m erica n I n dia n or Alas ka n Nati ve, Asia n, Blac k or Africa n -A merica n, Nati ve 
Ha waiia n or Ot her Pacifi c Isla n der, W hite, a n d Ot her); s u bjects w h o i de ntif y m ore t h a n 
o ne race will be cate g ori ze d as  “ Ot her”;  

P a ge 6 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• Hei g ht  ( c m); 
• Wei g ht  ( k g); 
• B o d y mass i n de x ( k g/ m 2) = ( Wei g ht i n k g)/ ( Hei g ht i n  m) 2;  
• Re gi o n ( U S/ Rest Of  W orl d).
 
B aseli ne c h ar acteristi cs:  
 
All baseli ne s u bject c h ar acteristics i ncl u di n g de m o gra p hic data ( o utli ne d a b o ve), baseli ne 
C D AI a n d S E S -C D sc ores, d urati o n of t he disease ( years), l ocati o n of disease, pre vi o us 
ster oi d use ( d ose, d ur ati o n), pre vi o us s ur ger y f or C D, s m o ki n g hist or y ( n o ns m o ker/e x - 
s m o ker/s m o ker), bas eli ne C R P a n d fecal cal pr otecti n val ues will be s u m marize d b y treat me nt 
ar m. Baseli ne c o m para bilit y will be assesse d via d escri pti ve meas ures, e. g., b y c o m p ari n g 
mea ns, 9 5 % c o nfi de nce i nter vals a n d pr o p orti o ns.  
8. 6  
A n al ysis  Met h o ds  
 
T he p hrases ‘statisti cal a nal ysis’ or ‘a n al ysis’ will be use d t o mea n i nfere ntial a nal ysis (s u c h 
as perf or mi n g tests of si g nifica nce, re p orti n g p -v al ues a n d c o nfi d e nce i nter vals). W he n n o 
i nfere ntial a n al ysis will b e perf or me d, t he p hrases ‘ descri pti ve a n al ysis’ or ‘ descri pti ve 
statistics’ will be use d (f or i nsta nce, pr o d u ci n g s u m mar y ta bl es of mea ns, sta n dar d de viati o ns, 
perce nt a ges of res p o n ders). All efficac y a n al ys es will be c o n d ucte d o n I T T a n d P P 
p o p ulati o ns. All efficac y a nal ys es will a dj ust f or c o u ntr y.  
8. 6. 1  
Pri m ar y Effic ac y  A n al ysis  
I n d ucti o n P h ase  
T here will be t w o c o -pri mar y m eas ures of efficac y ass esse d d uri n g t he I n d ucti o n P hase. T he 
first c o-pri mar y e n d p oi nt is:  
 
• Cli nical  s y m pt o m re missi o n defi ne d  b y  ( 1) t he t otal n u m ber  of  li q ui d/ ver y s oft st o ols f or 
t he 7 da ys pri or t o t he Wee k 1 6 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1(fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 1 6  visit.  
T he sec o n d c o -pri mar y e n d p oi nt  is: 
 
• E n d osc o pic res p o ns e defi ne d as a ≥3 -p oi nt decreas e i n t he S E S -C D fr o m baseli ne t o t he 
S E S -C D sc ore o btai ne d bet wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D sc ores will be 
calc ulate d fr o m ce ntrall y -rea d di gital vi de o of ile o c ol o n osc o pies perf or me d at baseli ne a n d 
bet wee n Wee k 1 6 a n d Wee k  1 7.  
F or eac h e n d p oi nt, t he n ull h y p ot hesis H 0: π R -π P = 0 vers us t he alter n ati ve H A: π R -π P ≠0 is of 
i nterest, w her e π R is t he bi n o mial para meter f or i n d ucti o n of re missi o n/res p o nse f or t he 

P a ge 6 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
Rifa xi mi n D R gr o u p, a n d π P is t he bi n o mial para meter f or i n d ucti o n of re missi o n/res p o nse 
f or t he place b o gr o u p. S u bjects w h o re q uire t he i nitiati o n of resc ue me di cati o n a n d/ or s ur ger y 
f or C D will be c o nsi der e d treat me nt fail ures fr o m t he date of t he i ntr o d u cti o n of t he resc ue 
me dicati o n a n d/ or s ur g er y, r e gar dl ess of t heir act u al res p o nse dat a. T he C o c hra n -M a ntel - 
Hae nszel ( C M H) test, str atifie d b y c o u ntr y, will b e use d t o test t he h y p ot hesis. Eac h n ull 
h y p ot hesis of n o differ e n ce will be rej ecte d if t he res ulti n g p -val u e f or t he res pecti ve 
statistical test is less t ha n 0. 0 5. Si g nifica nce f or t h e i n d ucti o n clai m will o nl y be d eclare d if 
b ot h n ull h y p ot h eses ar e rejecte d. As s uc h, t he o v erall T y pe I err or rat e will be mai ntai ne d at 
t he 5 % le vel wit h o ut a dj ust me nt f or m ulti ple c o m paris o ns. 
If it is e vi de nt t hat t he res p o nse varia ble is c o nf o u n de d wit h s o me of t he bac k gr o u n d 
varia bles, t he n l o gistic re gr essi o n will be perf or me d usi n g t he b ac k gr o u n d varia bles as 
c o variates. T h e diff ere n ces bet wee n t his a dj uste d a nal ysis a n d t he pre vi o us u na dj uste d 
a nal ysis  will be n ote d, a n d t he i m pact of s uc h differe nces will be disc usse d.  
T he pri mar y efficac y a n al ysis will be re peate d o n t he P P p o p ulati o n t o assess t he r o b ust ness 
of t he res ults of t he pri m ar y o utc o me.  
 
L o n g Ter m Tre at me nt P h ase  
 
T here will be t w o k e y c o -sec o n dar y e n d p oi nts of efficac y ass esse d d uri n g t he L o n g T er m 
Treat me nt P hase. T h e first is:  
 
• Cli nical s y m pt o m r e missi o n defi ne d b y ( 1) t he t ot al n u m ber of li q ui d/ ver y s oft st o ols  f or 
t he 7 da ys pri or t o t he Wee k 5 2 visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D ( 2) a n 
a b d o mi nal pai n rati n g of ≤ 1 (fr o m C D AI It e m 2) o n eac h d a y f or t he 7 d a ys pri or t o t he 
Wee k 5 2  visit.  
T he sec o n d is:  
 
• E n d osc o pic re missi o n defi ne d as a S E S -C D sc ore of ≤ 2 at Wee k 5 2. S E S -C D sc ores will 
be calc ul ate d fr o m ce ntrall y-r ea d di gital vi de o of ile oc ol o n osc o pies perf or me d at Wee k 5 2.  
F or eac h e n d p oi nt, t he n u m ber a n d pr o p orti o n of s u bjects wit h cli nical a n d e n d osc o pic 
re missi o n will be s u m marize d b y treat me nt gr o u p f or t he I T T P o p ulati o n. 
F or  eac h e n d p oi nt, t he n ul l h y p ot hesis H 0:  π R -π P = 0  vers us t he  alter n ati ve H A:  π R -π P  ≠0  is of 
i nterest, w her e π R is t he bi n o mial para meter f or re missi o n f or t he Rifa xi mi n D R gr o u p, a n d 
π P is t he bi n o mial par a meter f or re missi o n f or t he place b o gr o u p. S u bjects w h o re q uire t h e 
i nitiati o n of resc ue me dicati o n a n d/ or s ur ger y f or C D will be c o nsi dere d treat me nt fail ures 
fr o m t he date of t h e i ntr o d ucti o n of t he resc u e me dicati o n a n d/ or s ur ger y, re gar dless of t h eir 
act ual res p o ns e data. T h e C oc hra n -Ma nt el -Hae nszel ( C M H) test, stratifie d b y c o u ntr y, will 
be use d t o test t he h y p ot hesis. Eac h n ull h y p ot h esis of n o differe nce will be rejecte d if t he 
res ulti n g p-v al ue f or t h e r es pecti ve statistical test is less t ha n 0. 0 5. Si g nifica nce f or cli nical 

P a ge 6 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
a n d e n d osc o pic re missi o n will o nl y b e declare d if b ot h n ull h y p ot h eses are rejecte d. As s uc h, 
t he o verall T y pe I err or r ate will be mai ntai ne d at t he 5 % le vel wit h o ut a dj ust me nt f or 
m ulti ple c o m paris o ns.  
If it is e vi de nt t hat t he res p o nse varia ble is c o nf o u n de d wit h s o me of t he bac k gr o u n d 
varia bles, t he n l o gistic re gr essi o n will be perf or me d usi n g t he b ac k gr o u n d varia bles as 
c o variates. T h e diff ere n ces bet wee n t his a dj uste d a nal ysis a n d t he pre vi o us u na dj uste d 
a nal ysis will be n ote d, a n d t he i m pact of s uc h differe nces will be disc usse d.  
8. 6. 2  
Sec o n d ar y Effic ac y  A n al yses  
 
A nal ysis of bi n ar y e n d p oi nts will be base d o n t he met h o ds o utli ne d a b o ve f or t he pri mar y 
efficac y a n al ysis.  
 
F or ti me u ntil d ura ble r es p o ns e t o t he li q ui d/ ver y s oft st o ol c o m p o ne nt of t he c o -pri mar y 
e n d p oi nt d uri n g t he 5 2 -Wee k Treat me nt P hase, a res p o nse will be c o nsi dere d d ura bl e if it 
starte d at Wee k 4 a n d l aste d t hr o u g h Wee k 5 2. A res p o nse is d efi ne d as t otal n u m ber of 
li q ui d/ ver y s oft st ools f or t he 7 da ys pri or t o t he visit bei n g ≤ 1 0 (fr o m C D AI Ite m 1). T h e 
e n d p oi nt is t he n t he ti me w he n t he d ura ble res p o ns e be ga n, or t he first w ee k of res p o nse t h at 
be ga n t he stri n g of c o ns ec uti ve visits wit h res p o nse t hr o u g h Wee k 5 2. It is w ort h re mar ki n g 
t hat t his e n d p oi nt w o ul d n ot be defi ne d f or a s u bject w h o d oes n ot ha ve a d ura ble res p o nse, s o 
we c o nsi der i nstea d t he ti me of t he last visit at w hic h res p o nse was ac hie ve d. F or e x a m ple, if 
a s u bject is cate g orize d as a res p o n der at Wee k 5 2, t he n a d ura ble res p o nse was n ot ac hie v e d. 
If a s u bject is cate g orize d as a res p o n d er at Wee k 2 0, t he n a d ura ble res p o nse starte d o n  Wee k  
2 4. Ti me u ntil d ura ble res p o nse will be a nal yz e d b y t he K ol m o g or o v -S mir n o v test. Ti me 
u ntil d ura ble res p o nse t o t he a b d o mi nal pai n c o m p o ne nt of t he c o -pri mar y e n d p oi nt d uri n g 
t he 5 2-Wee k Treat me nt P hase is a nal yze d si milarl y. A res p o nse is defi n e d as a b d o mi nal pai n 
rati n g of ≤ 1(fr o m C D AI Ite m 2) o n eac h da y f or t he 7 da ys pri or t o t he visit. 
C ha n ge fr o m bas eli ne i n c o n ti n u o us o utc o mes (f or e x a m ple, t he c ha n ge fr o m baseli ne i n t he 
S E S -C D at Wee k 1 6) will be a nal yz e d b y fitti n g fi x e d effects li near m o dels t o t he data. A n 
i nitial m o del wit h ter ms f or treat me nt, c o u ntr y, b aseli ne, a n d baseli ne b y treat me nt i nteracti o n 
will be fitte d.  T he i nteracti o n ter m will be teste d at a 0. 1 0 le vel.  A n o n -si g nifica nt 
i nteracti o n will res ult i n dr o p pi n g t he ter m fr o m t he m o del i n s u bse q ue nt a nal yses. If t he fi nal 
m o del i n v ol ves heter o ge ne o us sl o pes, t he n t he a n al ysis will i ncl u de o verall  pl ots of baseli ne 
vers us c ha n ge fr o m b aseli ne b y tr eat me nt gr o u ps, a n d pl ots of t he esti mate d re gressi o n li nes. 
Treat me nt diff ere n ces will be esti mate d a n d teste d at 2 5t h, 5 0t h a n d 7 5t h perce ntiles of t he 
baseli ne  val ue.  
Ti me t o e ve nt data (f or e x a m ple, t i me t o cli nical re missi o n) will be a nal yze d b y K a pla n-Mei er 
a nal ysis ( P R O C LI E F T T E S T i n S A S/ S T A T) stratifie d b y c o u ntr y. A d diti o nall y, t he c ha n ge 
fr o m baseli ne i n c o nti n u o us o utc o mes meas ure d at m ulti ple p ost-baseli ne ti me p oi nts will be 
a nal yze d l o n git u di nall y usi n g a mi x e d m o del. M o dels will i ncl u de fi x e d effects f or b aseli ne  

P a ge 6 6  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
val ue, c o u ntr y, tr eat me nt, wee k a n d t h e treat me nt b y w ee k i nteracti o n a n d all o w f or ra n d o m 
s u bject eff ects. Tr eat me nt a n d wee k will eac h be fit as cate g ori cal vari a bles . M o dels will be 
fit usi n g  S A S  Pr oc  Mi x e d  ass u mi n g a c o m p o u n d  s y m metric c orrel ati o n  str uct ure all o wi n g f or 
heter o ge n e o us varia n ces b y w ee k. T he Ke n w ar d -R o gers a p pr oac h f or c o m p uti n g 
de n o mi nat or de gr ees of free d o m will be use d t o acc o u nt a p pr o priatel y f or p o oli n g of wit hi n - 
a n d bet wee n -s u bject v ari a nce esti mates. Least s q u ares mea ns wit h 9 5 % c o nfi de nce i ntervals 
will be prese nte d f or eac h treat me nt * wee k cr oss -classificati o n. T he basic S A S c o de will 
f oll o w t he str uct ure b el o w:  
pr oc mi xe d ; 
class treat me nt c o u ntr y wee k s u bjectI D;  
m o del Y = baseli ne c o u ntr y tr eat me nt wee k treat me nt * wee k/ d df m = K e n w ar d R o ger s ol uti o n ; 
ra n d o m i nt/ s u bject =s u bjectI D t y pe = V C; 
ls mea ns treat me nt * wee k/st derr; 
r u n ; 
 
Esti mate a n d c o ntrast state me nts will be i ncl u de d t o c o m pare t he mea n c h a n ge fr o m baseli ne 
a vera ge d o ver all wee ks f or t he treat me nt c o m paris o n.  
T o deter mi ne w h et her t h e declara ti o n of res p o nse base d o n t he c o-pri mar y e n d p oi nts f or 
i n d ucti o n parallels t he patter n of C D AI sc ores, S p ear ma n c orrelati o n a nal yses will be a p plie d 
t o C D AI s c ores wit h t he occ urr e nce or n o n-o cc urre nce of res p o nse b ase d o n t he c o -pri mar y 
e n d p oi nts ( Yes or N o). Wilc o x o n ra n k -s u m test will be c o n d ucte d t o c o m pare c h a n ges i n t he 
C D AI s c ores b et wee n res p o n ders a n d n o n -res p o n d ers t o t he c o-pri mar y e n d p oi nts.  
 
T he W or k Pr o d ucti vit y a n d Acti vit y I m pair m e nt Q uesti o n naire: Cr o h n’s disease ( W P AI:  C D) 
is a n i nstr u me nt wit h 6 q uesti o ns t hat will be use d t o assess t he effect of C D o n s u bjects’ 
w or k ha bits. A c o p y of t h e W P AI: C D q uesti o n naire is pr o vi de d i n A p pe n di x  6.  
W P AI: C D o utc o mes ar e e x presse d as i m pair me nt perce nt a ges, wit h hi g her n u m bers 
i n dicati n g gr eater i m pair me nt a n d less pr o d ucti vit y, i.e., w orse o utc o mes. T he f o ur W P AI: 
C D o utc o me sc ores are c o m p ute d as f oll o ws:  
 
• % w or k ti me misse d d ue t o C D =  1 0 0 * Q 2/( Q 2 + Q 4)  
• % i m pair me nt w hile w or ki n g d ue t o C D =  1 0 0 * Q 5/ 1 0  
• % o verall w or k i m pair me nt =  1 0 0 *[ Q 2/( Q 2 + Q 4) +[( 1 -Q 2/( Q 2 + Q 4)] *( Q 5/ 1 0)]  
• % acti vit y i m pair me nt d u e t o C D =  1 0 0 * Q 6/ 1 0  
T he I B D Q Gl o bal Sc or e is t he s u m of 3 2 res p o nses, eac h ra n gi n g fr o m 1 t o 7, t h us t he Gl o bal 
Sc ore ra n ges fr o m 3 2 t o 2 2 4; a hi g her sc ore i n dicati n g a b etter q ualit y of life . A c o p y of t he 
I B D Q q u esti o n naire is pr o vi de d i n A p pe n di x 5. 

P a ge 6 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
C ha n ges fr o m bas eli ne i n t he f o ur W P AI: C D a n d I B D Q Gl o bal Sc ore o ut c o mes will be 
a nal yze d b y t h e met h o ds o utli ne d a b o ve f or c o nti n u o us o utc o mes.  
8. 6. 3  
S af et y  A n al yses  
 
Safet y e val uati o ns will b e base d o n t he i nci d e nce, i nte nsit y a n d t y pes of A Es, a n d c ha n ges i n 
vital si g ns, cli nical la b or at or y res ults, p h ysical e x a m a n d electr ocar di o gra ms. C o nc o mita nt 
me dicati o n, e x p os ure t o st u d y me dicati o n a n d treat me nt c o m plia nce will be s u m marize d 
descri pti vel y.  
8. 6. 4  
E xte nt of E x p os ure a n d Tre at me nt  C o m pli a nce  
 
T he n u m ber of s u bjects a d mi nistere d st u d y dr u g, t he d urati o n of e x p os ure t o st u d y dr u g, a n d 
c o m plia nce data will be s u m marize d descri pti vel y.  
8. 6. 5  
A d verse  E ve nts  
 
A d verse e ve nts will be c o de d u si n g t he M e dical Dicti o nar y f or Re g ul at or y A cti vities 
( Me d D R A) c o di n g dicti o nar y. Treat me nt-e mer ge nt A Es will be defi ne d as a n y e ve nt wit h a 
start date occ urri n g o n or after Visit 2 ( D a y 1) or, if pre-e xisti n g, w orse ni n g after Visit 2 ( D a y 
1).  
 
T he i nci de n ce of treat me nt -e mer ge nt A Es will be s u m marize d b y b o d y s yste m a n d Me d D R A 
preferre d t er m. If a s u bject re p orts t he sa m e A E m ore t ha n o nce, t he n t hat s u bject will o nl y 
be c o u nte d o nce f or t h e s u m mar y of t hat A E, usi n g t he m ost se vere i nte nsit y.  
 
Treat me nt -emer ge nt A Es will be s u m marize d as f oll o ws:  
 
• All treat me nt -e mer ge nt  A Es;  
• All treat me nt -e mer ge nt A Es b y  i nte nsit y; 
• All treat me nt -e mer ge nt A Es r elate d t o st u d y dr u g;  
• All treat me nt -e mer ge nt S A Es;  a n d  
• All treat me nt -e mer ge nt A Es t hat le d t o pre mat ure disc o nti n uati o n of st u d y  dr u g.  
 
8. 6. 6  
Cli nic al L a b or at or y  Assess me nts  
 
La b orat or y v al ues will be s u m marize d at baseli ne a n d at eac h ti me p oi nt. I n a d diti o n, c ha n ges 
fr o m baseli ne t o last visit will be s u m marize d. 
 
A s u m mar y of s hifts fr o m baseli ne t o fi nal e val u ati o n will be gi ve n f or eac h treat me nt gr o u p 
f or eac h par a meter. T he n or mal ra n ge f or eac h p ara meter will be use d t o create cate g ories of 
l o w, n or mal, or hi g h. A n y r es ult hi g her t ha n U L N or l o wer t ha n t he l o w er li mit of n or mal 
( L L N) will be cate g orize d as hi g h or l o w res pecti vel y, a n d a n y res ult wit hi n t he l o wer a n d  

Page 68 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
upper limits of normal will be categorized as normal. The number and percentage of subjects 
in each treatment group in each shift category from baseline to final evaluation will be shown 
for each parameter. 
All potentially clinically significant values for clinical laboratory tests will be assessed by the 
investigator. Out of range laboratory values that may be potentially clinically significant will 
be flagged for review. 
8.6.7 
Vital Signs 
 
Vital sign measurements will be summarized at baseline and at each time point. In addition, 
changes from baseline to last visit in vital sign measurements will be summarized. For each 
summary the number, mean, median, standard deviation, minimum, and maximum values will 
be presented by treatment and study phase. 
8.6.8 
Concomitant Medications 
 
Concomitant medications taken from screening and during the study will be categorized by 
World Health Organization (WHO) classification for therapeutic class and drug name and 
summarized by number and percentage of subjects. 
8.6.9 
Physical Examinations 
 
Physical examination data will be presented in a data listing. 
 
8.6.10 
Electrocardiogram 
 
ECG parameters will be summarized by treatment group using descriptive statistics. In order 
to assess the QT interval data, corrected QT (QTc) values will be calculated based on the 
following three methods. 
 
1) Fridericia’s correction: QTc=QT/RR0.33, 
 
2) Bazett’s Correction: QTc=QT/RR0.5 , 
And 
3) Correction based on linear regression techniques: Based on the data from 
baseline study population, the intercept(a) and slope (b) will be estimated 
separately for males and females using the equation QT=a+b(1-RR). Those 
estimates will be used to calculate the corrected QT values at post baseline 
time points. 

P a ge 6 9  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
Q Tc i nter val d ata at p ost -baseli ne visits will t he n be s u m marize d descri pti vel y b y ce ntral 
te n de nc y tec h ni q ues. I n a d diti o n, t he fre q ue nc y c o u nts a n d perce nta ges b y treat me nt  gr o u p 
f or t he f oll o wi n g cat e g ories will be  pr o vi de d:  
> 4 5 0 wit h Bas eli ne  < = 4 5 0,  
 
> 4 8 0 wit h Bas eli ne  < = 4 8 0,  
 
> 5 0 0 wit h Bas eli ne < = 5 0 0, 
I n creases fr o m baseli ne > 3 0 a n d 
I n creases fr o m baseli ne > 6 0. 
8. 7  
St atistic al a n d A n al ytic al  Iss ues 
 
8. 7. 1  
A dj ust me nt f or  C o v ari ates  
 
Efficac y a nal ys es will be a dj uste d f or c o u ntr y a n d baseli ne val ues.  
 
8. 7. 2  
H a n dli n g of Dr o p o uts or Missi n g  D at a  
 
Missi n g data will be ha n dle d usi n g t he W orst Case a nal ysis met h o d f or t he pri mar y a n d ke y 
sec o n dar y e n d p oi nts. I n t he W orst Case a nal ysis, s u bjects wit h fe wer t ha n 4 da ys of diar y 
data i n a gi ve n w ee k will be c o nsi dere d n o n -res p o n ders f or t hat w ee k. A d diti o nall y, s u bjects 
wit h missi n g S E S -C D data will be classifie d n o n -res p o n der f or t hat meas ure i n t hat wee k. 
T he f oll o wi n g t hr ee s e nsiti vit y a nal yses will be c o n d ucte d t o a d dress  t he i m pact of missi n g 
data o n t he pri mar y a n d ke y s ec o n dar y e n d p oi nts:  
L ast O bser v ati o n C arri e d F or w ar d ( L O C F) A n al ysis : I n t he first a nal ysis, missi n g val ues 
will be re place d wit h t he last pre vi o us n o n -missi n g val u e. T he bas eli ne val ues will n ot be 
carri e d f or w ar d.  
 
M ulti ple I m p ut ati o n A n al ysis : I n t he s ec o n d a n al ysis, missi n g val u es will be fille d i n b y t he 
m ulti ple i m p utati o n met h o d w hic h i n v ol ves t he f oll o wi n g disti nct p hases:  
 
• T he missi n g data will be fille d i n t o ge nerate c o m plete data sets usi n g S A S / S T A T 
pr oce d ur e P R O C  MI;
 
• T he c o m plete dat a sets will be a nal yze d usi n g P R O C L O GI S TI C i n  S A S/ S T A T;  
• T he a b o ve t w o ste ps will be re peate d 5  ti mes; 
• T he res ults fr o m t he c o m plete data sets will be c o m bi ne d f or statistical i nfere nce  usi n g 
S A S/ S T A T pr oce d ure P R O C  MI A N A L Y Z E.
 

Page 70 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
Observed Case Analysis: In the third analysis, subjects are excluded from the analysis if the 
subject has insufficient data to be determined as a responder or non-responder in a given 4- 
week assessment period. This analysis is not based on the ITT population and, therefore, 
interpretation of results from this analysis requires substantial caution. This is because the 
subjects who responded in the respective treatment groups may have different distributions 
for background characteristics. Thus, additional analysis may be undertaken by the use of 
statistical methods which provide adjustment for background characteristics. 
8.7.3 
Interim Analyses and Data Monitoring 
 
No interim analyses are planned for this study. 
 
8.7.4 
Multicenter Studies 
 
Centers will be pooled within countries for the assessment of country effects. 
 
8.7.5 
Multiple Comparisons/Multiplicity 
 
The study has a single primary endpoint as the primary hypothesis, therefore no multiplicity 
adjustment is needed to the overall significance level of 0.05. Additionally, the clinical trial 
will be providing data for two separate indications (induction and long term treatment) with 
each indication having its own separate endpoint. On that basis, no multiplicity adjustment is 
needed to the overall significance level of 0.05 per indication because conclusions will be 
reached independently for induction and separately for long term treatment. 
The complete evaluation of clinical efficacy in this study requires the study of multiple key 
secondary efficacy variables collected at numerous time points. It is therefore necessary to 
properly and sensitively control the probability of making erroneous conclusions based solely 
upon compounding the likelihood of a type I error. The issue of multiplicity of secondary 
measurements will be handled by statistical testing of these outcomes in a hierarchical 
fashion. The order of secondary endpoints for the Induction and Long Term Treatment 
Phases are described in Sections 2.2.2 and 2.2.3. Significance tests will be conducted until a 
non-significant p-value is found (p > 0.05). Once a non-significant p-value occurred, all 
subsequent significance tests will be considered exploratory in nature. 
8.7.6 
Use of an Efficacy Subset of Subjects 
 
The primary efficacy endpoint will be analyzed using the ITT Population. 
 
8.7.7 
Exploration of the Effects of Various Prognostic Factors on Efficacy 
 
This study is not formally intended to obtain data on the influence of demographic and 
baseline disease characteristics (e.g., gender, race, age, and region (US/ROW)) on efficacy 
outcomes by the explicit design or randomization. However, the potential influence of these 

Page 71 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
factors in efficacy outcomes will be investigated by pooled analysis across the two identical 
studies (RECD3125 and RECD3126, reference: FDA ISE guidance document). 
8.7.8 
Criteria for Stopping the Study 
 
It is expected that the study will be terminated when the enrollment goals are reached. It is 
not anticipated that the study will be stopped early for any reason. 

P a ge 7 2  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
9. 0  
S T U D Y  A D MI NI S T R A TI O N  
 
9. 1  
I n vesti g at or I nf or m ati o n a n d Tr ai ni n g  
 
T he i n vesti gat ors a n d ess e ntial s u p p ort staff will be trai ne d b y Sali x ( or desi g nee) i n re gar ds 
t o G o o d Cli nical Practices ( G C Ps) a n d all as pects of pr ot oc ol e x ec uti o n. It is t he 
res p o nsi bilit y of t he i n vesti gat or t o trai n a n cillar y st u d y staff. 
9. 2  
M o nit ori n g  
 
T his st u d y will be m o nit ore d b y Sali x ( or desi g nee), i n acc or da n ce wit h G C Ps a n d a p plica ble 
re g ulati o ns. B y si g ni n g t his pr ot oc ol, t he i n vesti gat or a grees t o peri o dic, o n-site m o nit ori n g of 
all a p pr o priate st u d y d oc u me ntati o n.  
 
T he pr o gress of t he st u d y will be m o nit ore d b y peri o dic o n -site visits a n d fre q ue nt 
c o m m u nicati o ns be t wee n t he Sali x ( or desi g nee) a n d t he i n vesti gat or (eit her b y p h o n e, fa x, 
e mail, or p ost).  
D uri n g t h ese c o ntacts, t he m o nit or will:  
 
• C hec k a n d ass ess t he pr o gr ess of t he  st u d y. 
• Re vie w st u d y d ata  c ollecte d.  
• C o n d uct s o urce d oc u me nt  verificati o n.  
• I d e ntif y a n y iss ues a n d a d dress t heir res ol uti o n. 
T he o bjecti ves of m o nit ori n g pr o ce d ures are t o verif y t h at data are a ut h e ntic, acc urate, a n d 
c o m plete; t hat t he safet y a n d ri g hts of s u bjects are bei n g pr otecte d; a n d t h at t he st u d y is 
c o n d ucte d i n acc or d a n ce wit h t he c urre ntl y a p pr o v e d pr ot oc ol (a n d a n y a me n d me nts), G C Ps, 
a n d all a p plica ble re g ulat or y re q uire m e nts.  
9. 3  
A u dits  
 
At its discreti o n, Sali x ( or desi g n ee) ma y c o n d uct a q ualit y ass ura nce a u dit of t his st u d y. If 
s uc h a n a u dit occ urs, t he i n vesti gat or a grees t o all o w t he a u dit or direct access t o all rele va nt 
d oc u me nts a n d t o sc h e d ule his/ her ti me a n d t he ti me of his/ her staff t o per mit meeti n gs wit h 
t he a u dit or t o disc uss fi n di n gs a n d a n y rele v a nt iss ues. 
 
I n a d diti o n, re g ulat or y a ge ncies ma y c o n d u ct a reg ulat or y i ns pecti o n of t his st u d y. If s u c h a n 
i ns pecti o n occ urs, t he i n v esti gat or a grees t o all o w t he i ns pect or direct access t o all rele va nt 
d oc u me nts a n d t o sc he d ule his/ her ti me a n d t he ti me of his/ her staff t o p er mit meeti n gs wit h 
t he i ns pect or t o discuss fi n di n gs a n d a n y rele v a nt iss ues. T he i n vesti gat or will n otif y Sali x 
i m me diatel y w h e n a Re g ulat or y A ge nc y n otifies t he site of a n i ns pecti o n. 

P a ge 7 3  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
1 0. 0  
E T HI C A L A N D L E G A L  A S P E C T S  
 
T he i n vesti gat or a n d t h e st u d y staff are res p o nsi ble f or c o n d ucti n g t his st u d y i n acc or da nce 
wit h t he a p plica ble pri nci ples w hic h ha ve t heir ori gi ns i n t he Declarati o n of Helsi n ki, I C H, 
G C Ps, a n d all ot her a p plica ble la ws a n d re g ul ati o ns.  
1 0. 1  
I nstit uti o n al Re vie w B o ar d/ I n de pe n de nt Et hics C o m mittee (I R B/I E C) A p pr o v al  
 
T his pr ot oc ol, t he i nf or me d c o nse nt f or m, rele v a nt s u p p orti n g i nf or mati o n, a n d all t y p es of 
s u bject recr uit me nt or a d vertise me nt i nf or mati o n m ust be a p pr o ve d b y t he a p pr o priate 
I R B/I E C bef ore t he st u d y is i nitiate d. A n y a me n d me nts t o t he pr ot oc ol m ust als o be 
ap pr o ve d, w h ere n ecessar y, b y t he I R B/I E C pri or t o i m ple me nti n g c ha n ges i n t he st u d y.  
D oc u me ntati o n of t hese a p pr o vals m ust be pr o vi d e d t o t he s p o ns or pri or t o t he i nitiati o n of 
t he a me n d me nt. 
T he i n vesti gat or’s r es p o nsi bilities re gar di n g t he I R B/I E C are as  f oll o ws: 
 
• O btai n I R B/I E C a p pr o v al of t he pr ot oc ol, i nf or me d c o nse nt f or m, a n d a n y  a d vertise me nts 
f or s u bject r ecr uit me nt pri or t o t heir use.  
• O btai n I R B/I E C a p pr o v al f or a n y pr ot oc ol a m e n d me nts a n d re visi o ns t o t he  i nf or me d 
c o nse nt d oc u me nt bef ore i m ple me nti n g t he c ha n ges.  
• Pr o vi de t he I R B/I E C wit h a n y re q uire d i nf or mati o n bef ore or d uri n g t he  st u d y. 
• S u b mit pr o gress r e p orts t o t he I R B/I E C, as re q uire d, d uri n g t he c o n d uct of t he st u d y; 
re q uest re-re vi e w a n d a p pr o val of t he st u d y, as nee de d; pr o vi de c opi es of all I R B/I E C  r e- 
a p pr o vals a n d rele va nt c o m m u nicati o n t o t he  s p o ns or. 
• N otif y t he I R B/I E C wit hi n 1 0 da ys ( u nless re q uire d s o o ner b y I R B/I E C) of all seri o us a n d 
u ne x pecte d A Es relat e d t o t he st u d y me dicati o ns t hat are re p orte d t o y o u b y t he s p o ns or. 
T he i n vesti gat or is res p o nsi ble f or u p dati n g t h e I R B/I E C o n t he pr o gress of t he st u d y a n d 
of a n y c ha n ges ma de t o t he pr ot oc ol at least o n ce a year or at re g ular i nter v als as dee me d 
a p pr o priate. T h e i n vesti gat or m ust als o kee p t he I R B/I E C i nf or me d of a n y A Es , acc or di n g 
t o t he I R B/I E C p olic y.  
 
N otif yi n g Sali x wit hi n 2 4 h o urs of a w are n ess a n d t he I R B/I E C wit hi n i n 1 0 da ys ( u nless 
re q uire d s o o n er b y I R B/I E C) of all u na ntici pate d pr o ble ms i n v ol vi n g ris k t o s u bjects or 
ot hers. F or t he p ur p oses of t his st u d y, a n U n a ntici p ate d Pr o ble m is defi ne d as a n y 
i nci de nt, e x perie nce, or o utc o me t h at meets all of t he f oll o wi n g criteri a: 
• U ne x pecte d i n nat ure, s e verit y, or fre q ue n c y (i.e. n ot descri be d i n st u d y-rel ate d d oc u me nts 
s uc h as t he I R B-a p pr o ve d pr ot oc ol or c o nse nt f or m, t he i n vesti gat ors br o c h ure,  et c.)  
• Re late d or p ossi bl y relate d t o partici pati o n i n t he researc h (i.e. p ossi bl y rel ate d mea ns  t here 
is a r eas o na bl e p ossi bilit y t hat t he i nci d e nt e x perie nce, or o utc o me ma y h a ve bee n ca use d 
b y t he pr oce d ures i n v ol ve d i n t he  researc h) 

P a ge 7 4  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
• S u g gests t hat t he res ear c h places s u bjects or ot hers at greater ris k of har m  (i ncl u di n g 
p h ysical, ps yc h ol o gi cal, ec o n o mic, or s ocial har m).  
1 0. 2  
S u bject I nf or m ati o n a n d I nf or me d  C o nse nt  
 
T he i n vesti gat or is res p o nsi ble f or o btai ni n g writte n i nf or me d c o ns e nt fr o m eac h i n di vi d ual 
partici pati n g i n t his st u d y after a de q uat e e x pla nati o n i n la y ma n’s t er ms re gar di n g t h e nat ure 
of t he st u d y, al o n g wit h t he ai ms, met h o ds, o bjecti ves, a n d a n y p ote ntial ris ks. T he i nf or me d 
c o nse nt f or m m ust be a p pr o priatel y si g n e d a n d d ate d b y t he s u bject or t he s u bject’s le gall y 
a ut h orize d re pres e ntati ve a n d t he pers o n o btai ni n g t he c o nse nt (if re q uire d b y t he I R B/I E C) 
pri or t o c o n d ucti n g/ o btai ni n g a n y st u d y -relate d assess me nts i ncl u di n g t he disc o nti n uati o n of 
a n y m e dicati o ns pr o hi bite d f o r t he st u d y. 
If t he i nf or me d c o nse nt f or m is a me n de d d uri n g t he st u d y, t he i n vesti gat or m ust f oll o w all 
a p plica ble r e g ulat or y r e q uire me nts pertai ni n g t o a p pr o val of t he a m e n de d i nf or me d c o ns e nt 
f or m b y t h e I R B/I E C a n d use of t he a me n d e d d oc u me nt (i ncl u di n g f or o n g oi n g s u bjects). 
T he i nf or me d c o ns e nt f or m s hall als o c o ntai n t he s u bject's a ut h orizati o n f or t he use a n d 
discl os ure of his/ her pr ot ecte d healt h i nf or mati o n ( P HI) i n c o n necti o n wit h t he st u d y. T he 
a ut h orizati o n s hall i ncl u de at a mi ni m u m a clear d es cri pti o n of t he f oll o wi n g: t he d urati o n of 
t he a ut h orizati o n, t he s u bject's ri g ht of access t o t he P HI ( or a n y s us pe nsi o n t here of d uri n g t he 
c o urse of t he st u d y), t y p e of i nf or mati o n t o be use d/ discl ose d i n t he st u d y, t he na mes or 
classes of parties t hat m a y use or discl ose t he P HI, t he p ur p ose of t he us e/ discl os ure of P HI, 
t he e xte nt of t he s u bject's ri g ht t o re v o k e t he a ut h orizati o n, t he e xte nt t o w hic h partici pati o n i n 
t he st u d y is c o n diti o ne d o n si g ni n g t he a ut h orizati o n, a n d t he p ote ntial f or re-discl o s ure of 
P HI.  
 
T he ori gi nal a n d a n y a me n de d si g n e d a n d date d i nf or me d c o nse nt f or ms m ust be retai ne d at 
t he st u d y site; a n d a c o p y m ust be gi ve n t o t he s u bject or s u bject’s le gall y a ut h orize d 
re pres e ntati ve(s). 
1 0. 3  
St u d y a n d Site Cl os ure or  Disc o nti n u ati o n  
 
U p o n c o m pleti o n of t he st u d y, t he f oll o wi n g acti vities, w he n a p plica ble, m ust be c o n d ucte d 
b y t he m o nit or i n c o nj u n cti o n wit h t he i n vesti gat or, as a p pr o priate:  
 
• Ret ur n of all st u d y d ata t o Sali x ( or  desi g nee).  
• Data clarificati o ns a n d/ or  res ol uti o ns. 
• Acc o u nti n g, rec o nciliati o n, a n d fi nal dis p ositi o n of use d a n d u n use d st u d y dr u g  a n d 
place b o.  
• Re vie w of site st u d y rec or ds f or  c o m plete n ess.  

P a ge 7 5  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
I n a d diti o n, Sali x reser ves t he ri g ht t o te m p oraril y s us pe n d or pre mat urel y disc o nti n ue t his 
st u d y eit her at a si n gle site or at all sites at a n y ti m e a n d f or a n y reas o n. If s uc h acti o n is 
ta ke n, Sali x will disc uss t his wit h t he i n vesti gat or (i ncl u di n g t he reas o ns f or ta ki n g s uc h 
acti o n) at t hat ti me. Sali x will pr o m ptl y i nf or m all ot her i n vesti gat ors a n d/ or i nstit uti o ns 
c o n d ucti n g t h e st u d y if t h e st u d y is s us pe n de d or ter mi nate d f or safet y reas o ns, a n d will als o 
i nf or m t he re g ulat or y a ut h orities of t he s us pe nsi o n or ter mi nati o n of t he st u d y a n d t h e 
reas o n(s) f or t he acti o n. If re q uire d b y  a p plica ble re g ul ati o ns, t he i n vesti gat or m ust i nf or m t he 
I R B/I E C pr o m ptl y a n d pr o vi de t he reas o n f or t he s us pe nsi o n or  ter mi nati o n. 
1 0. 3. 1  
St u d y  Disc o nti n u ati o n  
 
S h o ul d t he i n vesti gat or, Sali x, t he F D A or l ocal re g ul at or y a ut h orities bec o me a ware of 
c o n diti o ns arisi n g d uri n g t he c o n d uct of t his st u d y t hat ma y w arra nt t he cessati o n of t he st u d y, 
s uc h acti o n ma y be ta k e n. Pri or t o s uc h acti o n, c ons ultati o n bet wee n Sali x, t he i n vesti gat or, 
a n d, as a p pr o priate, t he F D A a n d/ or l ocal re g ulat or y a ut h orities will ta ke place. C o n diti o ns 
t hat ma y r es ult i n t he ter mi nati o n of t he st u d y or parts t here of i ncl u de, b ut are n ot li mite d t o, 
t he f oll o wi n g: 
 
• T he d isc o ver y of a n u ne x pecte d, seri o us, or u nacce pta ble ris k t o t he s u bjects e nr olle d i n 
t he st u d y 
• A decisi o n o n t he part of Sali x t o alter, s us pe n d, or disc o nti n ue t he de vel o p me nt of  t he 
i n vesti gati o nal pr o d uct  
1 0. 3. 2  
St u d y Site  Disc o nti n u ati o n  
 
T he st u d y site ca n be dis c o nti n ue d at t he re q u est of Sali x, t he i n vesti gat or, or b y t he F D A or 
l ocal re g ulat or y a ut h orities. 
C o n diti o ns t hat ma y w arr a nt disc o nti n uati o n of t he st u d y site i ncl u de, b ut are n ot li mite d t o, 
a n y of t he f oll o wi n g:  
 
• Fail ure of t he i n vesti gat or t o accr ue s u bjects i nt o t he st u d y at a n acce pta bl e rate. 
• Fail ure of t he i n vesti gat or t o c o m pl y wit h G C Ps a n d/ or a p plica ble c urre nt  re g ul ati o ns. 
• S u b missi o n of k n o wi n gl y f alse i nf or mati o n fr o m t he researc h facilit y t o t h e s p o ns or,  F D A, 
or ot her re g ulat or y a ut h orities.  
• I ns ufficie nt a d h ere n ce t o pr ot oc ol re q uire m e nts a n d pr oce d ures.  
If t he st u d y is pre mat ur el y disc o nti n ue d, all st u d y data m ust be ret ur n e d t o Sali x or desi g nee. 
I n a d diti o n, t he site m ust c o n d uct fi nal dis p ositi o n of all use d a n d u n use d st u d y dr u gs i n 
acc or d a nce wit h Sali x pr oce d ures f or t he st u d y. St u d y ter mi nati o n a n d f oll o w -u p will be 
perf or me d i n c o m plia nce wit h G C P a n d a p plica ble re g ulati o ns.  

Page 76 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
Financial compensation to investigators and/or institutions will be in accordance with the 
agreement established between the investigator and Salix. 
10.4 
Handling and Record Keeping 
 
10.4.1 
Case Report Forms and Database Processing 
 
Subject data will be collected in an electronic CRF using Electronic Data Capture (EDC). 
The EDC system will be Part 11 compliant and will have a documented audit trail for all 
changes made to the electronic CRF. 
 
The Investigator or designee must enter all required subject data using the specified data 
collection method defined by Salix. The Investigator must sign and date a declaration on the 
electronic CRF attesting to his/her responsibility for the quality of all data entered and that the 
data represents a complete and accurate record of each subject's participation in the study. 
Electronic case report form data will be provided to the Investigator at the end of the study 
and will need to be retained by the Investigator. 
10.4.2 
Source Documents 
 
Source documents consist of, but are not limited to, in-patient hospital charts, clinic notes, 
out-patient records, original test results, laboratory data, worksheets, drug accountability 
records, informed consent forms, etc. Source documents must be available for review and 
inspection during on-site monitoring of the study by Salix, their designees, IRB/IEC, and/or 
appropriate regulatory authorities. 
10.4.3 
Subject Tracking 
 
A drug accountability log, subject identification log (to be retained by the investigator only), 
and subject screening/enrollment log will be used to track subject participation in the study. 
10.4.4 
Study Files 
 
The investigational center will maintain a special study file. This file is subject to review and 
inspection as described under Section 9.2 and Section 9.3 of this protocol. 
10.4.5 
Data Management 
 
Data management will be performed in accordance with the standard operating procedures of 
Salix or its designee. 
10.5 
Confidentiality 
 
Anonymity of subjects participating in this study will be maintained. Only subject initials and 
subject number will be on any study documents submitted to the sponsor. Every effort will be 

P a ge 7 7  of 1 1 6  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
ma de t o mai ntai n t he c o nfi de ntialit y of d o c u me nts t hat i de ntif y t he s u bject b y na m e (e. g., 
si g ne d i nf or me d c o nse nt d oc u me nt, la b orat or y re p orts, cli nic c harts), e x ce pt t o t he e xte nt 
necessar y t o all o w a u diti n g b y t he F D A, or ot her re g ul at or y a ut h orities. S h o ul d t he na me 
a n d/ or a d dr ess of a s u bject partici pati n g i n t his trial be o n a d oc u m e nt s u b mitte d t o t he F D A, 
or ot her re g ul at or y a ut h orities (e. g., la b orat or y re p ort), t he na me a n d/ or a d dress will be 
c o m pletel y bl o c ke d o ut a n d  re place d wit h t he s u bject i nitials a n d n u m ber. 
T he i n vesti gat or a n d ot her st u d y site pers o n nel will kee p c o nfi de ntial a n y i nf or mati o n 
pr o vi de d b y Sali x (i ncl u di n g t his pr ot oc ol) relate d t o t his st u d y a n d all data a n d rec or ds 
ge n erat e d i n t he c o urs e of c o n d ucti n g t he st u d y, a n d will n ot use t he i nf or mati o n, data, or 
rec or ds f or a n y p ur p ose ot her t ha n c o n d ucti n g t he st u d y. T hes e restricti o ns d o n ot a p pl y t o: 
( 1) i nf or mati o n w hic h b ec o mes p u blicl y a vaila ble t hr o u g h n o fa ult of t he i n vesti gat or or st u d y 
site pers o n nel; ( 2) i nf or m ati o n w hic h it is necessar y t o discl ose i n c o nfi d e nce t o a n I R B/I E C 
s olel y f or t he e val u ati o n of t he st u d y; ( 3) i nf or mati o n w hic h it is necessar y t o discl ose i n 
or der t o pr o vi de a p pr o pri ate me dical care t o a st u d y s u bject, or ( 4) st u d y res ults w hic h ma y be 
p u blis he d as descri be d i n Secti o n 1 0. 8. If a writte n c o ntract f or t he c o n d u ct of t he st u d y  w hic h 
i ncl u des c o nfi de ntialit y pr o visi o ns i nc o nsiste nt wit h t his state me nt is e x ec ute d, t hat c o ntract’s 
c o nfi de ntialit y pr o visi o ns s hall a p pl y r at her t ha n t his  state me nt. 
1 0. 6  
Rec or d  Ret e nti o n  
 
Esse ntial d oc u me nts as d escri be d a b o ve s h o ul d be retai ne d f or o ne of t h e f oll o wi n g ti me 
peri o ds:  
 
• At least 2 years after a p pr o val of t he last mar k eti n g  a p plicati o n,  
O R  
 
• At least 2 years h a ve el a pse d si nce t he f or mal disc o nti n uati o n of cli nical d e vel o p me nt of 
t he i n vesti gati o nal pr o d u ct.  
T hese d oc u me nts s h o ul d be retai ne d f or a l o n ger p eri o d h o we ver if re q uire d b y a p plica ble 
re g ulat or y r e q uire me nts (i.e., l ocal or c o u ntr y-s pecific re g ulati o ns) or b y a n a gree m e nt wit h 
t he s p o ns or. It is t he res p o nsi bilit y of Sali x t o i nf or m t he i n vesti gat or/i nstit uti o n as t o w he n 
t hese d oc u me nts n o l o n ger nee d t o b e ret ai ne d. It is t he i n vesti gat or res p o nsi bilit y t o n otif y 
Sali x if t he y m o ve or retire s o t hat d oc u me nt st ora ge ca n b e a d dresse d.  
1 0. 7  
Fi n a nci n g a n d  I ns ur a nce 
 
1 0. 7. 1  
Fi n a nce  
 
T he st u d y is s u p p orte d b y Sali x.  

Page 78 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
10.7.2 
Insurance and Indemnification 
 
Documentation of product liability insurance is on file at Salix and is available upon request. 
 
10.8 
Publication Policy 
 
An Institution and/or the investigator shall have the right, consistent with academic standards, 
to publish or present the results of the study, provided such publication or presentation does 
not disclose confidential information or other proprietary trade secrets of Salix. Salix will 
work with the protocol development team to identify a lead author for manuscript 
development. The manuscript authors will be determined by the amount of effort and 
participation each investigator contributes towards the study design, the conduct of the study 
and the analysis of the study data. Prior to any publication, presentation or other disclosure, 
the institution and/or investigator will submit the manuscript of any proposed publication 
(including abstracts, or presentation to a journal, editor, meeting, seminar, or other third 
party) to Salix at least sixty (60) days before publication, and Salix shall have the right to 
review and comment upon the proposed publication. Upon sponsor's request, publication will 
be delayed up to ninety (90) additional days to enable Salix to secure adequate intellectual 
property protection of property of Salix that could be affected by said publication. Salix shall 
have the right to require the deletion of any trade secret, or proprietary or confidential 
information of sponsor. Any publication or disclosure by the Institution and/or Investigator 
shall give appropriate credit to Sponsor. Where title is not retained by the publisher, title to 
and the right to determine the disposition of any copyrightable material, first produced or 
composed in the performance of the study, shall remain with the Institution and/or 
investigator. With respect to such materials, the Institution and/or investigator hereby grants 
to Salix an irrevocable, royalty-free, nonexclusive right to reproduce, translate, and use any 
such copyrighted material for its own research and commercial purposes. Investigator 
acknowledges and agrees that the study data and results may be disclosed by Salix to other 
clinical investigators, the FDA, and other regulatory authorities. 
10.9 
Ownership 
 
All data and records provided by Salix or generated during the study (other than a subject’s 
medical records) and all inventions discovered during the course of conducting the study are 
the property of Salix. If a written agreement is executed by the parties for the conduct of the 
study, which includes ownership provisions inconsistent with this statement, the ownership 
provisions contained in the written agreement between the parties shall control. 

Page 79 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
11.0 
REFERENCES 
 
Reference List 
 
(1) Stenson WF. Inflammatory Bowel Disease. In: Yamada T, Alpers DH, Laine L, Owyang 
C, Powell D, editors. Textbook of Gastroenterology. 2 ed. Philadelphia: Lippincott, 
Williams, and Wilkins; 1999. p. Table 81-1:1776. 
 
(2) Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn's disease. Inflamm Bowel 
Dis 2005 Aug;11(8):765-77. 
 
(3) Nos P, Domenech E. Postoperative Crohn's disease recurrence: a practical approach. 
World J Gastroenterol 2008 Sep 28;14(36):5540-8. 
 
(4) Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery 
for ileo-caecal Crohn's disease. Aliment Pharmacol Ther 2007 Nov 15;26(10):1303-12. 
 
(5) Lemann M. Review article: can post-operative recurrence in Crohn's disease be 
prevented? Aliment Pharmacol Ther 2006 Oct;24 Suppl 3:22-8. 
 
(6) Terdiman JP. Prevention of postoperative recurrence in Crohn's disease. Clin 
Gastroenterol Hepatol 2008 Jun;6(6):616-20. 
 
(7) Rutgeerts P, Van AG, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for 
prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, 
placebo-controlled trial. Gastroenterology 2005 Apr;128(4):856-61. 
 
(8) Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in 
Crohn's disease. Ann Surg 2000 Jan;231(1):38-45. 
 
(9) 
In: Yamada T, editor. Textbook of Gastroenterology. 2 ed. 1999. p. Table 81-1:1776. 
 
(10) Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of 
etiopathogenesis. Journal of digestive diseases 2007 Nov;8(4):171-8. 
 
(11) Sartor RB. Microbial influences in inflammatory bowel diseases. [Review] [213 refs]. 
Gastroenterology 2008 Feb;134(2):577-94. 
 
(12) Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and 
ulcerative colitis - an overview. J Physiol Pharmacol 2009 Dec;60 Suppl 6:61-71. 
 
(13) Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y. Active Crohn's disease 
and ulcerative colitis can be specifically diagnosed and monitored based on the 
biostructure of the fecal flora. Inflamm Bowel Dis 2008 Feb;14(2):147-61. 

Page 80 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
(14) Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al. Alterations 
of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 
2003 Feb;52(2):237-42. 
 
(15) Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low 
counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009 
Aug;15(8):1183-9. 
 
(16) Scanlan PD, Shanahan F, Marchesi JR. Culture-independent analysis of desulfovibrios in 
the human distal colon of healthy, colorectal cancer and polypectomized individuals. 
FEMS Microbiol Ecol 2009 Aug;69(2):213-21. 
(17) Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M, Bouhnik Y, et al. Molecular 
inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol Ecol 
2004 Oct 1;50(1):25-36. 
 
(18) Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, et al. Culture 
independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia 
coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving 
the ileum. ISME J 2007 Sep;1(5):403-18. 
 
(19) Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, et al. CEACAM6 
acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in 
Crohn disease. J Clin Invest 2007 Jun;117(6):1566-74. 
 
(20) Brown EL, Xue Q, Jiang ZD, Xu Y, DuPont HL. Pretreatment of epithelial cells with 
rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents 
Chemother 2010 Jan;54(1):388-96. 
 
(21) Jiang ZD, Ke S, DuPont HL. Rifaximin-induced alteration of virulence of diarrhoea- 
producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010 
Mar;35(3):278-81. 
 
(22) Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, et al. Rifaximin 
modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach 
using a continuous culture colonic model system. J Antimicrob Chemother 2010 
Dec;65(12):2556-65. 
 
(23) Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of 
intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells 
reactivity and protects against inflammation in a rodent model of colitis. Digestion 
2002;66(4):246-56. 
 
(24) Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, et al. Rifaximin is a gut- 
specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007 
Jul;322(1):391-8. 

Page 81 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
(25) Mencarelli A, Migliorati M, Barbanti M, Cipriani S, Palladino G, Distrutti E, et al. 
Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on 
detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010 Dec 
1;80(11):1700-7. 
 
(26) Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, et al. Therapeutic role of 
rifaximin in inflammatory bowel disease: clinical implication of human pregnane X 
receptor activation. J Pharmacol Exp Ther 2010 Oct;335(1):32-41. 
 
(27) Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al. Double 
blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991 
Sep;32(9):1071-5. 
 
(28) Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al. An antibiotic 
regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial 
of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996 Feb;91(2):328-32. 
 
(29) Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, et al. A comparative 
study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative 
Crohn's disease study in Sweden. II. Result. Gastroenterology 1982 Sep;83(3):550-62. 
 
(30) Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, et al. 
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized 
controlled trial. Gastroenterology 2002 Jul;123(1):33-40. 
(31) Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and 
metronidazole for active Crohn's disease. Can J Gastroenterol 1998 Jan;12(1):53-6. 
 
(32) Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al. A 
controlled trial comparing ciprofloxacin with mesalazine for the treatment of active 
Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires 
Digestives (GETAID). Am J Gastroenterol 1999 Mar;94(3):674-8. 
 
(33) Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce 
Crohn's disease activity. Dig Dis Sci 2010 Apr;55(4):1079-84. 
 
(34) Thia K, Faubion WA, Jr., Loftus EV, Jr., Persson T, Persson A, Sandborn WJ. Short 
CDAI: development and validation of a shortened and simplified Crohn's disease activity 
index. Inflamm Bowel Dis 2011 Jan;17(1):105-11. 
 
(35) Sipponen T, Nuutinen H, Turunen U, Farkkila M. Endoscopic evaluation of Crohn's 
disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010 
Dec;16(12):2131-6. 
 
(36) Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, et al. 
Validation of endoscopic activity scores in patients with Crohn's disease based on a post 
hoc analysis of data from SONIC. Gastroenterology 2013 Nov;145(5):978-86. 

Page 82 of 116 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
(37) Moskovitz D, Daperno M, Van Assche G, Baert F, Gevers A, Sostegni R, et al. Defining 
and validating cut-offs for the Simple Endocopic Score for Crohn's Disease. 
Gastroenterology 2007;132:S1097. 
 
(38) Guidance for Industry. Patient-reported outcome measures: use in medical product 
development to support labeling claims. FDA Center for Drug Evaluation and Research 
(CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices 
and Radiological Health (CDRH). 2009. 
 
(39) Rifaximin Investigator's Brochure. 2013. 

Page 83 of 116 
 
 
RECD3125 
Salix Pharmaceuticals, Inc. 
Version Date: 15 May 2014 FINAL 
CRP-47 
Confidential 
APPENDIX 1: OVERALL TIME AND EVENTS SCHEDULE 
STUDY ASSESSMENTS 
Screening 
Period 
Treatment Period 
Follow-Up 
Period 
Unsche 
duled 
Visit 
Study Visit 
Visit 1 
Visit 2 
Visit 3, 4, 5, 6 
Visit 7 
Visit 8, 9, 10, 11,12, 13, 14, 15, 
Visit 16 
(EOT) 
Visit 17 
(EOS) 
Study Week 
0 
2, 4, 8 and 12 
16 
20, 24, 28, 32, 36, 40, 44, 48 
52 
54 
Study Day 
-21 to –14 
1 
14, 28, 56, 84 
(±3d) 
112 (±3d) 
140, 168, 196, 224, 252, 280, 308, 336 
(±3d) 
364 (±3d) 
378 (±3d) 
Informed Consent 
X 
Assign Subject Identification 
X 
Medical History and Demographics 
X 
Adverse Events and Concomitant 
Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Inclusion/Exclusion Criteria 
X 
X 
Vital Signs, Weight, and Physical 
Examinationa 
X(include 
height) 
X 
X 
X 
X 
X 
X(Vital Signs and 
Weight Only) 
X 
Electrocardiogram 
X(triplicate) 
X 
X 
X 
Pregnancy Test 
X(serum) 
X(urine) 
X(urine) 
X(urine) (V10 and V13 only) 
X(serum) 
Safety Laboratory Testsb 
X 
X 
X 
X 
X 
X 
X 
X 
Blood Sample for Inflammatory 
Markers and PXR (V2 only) 
X 
X 
X 
Pharmacokinetic Blood Sample 
X 
X (V6 only) 
X (V15 only) 
Stool Collection and Processing 
X 
X 
X 
Stool/Blood for Long-term Storage 
X 
X 
X 
CDAI assessment calculated by EDC 
X 
X 
X 
X 
X 
Ileocolonoscopy (SES-CD)c 
X 
X 
X 
IBDQ and WPAI-CD 
X 
X 
X (V10 and V13 only) 
X 
Electronic Daily Diary 
Instructions/Completion 
X 
X 
X 
X 
X 
X 
Randomization 
X 
Dispense Study Drug 
X(1st dose at 
clinic) 
X (except V3) 
X 
X 
Study Drug Collection/Compliance 
X 
X 
X 
X 
a. 
Perform a full physical examination at Screening (Visit 1), prior to the Long Term Treatment Phase (Visit 7), and at End of Treatment (Visit 16); perform disease and symptom driven physical examination 
(including assessments for abdominal mass and extraintestinal manifestations of Crohn’s disease based on CDAI – see Appendix 2) at other visits. 
b. 
Including C. Difficile safety testing as described in Section 6.3.5 
c. 
The baseline ileocolonoscopy will be performed between Day -12 and Day -5; it will provide the baseline SES-CD, and will be used to assess Inclusion Criterion #3. Bowel prep will be dispensed at Visit 1. 
Ileocolonoscopy to be completed within 7 days after Visit 7 and Visit 16. Bowel prep will be dispensed at Visit 7 and Visit 16, cleansing regimen to begin after Visit 7 and Visit 16 assessments. 

R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
A P P E N DI X 2: C R O H N’ S DI S E A S E A C TI VI T Y I N D E X ( C D AI)  
P a ge 8 4  of  
 
 
 
 
D A Y  
-7  
-6  
-5  
-4  
-3  
-2  
-1  
7 d a y  T otal  
1.  N u m ber of li q ui d  or  ver y  
X 2  =  
s oft st o ols * 
 
 
2.  A b d o mi nal  p ai n  
X 5  =  
 
0 = n o ne, 1 = mil d, 2 = m o derate, 3 = se vere  
 
3.  Ge ner al  well  b ei n g  
X 7  =  
 
0 = ge nerall y well, 1 = sli g htl y u n der par, 2 = p o or, 3 = ver y p o or, 4 = terri ble  
 
4.  E xtrai ntesti nal ma nifestati o ns s u bject h as n o w  (c h ec k A L L t h at a p pl y)  
 
 
 
 
 
Er yt h e ma n o d os u m/ p y o d er ma ga n gre n os u m/ a p ht h o us st o matitis  
 
 
 
 
 
Fe ver o ver 3 7. 8 °C  ( 1 0 0°
 
T otal  c h ec k e d  
X 2 0  =  
b o xes  
 
5.  A nti diarr heal dr u gs i n t h e last 7  da ys  
N o = 0, Yes  =  1  
X 3 0 =  
 
 
6.  A b d o mi nal  Mass  
N o n e = 0, Q u esti o n a ble = 2, Defi nite  =  5  
X 1 0 =  
 
 
7.  He mat ocrit ( %, r o u n de d t o w h ole  n u m ber ) 
Male  
4 7 - 
=  
or  Fe male  
4 2 - 
X 6  =  
 
8.  B o d y  Wei g ht  Calc ulati o n * *  
If ne g ative, e nter 0  
 
I d eal Wei g ht  
k g  
 
mi n us Act u al  Wei g ht  
k g  
 
=  
÷ I d eal Wei g ht  =  
X 1 0 0 =  
 
 
(r o u n de d t o w h ole n u m ber * * *) 
T O T A L C D AI =   
 
* Gra de d usi n g t he Brist ol St o ol F or m Scale ( A p pe n di x  3)  
* * See A p pe n di x 8 f or calc ulati o ns of I deal B o d y W ei g ht  
* * * If calc ulate d val ue > -1 0, rec or d – 1 0 ( ma xi m u m l o wer li mit)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

P a ge 8 5  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
A P P E N DI X 3: B RI S T O L S T O O L F O R M S C A L E ( B S F S)  
 
 
 
 
 

P a ge 8 6  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
A P P E N DI X 4: SI M P L E E N D O S C O PI C S C O R E F O R C R O H N’ S DI S E A S E ( S E S -C D)  
 
 
D E FI NI TI O N S O F S E S -C D V A RI A B L E S  
 
 
S E S -C D Sc ori n g F or m  
 
 
 
Da per n o M, D’ Hae ns G, Va n Ass c he G, et. al. D e v el o p me nt a n d v ali dati o n of a ne w a n d si m ple 
e n d osc o pic acti vit y sc ore f or Cr o h n’s disease: t he S E S -C D. Gastr oi ntest E n d osc 2 0 0 4; 6 0:  5 0 5 - 
5 1 2.  
 
 

P a ge 8 7  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
A P P E N DI X 5: I N F L A M M A T O R Y B O W E L DI S E A S E Q U E S TI O N N AI R E (I B D Q)  
 

P a ge 8 8  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 8 9  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 0  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 1  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 2  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 3  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 4  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 5  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 6  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

P a ge 9 7  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 

Page 98 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
APPENDIX 6: WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT 
QUESTIONNAIRE (WPAI: CD) 
 
Work Productivity and Activity Impairment Questionnaire: 
Crohn’s Disease V2.0 (WPAI: CD) 
 
 
 
The following questions ask about the effect of your CROHN’S DISEASE on your ability 
to work and perform regular activities. Please fill in the blanks or circle a number, as 
indicated. 
 
1. Are you currently employed (working for pay)? 
  
NO  
YES 
If NO, check “NO” and skip to question 6. 
The next questions are about the past seven days, not including today. 
 
2. During the past seven days, how many hours did you miss from work because of 
problems associated with your CROHN’S DISEASE? Include hours you missed on 
sick days, times you went in late, left early, etc., because of your CROHN’S 
DISEASE. Do not include time you missed to participate in this study. 
 
  
HOURS 
 
 
3. During the past seven days, how many hours did you miss from work because of 
any other reason, such as vacation, holidays, time off to participate in this study? 
 
  
HOURS 
 
 
4. During the past seven days, how many hours did you actually work? 
 
  
HOURS (If “0”, skip to question 6.) 

Page 99 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
 
 
 
 
 
 
5. During the past seven days, how much did your CROHN’S DISEASE affect your 
productivity while you were working? 
 
Think about days you were limited in the amount or kind of work you could do, days 
you accomplished less than you would like, or days you could not do your work as 
carefully as usual. If CROHN’S DISEASE affected your work only a little, choose a 
low number. Choose a high number if CROHN’S DISEASE affected your work a 
great deal. 
Consider only how much CROHN’S DISEASE affected 
productivity while you were working. 
 
CROHN’S 
DISEASE had 
no effect on my 
work 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
CROHN’S 
DISEASE 
completely 
prevented me 
from working 
 
CIRCLE A NUMBER 

Page 100 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
 
6. During the past seven days, how much did your CROHN’S DISEASE affect your 
ability to do your regular daily activities, other than work at a job? 
 
By regular activities, we mean the usual activities you do, such as work around the 
house, shopping, childcare, exercising, studying, etc. Think about times you were 
limited in the amount or kind of activities you could do and times you accomplished 
less than you would like. If CROHN’S DISEASE affected your activities only a little, 
choose a low number. Choose a high number if CROHN’S DISEASE affected your 
activities a great deal. 
 
Consider only how much CROHN’S DISEASE affected your ability 
to do your regular daily activities, other than work at a job. 
 
CROHN’S 
DISEASE had 
no effect on my 
daily activities 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
CROHN’S 
DISEASE 
completely 
prevented me 
from doing my 
daily activities 
 
 
 
WPAI: CD V2.0 (US English) 
CIRCLE A NUMBER 
 
 
 
Reilly MC, Zbrozek AS, Dukes E: The validity and reproducibility of a work productivity and activity impairment measure. 
PharmacoEconomics 1993; 4(5):353-365. 

P a ge 1 0 1  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
  
C o nfi de nti al  
 
 
 
A P P E N DI X 7: S U B J E C T D AI L Y DI A R Y R E C O R DI N G  
 
T he f oll o wi n g will be ca pt ure d dail y i n t he electr o nic diar y s yste m.  
 
Usi n g t he Brist ol St o ol F or m Scale pr o vi de d (s ee A p pe n di x 3), please rec or d t he T otal  N u m ber 
of Li q ui d/ ver y s oft St o o ls ( T y p e 6 or 7) y o u ha d  t o da y.     
 
 
H o w w o ul d y o u rate y o ur A b d o mi nal Pai n t o da y?  
 0 = n o ne  
 1 =  mil d  
 2 =  m o derate  
 3 =  se vere 
 
H o w w o ul d y o u rate y o ur Ge neral Well Bei n g t o d a y?  
 0 = ge ner all y  well  
 1 = sli g htl y u n d er  par  
 2 =  p o or  
 3 = ver y  p o or  
 4 =  terri ble 
 
Di d y o u use a n y A nti diarr heal Dr u gs t o d a y?  
 0 = N o  
 1 = Yes  
 
Di d y o u e x perie n ce ha v e a n y ele vat e d te m perat ure (fe ver) of m ore t ha n 3 7. 8 de grees Celsi us 
de gree C elsi us ( 1 0 0 de gr ees Fa hre n h eit) t o da y?  
 0 = N o  
 1 = Yes  

Page 102 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
APPENDIX 8: IDEAL BODY MASS OF NORMAL ADULTS (MEN & WOMEN) 
 
Ideal Body Mass of Normal Adults - MEN 
Actual Height 
Standard Weight in Clothing 
Inches with one inch heels 
Centimeters with 2.5 cm 
heels 
Pounds in indoor clothing 
weighing 5 pounds 
Kilograms in indoor clothing 
weighing 2.3 kg 
62 
157.5 
136 
61.7 
62.5 
158.8 
137 
62.1 
63 
160 
138 
62.6 
63.5 
161.3 
139 
63 
64 
162.6 
140 
63.5 
64.5 
163.8 
141.3 
64.1 
65 
165.1 
142.5 
64.6 
65.5 
166.4 
143.8 
65.2 
66 
167.6 
145 
65.8 
66.5 
168.9 
146.5 
66.4 
67 
170.2 
148 
67.1 
67.5 
171.5 
149.5 
67.8 
68 
172.7 
151 
68.5 
68.5 
174 
152.5 
69.2 
69 
175.3 
154 
69.8 
69.5 
176.5 
155.5 
70.5 
70 
177.8 
157 
71.2 
70.5 
179.1 
158.5 
71.9 
71 
180.3 
160 
72.6 
71.5 
181.6 
161.8 
73.4 
72 
182.9 
163.5 
74.1 
72.5 
184.2 
165.3 
75 
73 
185.4 
167 
75.7 
73.5 
186.7 
169 
76.6 
74 
188 
171 
77.5 
74.5 
189.2 
172.8 
78.4 
75 
190.5 
174.5 
79.1 
75.5 
191.8 
176.8 
80.2 
76 
193 
179 
81.2 

Page 103 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
  
Confidential 
 
 
 
Ideal Body Mass of Normal Adults – WOMEN 
 
Actual Height 
Standard Weight in Clothing 
Inches with one inch heels 
Centimeters with 2.5 cm 
heels 
Pounds in indoor clothing 
weighing 5 pounds 
Kilograms in indoor clothing 
weighing 2.3 kg 
58.0 
147.3 
115.0 
52.2 
58.5 
148.6 
116.0 
52.6 
59.0 
149.9 
117.0 
53.1 
59.5 
151.1 
118.3 
53.6 
60.0 
152.4 
119.5 
54.2 
60.5 
153.7 
120.8 
54.8 
61.0 
154.9 
122.0 
55.3 
61.5 
156.2 
123.5 
56.0 
62.0 
157.5 
125.0 
56.7 
62.5 
158.8 
126.5 
57.4 
63.0 
160.0 
128.0 
58.0 
63.5 
161.3 
129.5 
58.7 
64.0 
162.6 
131.0 
59.4 
64.5 
163.8 
132.5 
60.1 
65.0 
165.1 
134.0 
60.8 
65.5 
166.4 
135.5 
61.4 
66.0 
167.6 
137.0 
62.1 
66.5 
168.9 
138.5 
62.8 
67.0 
170.2 
140.0 
63.5 
67.5 
171.5 
141.5 
64.2 
68.0 
172.7 
143.0 
64.9 
68.5 
174.0 
144.5 
65.5 
69.0 
175.3 
146.0 
66.2 
69.5 
176.5 
147.5 
66.9 
70.0 
177.8 
149.0 
67.6 
70.5 
179.1 
150.5 
68.3 
71.0 
180.3 
152.0 
68.9 
71.5 
181.6 
153.5 
69.6 
72.0 
182.9 
155.0 
70.3 

RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Page 104 of 
 
 
  
Confidential 
 
APPENDIX 9: SUMMARY OF CHANGES FOR REVISION DATED 01 MAY 2014 
 
Page in 
Revised 
Document 
Section 
Number/Title 
Original Text 
Revised Text 
Rationale For 
Change 
Entire 
Document 
Protocol Title 
A Double-Blind, Placebo-Controlled, Parallel- 
Group, Multicenter, Multiregional Study to Assess 
the Efficacy and Safety of Rifaximin Delayed 
Release Tablets for the Induction and Maintenance 
of Remission in Subjects with Active Moderate 
Crohn’s Disease 
A Double-Blind, Placebo-Controlled, Parallel-Group, 
Multicenter, Multiregional, One Year Study to Assess the 
Efficacy and Safety of Twice Daily Oral Rifaximin 
Delayed Release Tablets for Induction of Clinical 
Remission with Endoscopic Response at 16 Weeks 
followed by Clinical and Endoscopic Remission at 52 
Weeks in Subjects with Active Moderate Crohn’s Disease 
All instances of the 
protocol title have 
been changed to 
reflect changes in the 
study objectives and 
endpoints. 
Page 1-2 
Sponsor 
Signatory and 
Medical 
Monitor 
Study Director: 
 
Medical Monitor: 
 
Study Director: 
 
Medical Monitor: 
 
Contact revised and 
phone numbers added. 
Pages 4 - 8 
Synopsis 
The synopsis has been updated to reflect changes in the 
current objectives of the study. 
Sections of synopsis 
updated based on 
changes made to the 
body of the protocol. 
Pages 17 - 
27 
1.0-1.6 
Introduction 
The introduction has been updated and the references 
renumbered. 
Additional detail 
provided on 
experience with 
rifaximin, 
development of the 
primary endpoint, and 
study rationale. 
Page 28 
2.1.1 
Primary Objective 
To determine the 16-week induction of remission 
and 36-week maintenance of remission efficacy of 
Rifaximin DR 800 mg BID versus placebo in 
subjects presenting with active moderate Crohn’s 
disease. 
Primary Objective 
To determine the efficacy of Rifaximin DR 800 mg BID 
vs. placebo on the induction of clinical remission and 
endoscopic response following 16 weeks of treatment in 
subjects presenting with active moderate Crohn’s disease. 
Revised to better 
reflect the change in 
endpoints requested by 
FDA from CDAI- 
based, to symptom and 
endoscopy based 
endpoints. The 
objectives and 
endpoints have been 
revised to (1) reflect 
the symptomatic and 
initial endoscopic 
improvement that may 
be achieved during 
initial (16-week) 

P a ge 1 0 5  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
 
 
treat me nt, a n d ( 2) 
all o w t he l o n ger, 
c o nti n u o us treat me nt 
ti me nee de d t o ac hie ve 
b ot h s y m pt o m 
i m pr o ve me nt A N D 
e n d osc o picall y- 
c o nfir me d m uc osal 
heali n g.  
 
P a ge 2 8  
2. 1. 2  
Sec o n d ar y O bj ecti v es  
T h e sec o n d ar y o bjecti ves of t his st u d y are t h e 
f oll o wi n g: 
• Assess t h e safet y of Rifa xi mi n D R f oll o wi n g  a 
1 6 -wee k i n d u cti o n, a n d a n a d diti o n al 3 6 -wee k 
mai nte n a n ce treat me nt re gi me n (i.e., u p t o 5 2 
we e ks of c o nti n u o us treat me nt f or eli gi ble 
s u bjects). 
Sec o n d ar y O bj ecti v es  
A k e y se c o n d ar y o bjecti ve is t o e val uate cli nical a n d 
e n d osc o pic re missi o n f oll o wi n g a n a d diti o nal 3 6-wee k 
l o n g ter m treat me nt p h ase of Rifa xi mi n D R 8 0 0 m g BI D 
vs. place b o.  
T h e sec o n d ar y o bjecti ves of t his st u d y are t he f oll o wi n g:  
• Assess t h e safet y of Rifa xi mi n D R f oll o wi n g a  1 6-week 
i n d u cti o n, a n d a n a d diti o n al 3 6-wee k  L o n g Ter m 
Treat me nt P h ase (i.e., u p t o 5 2 wee ks of treat me nt f or 
eli gi ble s u bjects). 
Sa me as a b o ve.  
P a ge 2 8 -2 9  
2. 2. 1  
Pri m ar y E n d p oi nt f or I n d ucti o n of Re missi o n  
T h ere will b e t w o c o -pri mar y me as ures of efficac y 
assess e d d uri n g t h e I n d u cti o n P h ase. T h e first c o - 
pri mar y e n d p oi nt is:  
• S y m pt o m re missi o n d efi n e d b y ( 1) t h e t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t h e 7 d a ys 
pri or t o t h e Wee k 1 6 visit b ei n g ≤ 1 0; A N D ( 2) a 
d ail y a b d o mi n al p ai n sc ore of ≤ 1 f or t h e 7 d a ys 
pri or t o t h e Wee k 1 6  visit.  
T h e sec o n d c o -pri mar y e n d p oi nt is:  
• Cli nicall y si g nifi ca nt e n d osc o pic i m pr o ve me nt 
d efi n e d as a ≥ 3 -p oi nt d ecrease i n t h e S E S -C D 
fr o m b aseli n e t o t h e S E S-C D sc ore o btai n e d 
b et wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D 
sc ores will be calc ulate d fr o m ce ntrall y-r ea d 
di gital vi d e o of ile o c ol o n osc o pies p erf or m e d at 
b aseli n e a n d b et wee n We e k 1 6 a n d Wee k 1 7  f or 
eac h ra n d o mize d  s u bject. 
 
Pri m ar y E n d p oi nt f or M ai nte n a nce of  
Re missi o n  
T h ere will b e t w o c o -pri mar y me as ures of efficac y 
assess e d d uri n g t h e Mai nte n a n ce P h ase. T h e first 
c o -pri mar y e n d p oi nt is:  
T h ere will  b e t w o c o -pri mar y me as ures of efficac y f or  
I n d u cti o n of Cli nical Re missi o n a n d E n d osc o pic 
Res p o nse. T h e first c o -pri mar y e n d p oi nt is:  
• Cli nical s y m pt o m re missi o n defi ne d b y ( 1) t he t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o 
t h e Wee k 1 6 visit b ei n g ≤ 1 0 (fr o m C D AI Ite m 1); 
A N D ( 2) a n a b d o mi n al p ai n rati n g of ≤ 1(fr o m C D AI 
Ite m 2) o n eac h d a y f or t h e 7 da ys pri or t o t he Wee k  1 6 
visit.  
T h e sec o n d c o -pri mar y e n d p oi nt is:  
• E n d osc o pic res p o nse d efi n e d as a ≥ 3 -p oi nt decrease in 
t h e S E S-C D fr o m b aseli n e t o t he S E S -C D sc ore 
o btai n e d b et wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D 
sc ores will be calc ulate d fr o m ce ntrall y-r ea d di gital 
vi d e o of ile o c ol o n osc o pies perf or me d at baseli ne a n d 
b et wee n Wee k 1 6 a n d Wee k  1 7.  
Sa me as a b o ve.  

P a ge 1 0 6  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
• S y m pt o m re missi o n d efi n e d b y ( 1) t h e t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t h e 7 d a ys 
pri or t o Wee ks 1 6 a n d 5 2 visit b ei n g ≤ 1 0;  A N D  
( 2) a d ail y a b d o mi n al p ai n sc ore of ≤ 1 f or t h e 7 
d a ys pri or t o Wee ks 1 6 a n d 5 2 visit.  
T h e sec o n d c o -pri mar y e n d p oi nt is:  
• A n i m pr o ve me nt or n o c h a n ge fr o m Wee k 1 6 in 
t h e t otal S E S-C D sc ore at Wee k 5 2. S E S -C D 
sc ores will be calc ulate d fr o m di gital vi d e o of 
ile o c ol o n osc o pies p erf or me d b et we e n Wee k 1 6 
a n d 1 7, a n d Wee k  5 2.  
 
 
 
P a ge 2 9  
2. 2. 2  
T h e ori gi n al secti o n 2. 2. 2 title d Pri mar y E n d p oi nt  
Assess me nt Defi niti o ns h as b ee n d elete d  
Secti o n 2. 2. 2 –  Pri m ar y E n d p oi nt Assess me nt 
Defi niti o ns  
N o w re a ds: 2. 2. 2 K e y Sec o n d ar y E n d p oi nts  
Sa me as a b o ve a n d  
Secti o n n u m beri n g has 
c ha n ge d.  
P a ge 2 9  
2. 2. 2  
2. 2. 3 K e y Sec o n d a r y E n d p oi nts 
I n d ucti o n P h ase 
• Cli nical re missi o n d efi n e d as a C D AI  sc ore 
ofless t h a n 1 5 0 p oi nts at Wee k 1 6.  
• C h a n ge fr o m b aseli n e i n S E S -C D sc ore at Week 
1 6.  
M ai nte n a nc e P h ase  
D ura ble re missi o n d efi n e d as:  
• t h e t otal n u m b er of li q ui d/ ver y s oft st o ols f or 
t h e 7 d a ys pri or t o t h e visit b ein g ≤ 1 0; A N D  ( 2) 
a d ail y a b d o mi n al p ai n sc ore of ≤ 1 f or t h e 7 
d a ys pri or t o t h e visit i n ≥ 8 0 % of t h e st u d y 
visits i n t h e Mai nte n a n ce P h ase, i n cl u di n g 
Wee k  5 2.  
• Ti me t o l oss of C D AI res p o nse d efi n e d b y  a 
C D AI s c ore of ≥ 1 5 0 p oi nts d uri n g t h e 
Mai nte n a n ce  P h ase.  
2. 2. 2 K e y Sec o n d a r y E n d p oi nts  
T h e ke y sec o n d ar y e n d p oi nt is cli nical a n d e n d osc o pic 
re missi o n. T w o ke y c o-sec o n dar y e n d p oi nts of efficac y 
will assess t his e n d p oi nt d uri n g t he L o n g Ter m Tre at me nt 
P h ase. T h e first is:  
• Cli nical s y m pt o m re mi ssi o n defi ne d b y ( 1) t he t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o 
t h e Wee k 5 2 visit b ei n g ≤ 1 0 (fr o m C D AI Ite m 1); 
A N D ( 2) a n a b d o mi n al p ai n rati n g of ≤ 1(fr o m C D AI 
Ite m 2) o n eac h d a y f or t h e 7 da ys pri or t o t he Wee k 5 2 
visit.  
T h e sec o n d is:  
• E n d osc o pic re missi o n d efi ne d as a S E S -C D sc ore of  ≤ 
2 at Wee k 5 2. S E S -C D sc ores will be calc ulate d fr o m 
ce ntrall y-r ea d di gital vi d e o of ile oc ol o n osc o pies 
p erf or me d at Wee k  5 2.  
Sa me as a b o ve.  
P a ge 2 9 -3 0  
2. 2. 3  
2. 2. 4 Sec o n d a r y Effic ac y E n d p oi nts  
T h e sec o n d ar y effi cac y e n d p oi nts of t his st u d y are 
t h e f oll o wi n g: 
• Pr o p orti o n of s u bjects wit h res p o nse t o t h e 
li q ui d/ ver y s oft st o ol c o m p o n e nt of t h e c o- 
pri mar y e n d p oi nt at p ost -b aseli n e ti me  p oi nts.  
• Pr o p orti o n of s u bjects wit h res p o nse t o t h e 
a b d o mi n al p ai n c o m p o n e nt of t h e c o -pri mar y 
e n d p oi nt at p ost -b aseli n e ti me  p oi nts.  
• C h a n ge fr o m b aseli n e i n S E S -C D sc ore at  Wee k  
2. 2. 3 Sec o n d a r y Effic ac y E n d p oi nts  
• I n d u cti o n of cli nical re missi o n defi ne d as a C D AI 
Sc ore of less t h a n 1 5 0 p oi nt s at Wee k 1 6.  
• Cli nical s y m pt o m re missi o n o ver ti me: T he t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or  t o 
eac h cli nic visit b ei n g ≤ 1 0; A N D ( 2) a n a b d o mi nal 
p ai n rati n g of ≤ 1 o n eac h da y f or t he last 7 da ys pri or 
t o eac h cli nic visit i n ≥ 8 0 % of t he st u d y visits d uri n g 
t h e 5 2-Wee k Treat me nt P eri o d, i ncl u di n g Wee k  5 2.  
• Ti me u ntil d ura ble res p o nse (see Secti o n 8. 6. 2) t o  t he 
Sa me as a b o ve.  

P a ge 1 0 7  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
5 2.  
• Pr o p orti o n of s u bjects w h o ac hie ve cli nical 
re missi o n b y t h e C D AI e n d p oi nt at  p ost -b aseli n e 
ti me p oi nts.  
• P erce nta ge of s u bjects w h o ac hie ve cli nical 
res p o nse at p ost-b aseli n e ti me p oi nts. Cli nical 
res p o nse is d efi n e d as a re d u cti o n of at least 1 0 0 
p oi nts fr o m t h e b aseli n e C D AI  sc ore. 
• Ti me t o cli nical res p o nse b ase d o n i nd u cti o n  co- 
pri mar y  e n d p oi nts. 
• Ti me t o cli nical res p o nse b ase d o n C D AI <  1 5 0.  
• C h a n ge i n i n dices of Healt h O utc o mes 
(I nfla m mat or y B o wel Disease Q u esti o n n aire 
[I B D Q], S F-3 6 ® , W or k Pr o d u cti vit y a n d 
Acti vit y I m p air me nt Q u esti o n n aire f or  Cr o h n's 
Disease [ W P AI-C D]) at p ost -b aseli n e ti me 
p oi nts.  
• C h a n ge fr o m b aseli n e i n mar kers of 
i nfla m mati o n (e. g. C R P, i nterle u ki ns, c yt o ki n es, 
fe cal cal pr otecti n) at p ost-b aseli ne ti me  p oi nts.  
• C ortic oster oi d -free re missi o n b ase d o n in d uctio n 
c o -pri mar y e n d p oi nts. C ortic oster oi d -free 
re missi o n b ase d o n C D AI <  1 5 0.  
li q ui d/ ver y s oft st o ol c o m p o ne nt of t he c o-pri mar y 
e n d p oi nt d uri n g t h e 5 2 -Wee k Tre at me nt  P eri o d.  
• Ti me u ntil d ura ble res p o nse ( See Secti o n 8. 6. 2) t o t he 
a b d o mi n al p ai n c o m p o n e nt of t he c o -pri mar y  e n d p oi nt 
d uri n g t h e 5 2-Wee k Tr eat me nt  P eri o d.  
• Pr o p orti o n of s u bjects wit h res p o nse t o t he ab d o minal 
p ai n c o m p o n e nt of t h e c o -pri mar y e n d p oi nt at p ost - 
b aseli n e ti me  p oi nts.  
• Pr o p orti o n of s u bjects wit h res p o nse t o t he liq uid/ ver y 
s oft st o ol c o m p o n e nt of t h e c o-pri mar y e n d p oi nt at 
p ost -b aseli n e ti me  p oi nts.  
• C h a n ge fr o m b aseli n e i n S E S -C D sc ore at Wee k 1 6 and 
Wee k  5 2.  
• Pr o p orti o n of s u bjects wit h S E S -C D sc ore of 0 at Week 
5 2.  
• Pr o p orti o n of s u bjects w h o ac hie ve cli nical re missi o n 
b y t h e C D AI e n d p oi nt at p ost -baseli ne ti me  p oi nts.  
• Ti me t o l oss of C D AI res p o nse defi ne d b y a C D AI 
sc ore of ≥ 1 5 0 p oi nts d uri n g t he L o n g Ter m Treat ment 
P h ase.  
• P erce nta ge of s u bjects w h o ac hie ve cli nical res p o nse  at 
p ost -b aseli n e ti me p oi nts. Cli nical res p o nse is defi ne d 
as a re d u cti o n of at least 1 0 0 p oi nts fr o m t he baseli ne 
C D AI  sc ore. 
• Ti me t o cli nical re missi o n base d o n a b d o mi nal pai n and 
li q ui d st o ol c o m p o n e nts of t he c o-pri mar y  e n d p oi nts. 
• Ti me t o cli nical re missi o n base d o n C D AI <  1 5 0.  
• C h a n ge fr o m b aseli n e i n i n dices of healt h o utc o mes 
(I nfla m mat or y B o wel Disease Q uesti o n naire [I B D Q], 
W or k Pr o d u cti vit y a n d Acti vit y I m pair me nt 
Q u esti o n n aire f or Cr o h n's Diseas e [ W P AI -C D]) at p ost - 
b aseli n e ti me  p oi nts.  
• C h a n ge fr o m b aseli n e i n mar kers of i nfla m mati o n (e. g. 
C R P, i nterle u ki ns, c yt o ki n es, fec al cal pr otecti n) at  p ost - 
b aseli n e ti me  p oi nts.  
 
 
P a ge 3 0 -3 1  
2. 2. 5  
Secti o n 2. 2. 6 E x pl or at or y Assess me nts  
• C h aracterizati o n of g ut micr o bi ota after 1 6 and 
5 2 wee ks of c o nti n u o us Rifa xi mi n D R 
treat me nt. N ote: Micr o bi ota after 1 6 a n d 5 2 
we e ks of c o nti n u o us Rifa xi mi n D R treat me nt 
will be c o m p are d t o t h e micr o bi ota pri or t o 
ra n d o mizati o n. 
2. 2. 5 E x pl or at or y Assess me nts  
E x pl orat or y assess me nts will i ncl u de:  
• C h aracterizati o n of st o ol micr o bi ota at baseli ne  and 
after 1 6 a n d 5 2 wee ks of treat me nt. 
• Baseli n e a n d p ost -treat me nt bacterial D N A isolated 
fr o m st o ol f or 1 6 S r R N A ge ne a m plificati o n. 
• Descri pti v e c h aracteriz ati o n of bacteria i n st o ol  b y: …  
Secti o n n u m ber 
c ha n ge d; descri pti ve 
e dits ma de.  

P a ge 1 0 8  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
• Descri pti ve c h aracteriz ati o n of selecte d bacteria 
(aer o bic a n d a n aer o bic) i n st o ol b y:  
• Ge n o mic pr ofili n g of P X R i n  bl o o d.  
• P o p ulati o n p h ar mac o ki n etics of rifa xi mi n after 
Rifa xi mi n D R  a d mi nistrati o n. 
• Ge n o mic pr ofili n g of pre g n a ne X rece pt or ( P X R)  
inbl o o d.  
• P o p ulati o n p h ar mac o ki n etics of  rifa xi mi n. 
 
 
P a ges 3 2 - 
3 3  
3. 1 O ver vie w  
of St u d y 
Desi g n  
 
T h e st u d y d esi g n h as b ee n clarifie d t o acc uratel y refl ect 
c h a n ges t o t h e e n d p oi nts. 
St u d y desi g n clarifie d.  
P a ge 3 5  
4. 1 I n cl usi o n 
Criteria  
1. S u bject is ≥ 1 8 years of a g e.  
3. S u bject has m o d erate, n o n -fist ulizi n g Cr o h n’s 
disease i n t h e ile u m a n d/ or c ol o n as d efi n e d b y 
a C D AI s c ore of ≥ 2 2 0 a n d ≤ 4 5 0 p oi nts pri or 
t o ra n d o mizati o n; a n d e vi d e n ce of acti v e 
ile o c ol o nic C D as d efi n e d b y a mi ni m u m S E S- 
C D sc ore of 7. T h e S E S -C D sc ore m ust be 
calc ulate d usi n g t h e b aseli n e ile oc ol o n osc o p y 
p erf or me d d uri n g t h e Scree ni n g  Peri o d.  
N O T E: A n i n d e p e n d e nt e n d osc o pist fr o m t h e 
Ce ntral E n d osc o p y La b orat or y will d eter mi n e 
w h et h er t h e s u bject meets t h e S E S -C D 
i n cl usi o n criteri o n. 
4. D uri n g t he Scree ni n g P h ase, t h e s u bject h as  t he 
f oll o wi n g a v era g e d ail y s c ores f or li q ui d/ ver y 
s oft st o ols ( wit h a c o nsiste n c y of T y p e 6 or 
T y p e 7 Brist ol St o ol F or m Scale [ B S F S]) a n d 
f or a b d o mi n al p ai n are re q uire d f or e ntr y i nt o 
t h e st u d y: 
• A n a v era g e d ail y s c ore of > 1. 5 for 
a b d o mi n al p ai n;  a n d 
• A n a v era g e d ail y s c ore of > 1. 5 for 
li q ui d/ ver y s oft st o ols. 
1. S u bject is ≥ 1 8 years of a g e at Scree ni n g.  
3. S u bject h as m o d erate, n o n -fist ulizi n g Cr o h n’s disease 
i n t h e ile u m a n d/ or c ol o n as defi ne d b y a C D AI sc ore 
of ≥ 2 2 0 a n d ≤ 4 5 0 p oi nts pri or t o ra n d o mizati o n; a n d 
a S E S -C D sc ore of ≥7. T h e S E S -C D sc ore will be 
calc ulate d usi n g t h e b aseli ne ile oc ol o n osc o p y 
p erf or me d d uri n g t h e Scree ni n g  Peri o d.  
N O T E: E n d osc o pists fr o m t h e Ce ntral E n d osc o p y 
La b orat or y will d eter mi n e w het her t he s u bject meets 
t h e S E S-C D i n cl usi o n criteri o n. E n d osc o pists 
p erf or mi n g t h e pr o ce d ures s h o ul d e ns ure t hat all areas 
of t h e c ol o n, i n cl u di n g t h e ter mi nal ile u m, are 
a d e q u atel y vis u alize d as t o e ns ure t hat a ce ntral  rea der 
ca n ma ke a d eter mi n ati o n of t he S E S -C D sc ore base d 
o n t h e vi d e o rec or di n g of t he pr oce d ure. Strict ures 
t h at d o n ot p er mit f urt h er passa ge of t he c ol o n osc o pe 
s h o ul d be a n n otate d as s u c h. 
4. D uri n g t h e Scree ni n g P h ase, t he s u bject has t he 
f oll o wi n g a v era g e d ail y s c ores f or a b d o mi nal pai n a n d 
a vera ge n u m b er of li q ui d/ ver y s oft st o ols  : 
• A n a v era g e d ail y s c ore of > 1. 5 f or a b d o mi nal  pain 
(fr o m C D AI Ite m 2); a n d 
• A n a v era g e d ail y c o u nt of > 1. 5 f or li q ui d/ ver y 
s oft st o ols (fr o m C D AI Ite m 1). Li q ui d/ ver y s oft 
st o ol will be d efi n e d as a c o nsiste nc y of T y pe 6  or  
T y p e 7 o n t h e B S F S.  
T hree i ncl usi o n 
criteria ha ve bee n  
clarifie d t o facilitate 
e nr oll me nt b y 
i n vesti gat ors. 
P a ge 3 6 -3 8  
4. 2 E xcl usi o n 
Criteria  
4. S u bject h as h a d e xte nsi ve c ol o nic resecti o n 
( d efi n e d as greater t h a n o n e-t hir d of t h e c ol o n), 
s u bt otal or t otal c olect o m y.  
5. S u bject h as prese n ce of a n ile ost o m y, 
c ol ost o m y or a n ileal p o u c h.  
1 0. S u bject h a d hist or y or e vi d e n ce of  
a d e n o mat o us c ol o nic p ol y ps t h at h a ve n ot b ee n 
re m o ve d. 
4. S u bject h as h a d m ore t h a n o ne se g me ntal c ol o nic 
resecti o n (i.e. m ore t h a n o ne of t he f oll o wi n g: ri g ht 
h e mic olect o m y, left h e mic olect o m y, tra ns verse 
c olect o m y,  ile o cec al rese cti o n, si g m oi d c olect o m y).  
5. S u bject h as prese n ce of a n ile ost o m y or c o l ost o m y. 
1 0. S u bject h a d hist or y or e vi de nce of a de n o mat o us  
c ol o nic p ol y ps t h at h a ve n ot bee n re m o ve d. N O T E: 
S u bjects ca n n ot b e e nr olle d if a n y a de n o mat o us  
T hirtee n e xcl usi o n 
criteria ha ve bee n 
clarifie d t o facilitate 
e nr oll me nt b y 
i n vesti gat ors. 

P a ge 1 0 9  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
1 3. S u bject h as hist or y of a maj or ps yc hiatric 
dis or d er, i n cl u di n g maj or d e pressi o n, 
ps yc h oses, alc o h ol or s u bsta n ce a b use wit hi n 
t h e p ast 2 4 m o nt hs pri or t o si g ni n g t h e 
i nf or me d c o nse nt p er D S M-5 ( Dia g n ostic a n d  
Statistical Ma n u al of Me ntal Dis or d ers, 5t h  
e diti o n .) 
1 8. S u bject h as a n y c o n diti o n or circ u msta n ce t h at 
a d versel y affects t h e s u bject or c o ul d ca use 
n o n c o m plia n ce wit h treat me nt or visits.  
2 2. S u bject h as a p ositi ve st o ol test f or Yersi ni a 
e nter o c olitic a, C a m p yl o b a cter jej u ni , 
S al m o n ell a, S hi g ell a , o v u m a n d parasites, 
a n d/ or Cl ostri di u m difficile . N O T E: Res ults of 
st o ol tests m ust b e c o nfir me d as n e gati v e pri or 
t o ra n d o mizati o n. A st o ol sa m ple m ust b e 
c ollecte d d uri n g t h e Scree ni n g P eri o d 7 -1 4 
d a ys pri or t o ra n d o mizati o n i nt o I n d u cti o n 
p h ase ( V 2).  
2 5.  S u bject is u n a ble t o be ta p ere d off 
c ortic oster oi ds b y Wee k 8 of t h e Treat me nt 
P eri o d. N O T E: Use of oral c ortic oster oi ds f or 
t h e treat me nt of acti ve Cr o h n’s disease is 
p er mitte d at st u d y e ntr y. P er mitte d 
me dicati o ns are pre d nis o n e if t h e d ose is ≤ 2 0 
m g ( or e q ui vale nt) p er d a y or b u des o ni d e if t h e 
d ose is ≤ 9 m g/ d a y. T h e s u bject m ust be 
ta p ere d off t h e c ortic oster oi ds as n ote d a b o ve. 
2 6.  S u bject use d i m m u n os u pressa nts (e. g., 
c ycl os p ori n e, tacr oli m us, sir oli m us or 
m yc o p h e n olate m ofetil) wit hi n 8 we e ks  pri or 
t o ra n d o mizati o n. 
2 9.  S u bjects use d t u b e or e nteral fee di n g, a n 
ele me ntal diet, or p are nteral ali me ntati o n 
wit hi n 2 wee ks pri or t o scree ni n g  visit.  
3 0.  S u bject  use d pr o bi otics, s y m bi otics or  si milar 
t y p e s u p ple me nts wit hi n 2 wee ks of t h e 
scree ni n g visit.  
3 1.  S u bject, if fe male, is pre g n a nt, h as a p ositi ve 
pre g n a n c y test at scr ee ni n g or is breast -fee di n g. 
3 3. S u bject h as use d a n y i n vesti gati o n al pr o d u ct or 
p artici p ate d i n a n ot h er researc h st u d y wit hi n  3 0 
d a ys pri or t o ra n d o mizati o n, or d uri n g  t h e 
p ol y p(s) re m o v e d d uri n g t he scree ni n g 
ile o c ol o n osc o p y h as e vi d e nce of d ys plasia or 
mali g n a n c y.  
1 3. S u bject h as hist or y of t h e f oll o wi n g c o n diti o ns per  
Dia g n ostic a n d Statistical Ma n ual of Me nta l 
Dis or d ers, 5t h e diti o n ( DS M -5):  
• 
a maj or ps yc hiatric dis or d er (i ncl u di n g  major 
d e pressi o n or  ps yc h osis)  
• 
alc o h ol or s u bsta n ce a b use wit hi n 2 4 m o nt hs pri or  
tosi g ni n g t h e i nf or me d c o nse nt 
1 8. Pri or Criteri o n # 1 8 h as b ee n delete d a n d ca pt ure d i n 
re vise d criteri o n # 3 4 
2 1. S u bject h as a p ositi ve st o ol test f or Yersi ni a 
e nter o c olitic a, C a m p yl o b acter jej u ni , S al m o nell a, 
S hi g ell a , o v u m a n d p arasites, a n d/ or Cl ostri di u m 
difficile . N O T E: Res ults of st o ol tests m ust be 
c o nfir me d as n e gati ve pri or t o ra n d o mizati o n. .  
2 4.  S u bject is u n willi n g t o be ta pere d off c ortic oster oi ds 
b y Wee k 8 of t h e Treat me nt P eri o d or t he s u bject is 
k n o w n b y t h e I n vesti gat or t o be ster oi d de pe n de nt. 
N O T E: Use of oral c ortic oster oi ds f or t he treat me nt  of 
acti ve Cr o h n’s disease is per mitte d at st u d y e ntr y. 
P er mitte d me dicati o ns are: pre d nis o ne if t he d ose is ≤ 
2 0 m g ( or e q ui vale nt) p er da y or b u des o ni de if t he 
d ose is ≤ 9 m g/ d a y. T h e s u bject m ust be ta pere d off 
t h e c ortic oster oi ds as n ote d a b o ve.  
2 5.  S u bject use d c ycl os p ori n e, tacr oli m us, sir oli m us, 
m yc o p h e n olate m ofetil, or si milar dr u gs wit hi n 8 
we e ks pri or t o  ra n d o mizati o n. 
2 8.  S u bjects use d t u b e or e nteral fee di n g, a n ele me ntal 
diet, or p are nteral ali me ntati o n wit hi n 2 wee ks pri or  t o 
scree ni n g visit. N ote: dietar y s u p ple me nts (e. g. B o ost, 
E ns ure) are all o we d.  
2 9.  S u bjects w h o are pla n ni n g t o be gi n ta ki n g pr o bi otics 
or si milar s u p ple me nts at or after t he Scree ni n g Visit, 
or s u bjects w h o b e ga n usi n g t hese s u p ple me nts  wit hi n 
2 wee ks pri or t o t h e Scree ni n g Visit. N O T E: T hes e 
s u p ple me nts are all o we d if t he s u bject has bee n o n a 
sta ble d ose f or 2 wee ks or m ore pri or t o t he Scree ni n g 
Visit a n d t h e s u bject pla ns t o re mai n o n t hat d ose 
t hr o u g h o ut t h e st u d y. T h e s u bject s h o ul d n ot 
i ntr o d u ce a n y n e w pr o bi otics or si milar s u p ple me nts 
f or t h e d urati o n of t h e st u d y. Pri or a n d c urre nt use of  
 
 

P a ge 1 1 0  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
st u d y. 
3 4. S u bject h as a n y c o n c urre nt ill n ess or disa bilit y 
t h at ma y affect t h e i nter pretati o n of cli nical 
d ata, or ot h er wise c o ntrai n dicates p artici p ati o n 
i n t his cli nical st u d y i n t h e discreti o n of t h e 
i n vesti gat or. 
pr o bi otics or si milar s u p ple me nts will be rec or de d i n 
t h e s u bject’s s o urce d o c u me nts a n d e C R F. 
3 0.  S u bject is c urre ntl y recei vi n g warfari n or ot her 4 - 
h y dr o x yc o u mari ns at t h e scree ni n g visit, or has pla ns 
t o i nitiate t h e me dicati o n  at a n y ti me d uri n g  t he st u d y. 
3 1.  S u bject, if fe male, is c urre ntl y pre g na nt or has pla ns t o 
b ec o me pre g n a nt at a n y ti me d uri n g t he st u d y, has a 
p ositi ve pre g n a n c y test at scree ni n g or is breast - 
fe e di n g. 
3 3.  S u bject h as use d a n y i n vesti gati o nal pr o d uct wit hi n  3 0 
d a ys pri or t o ra n d o mizati o n, or d uri n g t he  st u d y. 
3 4.  S u bj ect h as a n y c o n c urre nt ill ness, disa bilit y or 
circ u mst a n ce t h at ma y affect t he i nter pretati o n  of 
cli nical d ata, c o ul d ca use n o nc o m plia nce wit h 
treat me nt or visits or ot h er wise c o ntrai n dicates  
p artici p ati o n i n t his st u d y i n t he o pi ni o n of t he 
i n vesti gat or. 
 
 
P a ge 3 9  
4. 3. 2  
Pr o hi bite d T he r a p y  
• A n y oral or i ntra ve n o us a nti bi otic i n cl u di n g 
rifa xi mi n, rifa m pi n or a n y dr u gs i n t h e rifa m yci n 
gr o u p. N ote: A s h ort c o urse of a nti bi otic t o treat 
ac ute c o n diti o ns (e. g., si n usitis, uri n ar y tract 
i nfecti o n) is p er mitte d.  
• I m m u n os u p pressa nts (c ycl os p ori n e, tacr oli mus, 
sir oli m us or m yc o p h e n olate m ofetil)  
• Use of pr o bi otics, s y m bi otics, or si mil ar type 
s u p ple me nts. 
Pr o hi bite d T he r a p y  
• A n y oral or i ntra ve n o us a nti bi otic. N O T E: A sh ort 
c o urse of a nti bi otic t o treat ac ute c o n diti o ns (e. g., 
si n usitis, uri n ar y tract i nfe cti o n) is per mitte d.  
• Use of a n y dr u g fr o m t h e rifa m yci n class at a n y ti me 
d uri n g st u d y p artici p ati o n, i ncl u di n g rifa xi mi n, 
rifa m pi n, rifa p e nti n e, a n d rifa b uti n. C urre nt 
i nter n ati o n al tra d e n a mes of rifa xi mi n i ncl u de: Alfa 
N or mi x, C oli di mi n, Fa xi n or m, Fl o n or m, L or m y x, 
N or mi x, Refer o, Rifac ol, Rifa x -A w, Rifa xa n -A w, 
S pira xi n, Tar ga xa n, Ti xtar, Ti xteller, Xifa xa n, 
Xifa xa nta, a n d  Za xi n e.  
• C ycl os p ori n e, tacr oli m us, sir oli m us, m yc o p h e n olate 
m ofetil, or si milar  dr u gs  
• I ntr o d u cti o n of a n y n e w pr o bi otics or si milar 
s u p ple me nts d uri n g t h e st u d y. 
A nti bi otics, 
i m m u n os u pressa nts 
a n d pr o bi otics 
clarifie d.  
P a ge 4 0  
4. 5  
Pre m at ur e S u bject Disc o nti n u ati o n  
S u bject n o n c o m plia n ce. 
S u bject re q u est t o wit h dra w. 
Brea ki n g t h e st u d y bli n d (see Secti o n 3. 4). 
S p o ns or d ecisi o n t o ter mi n ate t h e st u d y.  
Pre m at ur e S u bject Disc o nti n u ati o n  
S u bject re q u est t o wit h dra w.  
S p o ns or d ecisi o n t o ter mi n ate t he st u d y.  
Re m o ve d Brea ki n g t he 
Bli n d (c o vere d i n  
Secti o n 3. 4) a n d 
s u bject n o n- 
c o m plia nce as a reas o n 
f or st u d y 
disc o nti n uati o n 
beca use t he st u d y will  
be c o n d ucte d t o e ns ure  

Page 111 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
compliance with the 
protocol, and because 
it is important to 
ensure that all subjects 
complete the study. 
Page 45 
6.0 
Study Procedures and Assessments 
Study Procedures and Assessments 
Added: Subjects will be provided bowel prep for use prior 
to the ileocolonoscopies. The bowel prep will be 
dispensed by study staff at Visits 1, 7, and 16. 
Bowel prep will be 
supplied to the subject. 
Pages 45 - 
49 
6.1.1 – 6.1.7 
Visit 1: Screening (Day –14 to Day -7) 
Visit 2: Baseline/Randomization, Week 0/Day 1 
Visits 3, 4, 5, 6: Weeks 2, 4,8,12 /Days 14, 28, 56, 
84 (± 3 day) 
Visit 7: Week 16/Day 112 (± 3 day) 
Visits 8, 9, 10, 11, 12, 13, 14, 15: Weeks 20, 24, 
28, 32, 36, 40, 44, 48 /Days 140, 168, 196, 252, 
280, 208, 336 ( ± 3 days) 
Visit 16: End of Treatment (EOT) Visit, Week 
52/Day 364 (± 3 days) 
Visit 17: End of Study (EOS) Visit, Week 
54/Day 378 (± 3 days) 
Unscheduled Visit 
Visit 1: Screening (Day –21 to Day -14) 
Visit 2: Baseline/Randomization, Week 0/Day 1 
Visits 3, 4, 5, 6: Weeks 2, 4, 8, 12 /Days 14, 28, 56, 84 (± 
3 days) 
Visit 7: Week 16/Day 112 (± 3 days) 
Visits 8, 9, 10, 11, 12, 13, 14, 15: Weeks 20, 24, 28, 32, 
36, 40, 44, 48 /Days 140, 168, 196, 224, 252, 280, 308, 
336 ( ± 3 days) 
Visit 16: End of Treatment (EOT) Visit, Week 52/Day 
364 (± 3 days) 
Visit 17: End of Study (EOS) Visit, Week 54/Day 378 
(± 3 days) 
Unscheduled Visit 
Visit procedures/ 
assessments have been 
updated to facilitate 
conduct at sites and 
meet revised 
endpoints. 
Page 50 
6.2.2 
Simple Endoscopic Score for Crohn’s Disease 
(SES-CD) 
Simple Endoscopic Score for Crohn’s Disease (SES- 
CD) 
Video recordings of ileocolonoscopies will be reviewed, 
and SES-CD scores will be calculated by blinded central 
laboratory endoscopists for the study. 
Added: In order to fully assess for the presence of 
ileocolonic Crohn’s Disease and calculate an accurate 
SES-CD score, the endoscopist must attempt to intubate 
and visualize the terminal ileum in order to determine 
presence and extent of disease during each 
ileocolonoscopy. To reduce the potential for bias or 
variability in endoscopy scoring, blinded central reading 
will be utilized to determine the SES-CD scores for all 
ileocolonoscopies obtained during the study. As such, 
every effort must be made at each procedure to fully 
visualize each segment of the terminal ileum and colon to 
facilitate central reading of the recorded procedures. The 
rate of withdrawal of the colonoscope during the 
procedure should also be sufficiently slow as to allow for 
adequate visualization and scoring of each segment in the 
video recording by a central reader.  Strictures that do not 
Clarification that 
video recordings of 
ileocolonoscopies will 
be evaluated and 
additional instruction 
given to the 
endoscopist to 
facilitate centralized 
reading. 

Page 112 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
permit further passage of the colonoscope should be 
annotated as such. 
Page 53 
6.3.3 
Stool Sample Collection and Testing 
ï 
Microbiota Characterization: Susceptibility 
Testing: A substudy (examining stool samples 
across all collection times in approximately 10% 
of the study population) will characterize the 
susceptibility of the stool microbiota to rifaximin, 
rifampin, and other selected antibiotics of clinical 
interest. 
ï 
Microbiota Characterization: Composition, 
Diversity, DNA Sequencing: A substudy 
(examining stool samples across all collection 
times in approximately 10% of the study 
population) will characterize intestinal microbiota 
in terms of composition and diversity, as well as 
sequencing for specific organisms of interest. 
Bacterial DNA will be isolated from fecal 
samples, and the hyper-variable regions of the 16S 
rRNA gene will be amplified using two-step PCR 
sequencing technology. 
Stool Sample Collection and Testing 
ï  Microbiota Characterization: Susceptibility Testing: In 
a subset of the study population (approximately 10%), the 
susceptibility of the stool microbiota to rifaximin, 
rifampin, and other selected antibiotics of clinical interest 
will be characterized. Stool samples will be inoculated 
onto various media to identify organisms. Stool cultures 
will identify and isolate yeast as well as selected bacteria, 
chosen to incorporate the most prevalent species of 
intestinal bacteria. Bacteria will be identified and 
characterized by morphology and physical tests, with 
identity confirmed with molecular identification systems. 
Yeast will be identified if present in stool, but will not be 
tested further. Bacterial sensitivity testing will be 
performed by broth microdilution (per Clinical Laboratory 
Standards Institute (CLSI) document M7-A8) for aerobic 
bacteria and by agar dilution for anaerobic bacteria using 
clinically relevant antibiotics. Duplicate samples of all 
isolates and stool aliquots will be stored to allow for 
potential future analysis. 
ï Microbiota Characterization: Composition, Diversity, 
DNA Sequencing: In a subset of the study population 
(approximately 10%), the intestinal microbiota from stool 
samples will be characterized in terms of composition and 
diversity, as well as sequencing for specific organisms of 
interest. Bacterial DNA will be isolated from fecal 
samples, and the hyper-variable regions of the 16S rRNA 
gene will be amplified using two-step PCR sequencing 
technology. All stool samples and DNA isolates will be 
stored to allow for potential future analysis. 
Study visit titles 
removed and details of 
Microbiota 
Characterization 
provided per FDA 
request. 
Page 55 
6.3.8 
Vital Sign Assessments 
Vital sign assessments (sitting blood pressure, 
pulse, weight and temperature) will be performed 
at each clinic visit. Height will only be collected 
at Visit 1. 
Vital Sign Assessments 
Vital sign assessments (sitting blood pressure, pulse, and 
temperature) will be performed at each clinic visit. Vital 
signs will be measured after the subject has been seated 
for 5 minutes. Weight will be measured at each clinic 
visit. Height will only be collected at Visit 1. 
Details added to 
ensure consistency at 
sites. 
Page 55 
6.5 
Pharmacokinetics 
Samples will be collected immediately prior to and 
1 hour after dose administration at Visit 2, at Visit 
6, and at Visit 15. Collection and recording of the 
date and time of last dose is required at each visit 
Pharmacokinetics 
Samples will be collected at Visit 2, at Visit 6, and at Visit 
15. At each of these visits, at least one sample will be 
taken. If elected by the subject and the site, dose 
administration of the first dose of the day will be 
Details added to 
ensure consistency at 
sites and proper 
capture of data. 

Page 113 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
in order to correctly estimate rifaximin exposure. 
Steady-state rifaximin concentrations are 
anticipated for collections at Visits 6 and 15. The 
timing of sample collection pre-dose and 1-hour 
post-dose will allow population-based assessments 
of Cmax and half-life. 
performed in the clinic, and an optional second sample 
will be collected approximately one hour after dose 
administration. Collection and recording of the date and 
time of the last dose administered prior to the visit is 
required at each visit in order to most accurately estimate 
rifaximin exposure. Steady-state rifaximin concentrations 
are anticipated for collections at Visits 6 and 15. The 
timing of sample collection will allow population-based 
assessments of Cmax and half-life. 
Page 62 
8.2 
Determination of Sample Size 
The table below provides background information 
for sample size determination for the induction and 
maintenance of remission. This information 
includes expected induction of remission rates, 
expected recurrence rates, and expected rates for 
maintenance of remission at Week 52. For 
placebo, the expected rates are based on data from 
the RETIC 03/06 study conducted in subjects with 
active moderate Crohn’s disease. The rates for 
Rifaximin DR are based on the assumption that 
Rifaximin DR would provide a higher induction 
remission rate and a lower recurrence rate than 
placebo. 
Determination of Sample Size 
The information below provides the background 
information for sample size determination for the 
induction of clinical remission with endoscopic response 
at 16 weeks followed by clinical and endoscopic 
remission at 52 weeks. For placebo, the expected rates are 
based on data from a Phase 2 study (RETIC 03/06) 
conducted in subjects with active moderate Crohn’s 
disease. The rates for Rifaximin DR are based on the 
assumption that Rifaximin DR will provide a somewhat 
higher induction of remission rate. 
Expected rates for induction of clinical remission with 
endoscopic response at Week 16 are 40% for placebo and 
55% for Rifaximin DR. 
Portions of the section 
have been updated to 
reflect revised 
endpoints. 
Expected Rates for Induction of Remission and 
Maintenance of Remission 
Placebo Rifaximin 
DR 
Expected induction rate          40%        55% 
Expected 
recurrence 
rate 
35% 
25%  
Expected maintenance of remission rate26% 
100(0.40)(0.65) 41% 
100(0.55)(0.75) 
Based on a significance level of 5% (alpha 0.05), a sample 
size of approximately 240 subjects per treatment group 
will have at least 90% power to test the hypothesis that 
Rifaximin DR is superior to placebo for each co-primary 
endpoint considered individually. Approximately 80% 
power is available to detect significant differences 
between Rifaximin DR and placebo for both co-primary 
endpoints. 
Assuming a placebo maintenance of remission rate 
(see table above) of 26% and a therapeutic benefit 
due to Rifaximin DR treatment of at least 15%; 
and testing at a significance level of 5% (alpha 
0.05), a sample size of approximately 210 subjects 
per treatment group will have at least 90% power 
to test the primary efficacy hypothesis for 
maintenance of remission. In addition, 
approximately 80% power is available to detect 
For the Long Term Treatment Phase, a 15% treatment 
effect is expected for both clinical symptom and 
endoscopic remission at Week 52. Based on this 
assumption and testing at a significance level of 5% (alpha 
0.05), a sample size of approximately 210 subjects per 
treatment group will have at least 90% power to test the 
key secondary efficacy hypothesis that Rifaximin DR is 
superior to placebo when each key co-secondary endpoint 
is considered individually. In addition, approximately 

P a ge 1 1 4  of  
R E C D 3 1 2 5  
Versi o n D ate: 1 5 M a y 2 0 1 4 FI N A L  
S ali x P h ar m ace utic als,  I nc. 
C R P -4 7  
C o nfi de nti al  
 
 
 
 
si g nifica nt differe n ces b et we e n Rifa xi mi n D R a n d 
place b o f or b ot h c o -pri mar y e n d p oi nts.  
8 0 % p o wer is a vaila ble t o d etect si g nifica nt differe nces 
b et wee n Rifa xi mi n D R a n d place b o f or eac h of t he ke y 
c o -sec o n d ar y e n d p oi nts. 
 
 
P a ge 6 4  
8. 6. 1  
Pri m ar y Effic ac y A n al ysis  
Pri mar y E n d p oi nt f or Mai nte n a n ce of Re missi o n 
Pri mar y e n d p oi nt a n al ysis f or mai nte n a n ce of 
re missi o n will f oll o w t h e met h o ds o utli n e d a b o ve. 
Pri m ar y Effic ac y A n al ysis 
I n d ucti o n P h ase 
T h ere will b e t w o c o -pri mar y me as ures of efficac y 
assess e d d uri n g t h e I n d u cti o n P hase. T he first c o -pri mar y 
e n d p oi nt is: 
Cli nical s y m pt o m re missi o n d efi ne d b y ( 1) t he t otal 
n u m b er of li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o 
t h e Wee k 1 6 visit b ei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D 
( 2) a n a b d o mi n al p ai n rati n g of ≤ 1(fr o m C D AI Ite m 2) o n 
eac h d a y f or t h e 7 d a ys pri or t o t he Wee k 1 6 visit.  
T h e sec o n d c o-pri mar y e n d p oi nt is:  
E n d osc o pic res p o nse d efi n e d as a ≥3 -p oi nt decrease i n t he 
S E S -C D fr o m b aseli n e t o t h e S E S -C D sc ore o btai ne d 
b et wee n Wee k 1 6 a n d Wee k 1 7. S E S -C D sc ores will be 
calc ulate d fr o m ce ntrall y-rea d di gital vi de o of 
ile o c ol o n osc o pies p erf or me d at baseli ne a n d bet wee n 
Wee k 1 6 a n d Wee k 1 7.  
L o n g Ter m T re at me nt P h ase  
T h ere will b e t w o ke y c o -sec o n dar y e n d p oi nts of effic ac y 
assess e d d uri n g t h e L o n g Ter m Treat me nt P hase. T he 
first is: 
Cli nical s y m pt o m re missi o n d efi ne d b y ( 1) t he t otal 
n u m b e r of li q ui d/ ver y s oft st o ols f or t he 7 da ys pri or t o 
t h e Wee k 5 2 visit b ei n g ≤ 1 0 (fr o m C D AI Ite m 1); A N D 
( 2) a n a b d o mi n al p ai n rati n g of ≤ 1 (fr o m C D AI Ite m 2) 
o n eac h d a y f or t h e 7 d a ys pri or t o t he Wee k 5 2 visit. 
T h e sec o n d is:  
E n d osc o pic re missi o n d efi n e d as a S E S -C D sc ore of ≤ 2 at 
Wee k 5 2. S E S -C D sc ores will be calc ulate d fr o m 
ce ntrall y-r ea d di gital vi d e o of ile oc ol o n osc o pies 
p erf or me d at Wee k 5 2.  
F or eac h e n d p oi nt, t h e n u m b er a n d pr o p orti o n of s u bjects  
wit h cli nical a n d e n d osc o pic re missi o n will be 
su m marize d b y treat me nt gr o u p f or t he I T T P o p ulati o n.  
P orti o ns of t he secti o n 
ha ve bee n u p date d t o 
refle ct re vise d 
e n d p oi nts. 
P a ge 6 8  
8. 6. 2  
8. 6. 2. Sec o n d a r y Effic ac y A n al yses  
8. 6. 2 Sec o n d a r y Effic ac y A n al yses  
A nal ys es ha ve bee n 
u p date d t o reflect t he 
c ha n ges t o t he 
sec o n dar y e n d p oi nts. 
P a ge 6 9  
8. 6. 1 0  
N o Pri or Te xt  
8. 6. 1 0  
Electr o c ar di o g r a m  
E C G a nal ysis a d de d.  

Page 115 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
ECG parameters will be summarized by treatment group 
using descriptive statistics. In order to assess the QT 
interval data, corrected QT (QTc) values will be 
calculated based on the following three methods. 
1) Fridericia’s correction: QTc=QT/RR0.33, 
2) Bazett’s Correction: QTc=QT/RR0.5, 
And 
3) Correction based on linear regression techniques: 
Based on the data from baseline study population, the 
intercept(a) and slope (b) will be estimated separately for 
males and females using the equation QT=a+b(1-RR). 
Those estimates will be used to calculate the corrected QT 
values at post baseline time points. 
QTc interval data at post-baseline visits will then be 
summarized descriptively by central tendency techniques. 
In addition, the frequency counts and percentages by 
treatment group for the following categories will be 
provided: 
>450 with Baseline <=450, >480 with Baseline <=480, 
>500 with Baseline <=500, Increases from baseline > 30 
and increases from baseline > 60. 
Page 71 
8.7.5 
Multiple Comparisons/Multiplicity 
The clinical trial would be providing data for two 
separate indications (induction and maintenance of 
remission) with each indication having its own 
separate primary endpoint. On that basis, no 
multiplicity adjustment is needed to the overall 
significance level of 0.05 per indication because 
conclusions will be reached independently for 
induction and separately for maintenance of 
remission. 
The complete evaluation of clinical efficacy in this 
study requires the study of multiple key secondary 
efficacy variables collected at numerous time 
points. It is therefore necessary to properly and 
sensitively control the probability of making 
erroneous conclusions based solely upon 
compounding the likelihood of a type I error. The 
issue of multiplicity of key secondary 
measurements will be handled by statistical testing 
of these outcomes in a hierarchical fashion. The 
order of key secondary endpoints for the Induction 
Multiple Comparisons/Multiplicity 
The study has a single primary endpoint as the primary 
hypothesis, therefore no multiplicity adjustment is needed 
to the overall significance level of 0.05 per region. 
Additionally, the clinical trial will be providing data for 
two separate indications (induction and long term 
treatment) with each indication having its own separate 
endpoint. On that basis, no multiplicity adjustment is 
needed to the overall significance level of 0.05 per 
indication because conclusions will be reached 
independently for induction and separately for long term 
treatment. 
The complete evaluation of clinical efficacy in this study 
requires the study of multiple key secondary efficacy 
variables collected at numerous time points. It is therefore 
necessary to properly and sensitively control the 
probability of making erroneous conclusions based solely 
upon compounding the likelihood of a type I error. The 
issue of multiplicity of secondary measurements will be 
handled by statistical testing of these outcomes in a 
hierarchical fashion. The order of secondary endpoints for 
Section updated to 
reflect revised 
endpoints. 

Page 116 of 
RECD3125 
Version Date: 15 May 2014 FINAL 
Salix Pharmaceuticals, Inc. 
CRP-47 
Confidential 
 
 
and Maintenance Phases are described in Section 
2.2.3. Significance tests will be conducted until a 
non-significant p value is found (p > 0.05). Once a 
non-significant p-value occurred, all subsequent 
significance tests will be considered exploratory in 
nature. 
the Induction and Long Term Treatment Phases are 
described in Sections 2.2.2 and 2.2.3. Significance tests 
will be conducted until a non-significant p value is found 
(p > 0.05). Once a non-significant p-value occurred, all 
subsequent significance tests will be considered 
exploratory in nature. 
Page 85 
Appendix 1: 
Overall 
Timelines and 
Events 
Schedule 
Time and Events Schedule 
Time and Events Schedule 
Updated to match 
changes made to study 
visits in amendment. 
Page 103 
Appendix 7: 
Subject Daily 
Diary 
Recording 
The following will be captured daily in the IVRS 
system. 
The following will be captured daily in the electronic 
diary system. 
IVRS has been 
replaced by an 
electronic diary.